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Abstract 
 
 
Understanding how drug molecules interact with our body and what effects 
they may induce as a result is of fundamental concern to the pharmaceutical 
industry. Crucially we want to use this knowledge to our advantage during the 
drug discovery process in order to manipulate a drug’s efficacy in vivo - 
therefore the development of new technologies, able to effectively screen 
numerous desirable drug-membrane interactions, is of key importance. 
 
The first half of this thesis details the development of a vesicle leakage assay, as 
a means to assess the effect of cationic amphiphilic drugs (CADs) on model 
lipid membranes. Having demonstrated the reproducibility of the assay, the 
assay was transferred into a microfluidic format where water-in-oil droplet 
systems act as individual experimental vessels. As such, it has been 
demonstrated that the use of fluorescence lifetime techniques can provide a 
way in which to translate this assay into a high-throughput format. 
 
The second part of the thesis is concerned with using droplet interface bilayers 
(DIBs) as a means to probe the effect of exogenous species upon a single lipid 
bilayer, as opposed to bulk vesicle populations. Several advantages exist for 
using such a system, including for example the ease with which one is able to 
control the composition of the aqueous compartments on either side of the 
bilayer and to form asymmetric bilayers. An assay, involving the use of pH 
gradients, is detailed, where proof-of-concept experiments illustrate that pH 
sensitive dyes could be used to report the extent to which lipid bilayers are 
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perturbed by drug molecules for example. Furthermore, a novel automated 
approach has been developed, offering advantages over the manual 
manipulation of lipid-containing droplets for DIB formation, where a 
microfluidic approach is used for their generation in high-throughput. 
Consequently, this approach enables the formation of multiple DIBs, where 
the composition may be differed and the droplet dimensions controlled, 
enabling the formation of DIB networks that can be arranged in either two- or 
three-dimensions.
 iii 
Acknowledgements 
 
 
This thesis could not have been produced without the help and support of 
many people over the last four years. I would therefore like to convey my 
gratitude to everyone who has contributed to this [long!] journey.  
 
First and foremost unconditional thanks must be given to each of my 
supervisors for their advice and guidance throughout the course of this project. 
I would like to thank Oscar Ces for his constant enthusiasm and knowledge in 
the area of biophysics, Andrew deMello for his invaluable expertise in the field 
of microfluidics and Tony Gee for his experiences brought to the project from 
an industrial point of view. I would also like to thank the EPSRC and GSK for 
funding this PhD and the Society of the Chemical Industry for the prestigious 
scholarship awarded to me during my second year at Imperial.  
 
I would especially like to thank and acknowledge Xize Niu, Katherine Elvira, 
Tom Robinson and Monpichar Srisa-Art for their advice and collaboration 
with respect to the microfluidic and droplet interface bilayer work presented in 
this thesis. It has been a pleasure working with each of you and much fun! 
Thank you also to Nick Brooks, Annela Seddon, Christina Turner and Gemma 
Shearman for teaching me about various lipid-related “stuff” and Marie 
Kirsten, Duncan Casey, Andre Studer, Kalypso Charalambous and Dave Miller 
for always lending a helping hand. 
 
Acknowledgements 
iv 
Thank you also to each member of the membrane biophysics, non-specific 
binding and deMello / Edel research groups for their contributions during 
group meetings.  
 
Special thanks to all fellow “5th floorers” – past and present – for the many 
discussions, friendship and, of course, constant flow of tea, biscuits and super 
strong coffee! Thank you to Natalia Goehring, Dora Tang, Arwen Tyler, 
Jessica Knott, and Hanna Barriga for their friendship and support over the last 
few years. I would especially like to thank Natalia for rekindling my love of 
drawing and for the constant laughter she brings into every day.  
 
Most importantly, thank you to Adam for his support, love and friendship over 
the last nine years and to my amazing Mum and Dad for their continual 
encouragement, love and unconditional support.  
 
 
 v 
Table of Contents 
 
 
ABSTRACT............................................................................................................... i 
ACKNOWLEDGEMENTS........................................................................................ iii 
TABLE OF CONTENTS.......................................................................................... v 
LIST OF FIGURES................................................................................................... xiv 
LIST OF TABLES..................................................................................................... xxiv 
ABBREVIATIONS.................................................................................................... xxvii 
 
CHAPTER 1: Introduction 
 
 
 
1.1 OVERVIEW.......................................................................................................... 2 
 
1.2 CELL MEMBRANES AND THEIR BIOPHYSICAL PROPERTIES........................ 3 
1.2.1 Structure and function of biological membranes................................ 3 
1.2.1.1 Membrane lipids............................................................................... 4 
1.2.1.2 Asymmetrical lipid distribution in cell membranes.................... 8 
1.2.1.3 Proteins.............................................................................................. 9 
1.2.2 Membrane biophysics.............................................................................. 10 
1.2.2.1 Lipid mesophases............................................................................. 10 
1.2.2.2 Membrane curvature and curvature elasticity (gc).......................
 11 
1.2.2.3 Lateral stress and spontaneous mean curvature.......................... 12 
1.2.2.4 Stored curvature elastic stress........................................................ 14 
Table of Contents 
vi 
 
1.3 DRUG-MEMBRANE INTERACTIONS................................................................ 16 
1.3.1 Passive transport....................................................................................... 17 
1.3.2 Active transport........................................................................................ 18 
1.3.3 Drug translocation via membrane degradation................................... 20 
 
1.4 HIGH-THROUGHPUT TECHNOLOGIES FOR THE STUDY OF DRUG-
MEMBRANE INTERACTIONS................................................................................... 22 
1.4.1 Microfluidics............................................................................................. 22 
1.4.1.1 Introduction...................................................................................... 22 
1.4.1.2 Laminar flow in microfluidic systems........................................... 24 
1.4.1.3 Segmented flows.............................................................................. 25 
1.4.1.4 Methods for forming microfluidic droplets................................. 26 
1.4.1.5 Droplet manipulation...................................................................... 29 
1.4.1.6 Microfluidic technologies amenable for investigating drug-
membrane interactions................................................................................ 31 
1.4.2 Supported lipid bilayers........................................................................... 35 
1.4.2.1 Formation of supported lipid bilayers.......................................... 36 
1.4.2.2 Patterning supported lipid bilayers................................................ 39 
1.4.2.3 Production of composition arrays................................................. 49 
1.4.2.4 Problems associated with the SLB technique.............................. 51 
1.4.3 Droplet interface bilayers (DIBs)...........................................................53 
1.4.3.1 Definition.......................................................................................... 53 
1.4.3.2 Advantages of the DIB system...................................................... 55 
1.4.3.3 High throughput lipid bilayer formation...................................... 57 
 
1.5 CONCLUDING REMARKS AND THESIS AIM................................................... 62 
  
Table of Contents 
vii 
CHAPTER 2: Development of carboxyfluorescein leakage 
assay for the study of drug-membrane interactions 
 
 
2.1 OVERVIEW.......................................................................................................... 65 
 
2.2 INTRODUCTION................................................................................................. 65 
2.2.1 Properties of carboxyfluorescein........................................................... 65 
2.2.2 Carboxyfluorescein in liposomes........................................................... 68 
2.2.3 Summary and chapter aims..................................................................... 69 
 
2.3 MATERIALS AND METHODS............................................................................. 70 
2.3.1 Materials..................................................................................................... 70 
2.3.1.1 Vesicle preparation.......................................................................... 70 
2.3.1.2 Dye and buffer solutions................................................................ 70 
2.3.1.3 Drugs................................................................................................. 71 
2.3.1.4 Gel filtration column....................................................................... 71 
2.3.2 Methods..................................................................................................... 71 
2.3.2.1 Encapsulation of carboxyfluorescein............................................ 71 
2.3.2.2 Exclusion of external dye by gel filtration................................... 74 
2.3.2.3 Column calibration.......................................................................... 75 
2.3.2.4 Efflux measurements...................................................................... 75 
2.3.2.5 Critical micelle concentration (CMC) measurements.................76 
 
2.4 RESULTS AND DISCUSSION.............................................................................. 80 
2.4.1 Assay development.................................................................................. 80 
2.4.1.1 Assay format..................................................................................... 80 
2.4.1.2 Calibration of column..................................................................... 83 
2.4.1.3 Control measurements.................................................................... 85 
2.4.2 Reproducibility of assay: investigations with chlorpromazine, WAY 
and imipramine................................................................................................... 88 
Table of Contents 
viii 
2.4.3 Dependency of efflux rate on DOPE content.................................... 95 
2.4.3.1 Calibration of column using vesicles comprised of DOPC : 
DOPE............................................................................................................ 96 
2.4.3.2 Control for CF vs DOPC : DOPE samples................................ 97 
2.4.3.3 Results for DOPC : DOPE samples............................................ 98 
 
2.5 CHAPTER SUMMARY.......................................................................................... 102 
 
 
CHAPTER 3: Translation of carboxyfluorescein leakage assay 
into a microfluidic format 
 
 
3.1 OVERVIEW.......................................................................................................... 104 
 
3.2 INTRODUCTION................................................................................................. 104 
3.2.1 Droplet microfluidics............................................................................... 104 
3.2.2 Fluorescence lifetime measurements..................................................... 105 
3.2.3 Summary and chapter aims..................................................................... 108 
 
3.3 MATERIALS AND METHODS............................................................................. 109 
3.3.1 Materials..................................................................................................... 109 
3.3.1.1 Dye and buffer solutions................................................................ 109 
3.3.1.2 Photomasks....................................................................................... 109 
3.3.1.3 Soft-lithography and substrate materials...................................... 109 
3.3.1.4 Performing measurements in microfluidic devices.................... 110 
3.3.1.5 Carboxyfluorescein leakage assay.................................................. 110 
3.3.2 Methods..................................................................................................... 111 
3.3.2.1 Dye and buffer preparation............................................................ 111 
3.3.2.2 Creation of photomask................................................................... 111 
3.3.2.3 PDMS preparation........................................................................... 112 
Table of Contents 
ix 
3.3.2.4 Procedure for microfluidic device assembly................................ 113 
3.3.2.5 Carboxyfluorescein leakage assay.................................................. 117 
3.3.2.6 Fluorescence intensity measurements in a microfluidic 
format............................................................................................................. 118 
3.3.2.7 Fluorescence lifetime measurements in bulk............................... 118 
3.3.2.8 Fluorescence lifetime measurements in a microfluidic 
format............................................................................................................. 119 
3.3.2.9 Data analysis of lifetime measurements....................................... 121 
 
3.4 RESULTS AND DISCUSSION.............................................................................. 123 
3.4.1 Fluorescence intensity measurements................................................... 123 
3.4.2 Fluorescence lifetime experiments........................................................ 126 
3.4.2.1 Carboxyfluorescein calibration experiment performed in a cuvette 
format............................................................................................................. 127 
3.4.2.2 Carboxyfluorescein leakage assay performed using imipramine in 
a cuvette format............................................................................................ 130 
3.4.2.3 Carboxyfluorescein calibration experiment performed using a 
microfluidic format...................................................................................... 133 
3.4.2.4 Carboxyfluorescein leakage assay, performed using imipramine in 
a microfluidic format................................................................................... 135 
3.4.2.5 Comparison of the leakage data gained in the cuvette and 
microfluidic formats..................................................................................... 143 
3.4.2.6 Problems associated with the microfluidic format..................... 145 
 
3.5 CHAPTER SUMMARY.......................................................................................... 147 
 
CHAPTER 4: Droplet interface bilayers (DIBs) for probing 
drug-membrane interactions 
 
 
4.1 OVERVIEW.......................................................................................................... 149 
Table of Contents 
x 
4.2 INTRODUCTION................................................................................................. 149 
4.2.1 Liposomes versus artificial planar bilayers.......................................... 149 
4.2.2 Traditional methods for forming artificial planar bilayers................. 150 
4.2.3 Droplet interface bilayers........................................................................ 152 
4.2.4 Summary and chapter aims..................................................................... 155 
 
4.3 MATERIALS AND METHODS............................................................................. 157 
4.3.1 Materials..................................................................................................... 157 
4.3.1.1 Lipids................................................................................................. 157 
4.3.1.2 Dye and buffer solutions................................................................ 157 
4.3.1.3 DIB formation................................................................................. 158 
4.3.1.4 Interfacial tension measurements.................................................. 158 
4.3.2 Methods..................................................................................................... 158 
4.3.2.1 Vesicle preparation.......................................................................... 158 
4.3.2.2 DIB formation................................................................................. 159 
4.3.2.3 Leakage experiments....................................................................... 159 
4.3.2.4 Control experiments........................................................................ 159 
4.3.2.5 Pyranine fluorescence spectra........................................................ 160 
4.3.2.6 Imaging.............................................................................................. 160 
4.3.2.7 Image analysis................................................................................... 163 
4.3.2.8 Interfacial tension (IFT) measurements....................................... 164 
4.3.3 Movie.......................................................................................................... 164 
4.3.3.1 Movie 4.1: ‘Formation of droplet interface bilayer (DIB)’........ 164 
 
4.4 RESULTS AND DISCUSSION.............................................................................. 165 
4.4.1 Formation of droplet interface bilayers (DIBs)................................... 165 
4.4.1.1 Open channel format for DIB formation.................................... 165 
4.4.1.2 DIB formation with different lipids: DPhPC versus DOPC... 168 
4.4.2 Proof-of-concept DIB leakage experiments........................................ 171 
4.4.2.1 Carboxyfluorescein.......................................................................... 172 
Table of Contents 
xi 
4.4.2.2 Properties of pyranine..................................................................... 176 
4.4.2.3 DIB leakage assay with pyranine................................................... 180 
4.4.2.4 Limitations of method.................................................................... 187 
 
4.5 CHAPTER SUMMARY.......................................................................................... 189 
 
 
CHAPTER 5: A microfluidic approach for high-throughput 
droplet interface bilayer (DIB) formation 
 
 
5.1 OVERVIEW.......................................................................................................... 191 
 
5.2 INTRODUCTION................................................................................................. 191 
5.2.1 Use of mechanical pumping for bilayer formation............................. 191 
5.2.2 Formation of DIB networks.................................................................. 193 
5.2.3 Electrical methods.................................................................................... 194 
5.2.4 High-throughput approaches................................................................. 196 
5.2.5 Summary and chapter aims..................................................................... 198 
 
5.3 MATERIALS AND METHODS............................................................................. 198 
5.3.1 Materials..................................................................................................... 199 
5.3.1.1 Lipids................................................................................................. 199 
5.3.1.2 DIB formation................................................................................. 199 
5.3.1.3 Devices.............................................................................................. 199 
5.3.2 Methods..................................................................................................... 200 
5.3.2.1 Vesicle preparation.......................................................................... 200 
5.3.2.2 Device fabrication........................................................................... 200 
5.3.2.3 Water-in-oil droplet formation...................................................... 202 
5.3.2.4 Fluorescence leakage experiments................................................ 204 
5.3.2.5 Control experiments........................................................................ 205 
Table of Contents 
xii 
5.3.2.6 Imaging.............................................................................................. 205 
5.3.3 Movies........................................................................................................ 206 
5.3.3.1 Movie 5.1: ‘Small droplets filling the chamber in 
device 4’.......................................................................................................... 206 
5.3.3.2 Movie 5.2: ‘Large droplets filling the chamber in  
device 4’.......................................................................................................... 207 
5.3.3.3 Movie 5.3: ‘Formation of large droplet DIB network in  
device 4’.......................................................................................................... 208 
5.3.3.4 Movie 5.4: ‘‘Formation of DIBs with DOPC using 
device 4’.......................................................................................................... 209 
 
5.4 RESULTS AND DISCUSSION.............................................................................. 209 
5.4.1 Preliminary investigations using first generation devices................... 210 
5.4.1.1 Device designs.................................................................................. 210 
5.4.1.2 First observation of stable DIB formation on-chip................... 215 
5.4.2 Second generation of devices................................................................. 216 
5.4.2.1 Device design................................................................................... 216 
5.4.2.2 High-throughput DIB formation.................................................. 218 
5.4.2.3 Control of droplet size.................................................................... 220 
5.4.2.4 Asymmetric droplet systems.......................................................... 223 
 
5.5 CHAPTER SUMMARY.......................................................................................... 226 
  
 
CHAPTER 6: Future Directions 
 
 
6.1 OVERVIEW…………………………………………………………… 229 
 
6.2 CHAPTERS 2 AND 3………………………………………………...…. 229 
Table of Contents 
xiii 
6.2.1 Critique of chapters 2 and 3…………………………………........ 229 
6.2.2 Non-specific binding (NSB) in positron emission tomography 
(PET)…………………………………………………………………. 231 
 
6.3 CHAPTERS 4 AND 5…………………………………………………..... 232 
6.3.1 Expansion of droplet interface bilayer (DIB) system for use with 
additional lipids……………………………………………………….. 232 
6.3.1.1 DLPC observations………………………………………… 233 
6.3.1.2 Cholesterol…………………………………………………. 235 
6.3.2 Expansion of automated approach for DIB formation…………... 236 
 
APPENDIX 1............................................................................................................... 237 
APPENDIX 2.............................................................................................................. 239 
APPENDIX 3.............................................................................................................. 242 
APPENDIX 4.............................................................................................................. 244 
APPENDIX 5.............................................................................................................. 245 
APPENDIX 6.............................................................................................................. 246 
APPENDIX 7.............................................................................................................. 247 
APPENDIX 8.............................................................................................................. 248 
APPENDIX 9.............................................................................................................. 249 
APPENDIX 10............................................................................................................. 250 
APPENDIX 11............................................................................................................. 251 
APPENDIX 12............................................................................................................. 253 
APPENDIX 13............................................................................................................. 255 
APPENDIX 14............................................................................................................. 256 
 
BIBLIOGRAPHY......................................................................................................... 258 
 
 xiv 
List of Figures 
 
CHAPTER 1 
Figure 1.1: The cell membrane............................................................................. 3 
Figure 1.2: Prime chemical motifs of glycerophospholipids........................... 6 
Figure 1.3: Chemical structure of sphingolipids............................................... 7 
Figure 1.4: The principle radii of curvature, R1 and R2 for a given 
surface....................................................................................................................... 11 
Figure 1.5: Lateral pressure profile of a lipid bilayer........................................ 13 
Figure 1.6: The spontaneous mean curvature (H0) exhibited by Type 0, I and 
II................................................................................................................................. 14 
Figure 1.7: Curvature elastic stress (CES).......................................................... 15 
Figure 1.8: Passive transport................................................................................ 18 
Figure 1.9: Active transport.................................................................................. 19 
Figure 1.10: Diagram illustrating the mechanistic implications of membrane 
degradation............................................................................................................... 21 
Figure 1.11: An example of a microfluidic device............................................. 23 
Figure 1.12: Laminar and turbulent flow............................................................ 25 
Figure 1.13: Continuous versus segmented flow.............................................. 26 
Figure 1.14: T-junction technique for the formation of microdroplets in a 
planar chip format (i.e. segmented flow)............................................................. 27 
List of Figures 
xv 
Figure 1.15: Flow focusing technique for the formation of microdroplets in a 
planar chip format (i.e. segmented flow)............................................................. 28 
Figure 1.16: Operations that can be performed on droplets after having been 
generated................................................................................................................... 30 
Figure 1.17: High-throughput formation of monodisperse, unilamellar GUVs 
using microfluidics.................................................................................................. 32 
Figure 1.18: Development of “lung-on-a-chip” devices.................................. 34 
Figure 1.19: Supported lipid bilayer.................................................................... 35 
Figure 1.20: Approaches used to deposit fluid phospholipid bilayers upon a 
substrate.................................................................................................................... 36 
Figure 1.21: Diagram illustrating the various mechanisms of vesicle rupture to 
yield SLB formation................................................................................................ 38 
Figure 1.22: Diagrams illustrating the “blotting” and “stamping” techniques 
developed by Hovis and Boxer to create patterned, supported lipid 
bilayers.......................................................................................................................41 
Figure 1.23: Protein stamping and caulking for patterned SLB 
formation.................................................................................................................. 43  
Figure 1.24: Polymer lift-off technique for the formation of patterned 
SLBs...........................................................................................................................44 
Figure 1.25: Aluminium lift-off technique for patterned SLB formation..... 46 
Figure 1.26: Patterned SLB formation via lipid polymerisation..................... 47 
Figure 1.27: Hydrogel stamping for the creation of patterned supported lipid 
bilayers.......................................................................................................................49 
List of Figures 
xvi 
Figure 1.28: Methods for forming supported lipid bilayer composition 
arrays......................................................................................................................... 51  
Figure 1.29: Droplet Interface Bilayer (DIB) definition.................................. 54 
Figure 1.30: Asymmetric droplet interface bilayer (aDIB) formation and the 
formation of droplet interface bilayer networks................................................. 56 
Figure 1.31: The falling drop method for high-throughput lipid bilayer 
formation.................................................................................................................. 58 
Figure 1.32: Black lipid membrane (BLM) approach for high-throughput lipid 
bilayer formation..................................................................................................... 60 
Figure 1.33: Hanging droplet screening chip using droplet interface bilayers 
(DIBs)........................................................................................................................61 
 
CHAPTER 2 
Figure 2.1: Molecular structure and excitation / emission spectra of 5(6)-
carboxyfluorescein.................................................................................................. 66 
Figure 2.2: Fluorescence properties of carboxyfluorescein (CF)................... 67 
Figure 2.3: Visualisation of carboxyfluorescein (CF) release from liposomes 
contained within a cuvette and viewed under an ultraviolet (UV) lamp........ 69 
Figure 2.4: Illustration of the steps involved in producing CF-encapsulated 
vesicles.......................................................................................................................73 
Figure 2.5: Separation of free carboxyfluorescein (CF) dye from CF-
containing vesicles via the principle of size exclusion....................................... 74 
Figure 2.6: Apparatus used to conduct interfacial surface tension (IFT) 
measurements.......................................................................................................... 77 
Figure 2.7: Determining equilibrium values for the interfacial surface tension 
(IFTeq)....................................................................................................................... 78 
List of Figures 
xvii 
Figure 2.8: Determination of the critical micelle concentration (CMC)...... 79 
Figure 2.9: Assay format...................................................................................... 81 
Figure 2.10: Carboxyfluorescein (CF) calibration curve................................. 82 
Figure 2.11: Column calibration.......................................................................... 84 
Figure 2.12: Control measurements.................................................................... 87 
Figure 2.13: Effects of three drugs (three repeats for each) on the efflux of 
carboxyfluorescein from DOPC vesicles (buffer only)..................................... 88 
Figure 2.14: The chemical motifs of imipramine, chlorpromazine and 
WAY.......................................................................................................................... 89 
Figure 2.15: Dependency of carboxyfluorescein (CF) leakage upon the 
introduction of chlorpromazine, WAY and imipramine................................... 91 
Figure 2.16: Comparison of the leakage data for chlorpromazine, WAY and 
imipramine with the data gained from interfacial surface tension 
measurements.......................................................................................................... 93 
Figure 2.17: Calibration of column 2.................................................................. 97 
Figure 2.18: Control investigating the effect of introducing DOPE into a 
DOPC bilayer upon the final fluorescence intensity......................................... 98 
Figure 2.19: Effect of introducing DOPE, into DOPC bilayers, upon the rate 
of carboxyfluorescein leakage............................................................................... 99 
Figure 2.20: Chemical motifs of DOPC and DOPE...................................... 101 
 
CHAPTER 3 
Figure 3.1: A typical plot of intensity versus time gained during a fluorescence 
lifetime experiment................................................................................................. 106 
Figure 3.2: Principle of time-correlated single-photon counting (TCSPC) used 
to extract information about the fluorescence lifetime..................................... 107 
Figure 3.3: Software used to create photomask designs................................. 112 
List of Figures 
xviii 
Figure 3.4: Processes involved in PDMS chip manufacture, using 
photolithography techniques................................................................................ 114 
Figure 3.5: Microfluidic chip assembly 1........................................................... 116 
Figure 3.6: Interfacing of the microfluidic chip with syringes........................ 117 
Figure 3.7: Device configuration for droplet formation................................. 121 
Figure 3.8: Screen dump of the software package, SPC Image, used to analyse 
the fluorescence lifetime data................................................................................ 122 
Figure 3.9: Carboxyfluorescein calibration curve gained using intensity 
measurements in a microfluidic format............................................................... 123 
Figure 3.10: The various control measurements conducted to ascertain which 
parameters, if any, may explain the shifted calibration curve........................... 125 
Figure 3.11: Summary of findings conducted using intensity measurements in 
a microfluidic format (“on-chip”) and compared to the measurements 
conducted on the fluorescence spectrophotometer.......................................... 126 
Figure 3.12: Carboxyfluorescein calibration experiment performed in a cuvette 
format (fluorescence lifetime)............................................................................... 127 
Figure 3.13: Carboxyfluorescein leakage assay performed using imipramine in 
a cuvette format (fluorescence lifetime data)...................................................... 131 
Figure 3.14: Fluorescence lifetime calibration measurements conducted in a 
microfluidic format and compared to experiments conducted in a bulk format 
/ literature values..................................................................................................... 134 
Figure 3.15: Optimisation of the flow conditions in a microfluidic device for 
performing the carboxyfluorescein leakage assay............................................... 136 
Figure 3.16: Comparison of the relative initial rates of change in the 
fluorescence lifetime and intensity measurements when 0.8 and 1.6 mM 
imipramine is introduced to carboxyfluorescein-containing vesicles.............. 139 
List of Figures 
xix 
Figure 3.17: Predicted lifetime values based on the theoretical concentration 
of carboxyfluorescein present in the interior regions of the vesicles after 
leakage induced by the presence of 0.8 and 1.6 mM imipramine.................... 142 
Figure 3.18: Comparison of leakage data gained in the cuvette and 
microfluidic formats................................................................................................ 144 
Figure 3.19: Static droplets adsorbed to the channel in a microfluidic 
device....................................................................................................................... 146 
 
CHAPTER 4 
Figure 4.1: Montal-Mueller method for the formation of artificial planar 
membranes............................................................................................................... 152 
Figure 4.2: Droplet Interface Bilayer (DIB) formation................................... 153 
Figure 4.3: Methods for forming droplet interface bilayers (DIBs), including 
asymmetric DIBs..................................................................................................... 155 
Figure 4.4: Experimental set-up for DIB experiments using manual 
manipulation............................................................................................................. 161 
Figure 4.5: Screen dump of the ImageJ software used for analysing 
fluorescence microscopy images........................................................................... 163 
Figure 4.6: Stills from Movie 4.1: ‘Formation of droplet interface bilayer 
(DIB)’........................................................................................................................ 165 
Figure 4.7: Experimental evidence for the formation of droplet interface 
bilayers (DIBs)......................................................................................................... 167 
Figure 4.8: DPhPC and DOPC for DIB formation........................................ 168 
Figure 4.9: Interfacial surface tension measurements of DOPC and 
DPhPC...................................................................................................................... 170 
Figure 4.10: Principle of DIB-leakage experiments.......................................... 172 
Figure 4.11: Carboxyfluorescein as a pH sensor for use in leakage experiments 
across DIBs.............................................................................................................. 173 
List of Figures 
xx 
Figure 4.12: Evidence for carboxyfluorescein leakage into the oil 
phase.........................................................................................................................  175 
Figure 4.13: Chemical structure of pyranine, 8-hydroxypyrene-1,3,6- 
trisulfonic acid (trisodium salt).............................................................................. 176 
Figure 4.14: Fluorescence properties of pyranine solutions........................... 177 
Figure 4.15: The dependence of pyranine fluorescence properties upon its 
concentration and pH in water............................................................................. 178 
Figure 4.16: Collated excitation spectra for serially diluted 1 mM pyranine 
stocks (in water) and in the presence of acidic and alkaline conditions......... 179 
Figure 4.17: First attempt at performing a DIB leakage assay, using a 60 µM 
aqueous pyranine solution (solution 4.11, pH 5.5, section 4.3.1.2)................. 181 
Figure 4.18: Dependency of excitation spectra on sample pH for 60 µM 
pyranine-containing solutions, plus control experiment................................... 183 
Figure 4.19: Observed relationships between the ratio of pyranine 
fluorescence intensity and time for different DIB systems (including 
control)...................................................................................................................... 185 
 
CHAPTER 5 
Figure 5.1: Devices for forming artificial lipid bilayers using 
microfluidics............................................................................................................. 192 
Figure 5.2: Droplet interface bilayer networks and their application............ 194 
Figure 5.3: EWOD for DIB formation............................................................. 195 
Figure 5.4: Current methods for using planar lipid bilayers in high-throughput 
screens....................................................................................................................... 197 
Figure 5.5: Method of device assembly.............................................................. 201 
Figure 5.6: First generation device used during preliminary investigations 
(devices 1-3)............................................................................................................. 201 
Figure 5.7: Schematic of the second generation device (device 4)................ 202 
List of Figures 
xxi 
Figure 5.8: Water-in-oil droplet formation using an auto-sampler................ 203 
Figure 5.9: Format of the fluorescein leakage assay......................................... 204 
Figure 5.10: Stills from Movie 5.1: ‘Small droplets filling the chamber in  
device 4’.................................................................................................................... 207 
Figure 5.11: Stills from Movie 5.2: ‘Large droplets filling the chamber in  
device 4’.................................................................................................................... 208 
Figure 5.12: Stills from Movie 5.3: ‘Formation of large droplet DIB network 
in device 4’................................................................................................................ 208 
Figure 5.13: Stills from Movie 5.4: ‘Formation of DIBs with DOPC using 
device 4’.................................................................................................................... 209 
Figure 5.14: Device 1.............................................................................................211 
Figure 5.15: Device 2.............................................................................................212 
Figure 5.16: Observations of potential on-chip DIB formation...................  213 
Figure 5.17: Device 3.............................................................................................214 
Figure 5.18:  First observation of stable DIB formation on-chip.................. 216 
Figure 5.19: Device 4 for high-throughput droplet interface bilayer (DIB) 
formation.................................................................................................................. 217 
Figure 5.20: Size variation of water-in-oil droplets.......................................... 218 
Figure 5.21: Examples of droplet interface bilayer (DIB) formed in high-
throughput................................................................................................................ 219 
Figure 5.22: Ability to tune droplet size, hence controlling droplet interface 
bilayer (DIB) contact area and the number of DIBs each droplet  
participates in........................................................................................................... 221 
Figure 5.23: Potential packing arrangements of droplets participating in 
DIBs.......................................................................................................................... 222 
Figure 5.24: Asymmetric DIB (aDIB) formation and fluorescein leakage assay 
showing successful DIB formation with DOPC................................................224 
List of Figures 
xxii 
Figure 5.25: Results of fluorescein control experiments................................. 225 
Figure 5.26: Formation of higher order a-DIBs............................................... 226 
 
CHAPTER 6 
Figure 6.1: Dosing system……………………………………………….. 230 
Figure 6.2: Effects of DLPC in hexadecane………………………...…… 234 
 
APPENDICES 
Figure A1.1: Column calibration.......................................................................... 237 
Figure A2.1: Experimental efflux data fitted to an exponential decay 
model......................................................................................................................... 240 
Figure A2.2: Control data confirming drug-dye interaction…………….... 241 
Figure A3.1: Column calibration 2...................................................................... 242 
Figure A4.1: Efflux of carboxyfluorescein from vesicle lumens upon the 
addition of chlorpromazine; dependence on mole percent of DOPE in a 
DOPC bilayer.........................................................................................................  244 
Figure A5.1: Efflux of carboxyfluorescein from vesicle lumens upon the 
addition of WAY; dependence on mole percent of DOPE in a DOPC 
bilayer........................................................................................................................ 245  
Figure A6.1: Efflux of carboxyfluorescein from vesicle lumens upon the 
addition of imipramine; dependence on mole percent of DOPE in a DOPC 
bilayer........................................................................................................................ 246 
Figure A7.1: The fluorescence lifetime gained for each of the ten solutions of 
carboxyfluorescein, present at different concentrations, based on the data 
provided in table A7.1............................................................................................ 247 
Figure A8.1: The change in fluorescence lifetime over time upon addition 
of imipramine to a DOPC vesicular solution (1.6 and 0.1 mM respectively, 
final concentrations), based on the data provided in table A8.1...................... 248 
List of Figures 
xxiii 
Figure A9.1: The change in fluorescence lifetime over time, based on the data 
provided in table A9.1 (above), of carboxyfluorescein-containing vesicles 
suspended in solution (DOPC, 0.1 mM see chapter 3, section 3.3.2.5) i.e.  
where no drug, solely buffer has been introduced............................................. 249 
Figure A10.1: The fluorescence lifetime gained for each of the ten solutions of 
carboxyfluorescein, present at different concentrations, based on the data 
provided in table A10.1.......................................................................................... 250 
Figure A11.1: The change in fluorescence lifetime over time upon addition of 
imipramine solutions (1.6 and 0.8 mM, final concentration) to a DOPC 
vesicular solution (0.1 mM, final concentration), based on the data provided in 
table A11.1................................................................................................................ 251 
Figure A12.1: The change in fluorescence intensity over time upon addition of 
imipramine solutions (1.6 and 0.8 mM, final concentration) to a DOPC 
vesicular solution (0.1 mM, final concentration)................................................ 253 
Figure A13.1: Bright field images of droplets 1-6............................................. 255 
Figure A14.1: Droplets 1 and 2............................................................................ 256 
Figure A14.2: Droplets 3 and 4........................................................................... 256 
Figure A14.3: Droplets 5 and 6........................................................................... 257 
Figure A14.4: Control droplets............................................................................ 257 
  
 xxiv 
List of Tables 
 
CHAPTER 3 
Table 3.1: The ten samples of carboxyfluorescein used to construct the 
calibration curves..................................................................................................... 119 
Table 3.2: The effect of propylene glycol on lifetimes of concentrated 
carboxyfluorescein.................................................................................................. 129 
Table 3.3: Summary of results regarding the optimisation of the aqueous 
(Aq1 and Aq2) and oil flow rates in the microfluidic device, used to perform 
the carboxyfluorescein leakage assay..........................................................................
 137 
Table 3.4: Theoretical concentration of carboxyfluorescein present in the 
interior and exterior regions of the vesicles after varying amounts of 
leakage....................................................................................................................... 142 
 
CHAPTER 4 
Table 4.1: Summary of the advantages that the droplet interface bilayer 
 system has over conventional methods for artificial planar bilayer 
 formation................................................................................................................. 154 
Table 4.2: Melting points of different solvents, including hexadecane......... 166 
 
APPENDICES 
Table A1.1: Column calibration data 1A............................................................ 237 
Table A1.2: Column calibration data 1B............................................................ 238 
List of Tables 
xxv 
Table A2.1: Table collating the different parameters associated with an 
exponential decay fit of the efflux data displayed in figure A2.1..................... 240 
Table A3.1: Column calibration data 2A............................................................ 242 
Table A3.2: Column calibration data 2B............................................................ 243 
Table A7.1:  Single exponential fit to carboxyfluorescein calibration data (in 
bulk), thus yielding the corresponding fluorescence lifetime (τ1) and χ2 
values......................................................................................................................... 247 
Table A8.1:  Single exponential fit to data gained during the 
carboxyfluorescein leakage assay, performed using imipramine (in bulk), thus 
yielding the corresponding fluorescence lifetime (τ1) and χ
2 values................ 248 
Table A9.1: Double exponential fit to control data, where the fluorescence 
lifetime of carboxyfluorescein-containing vesicles (DOPC, 0.1 mM see  
chapter 3, section 3.3.2.5) in solution is measured at various intervals during 
the time course of the experiment........................................................................ 249 
Table A10.1:  Single exponential fit to carboxyfluorescein calibration data  
(in a microfluidic format), thus yielding the corresponding fluorescence  
lifetime (τ1)................................................................................................................
 250 
Table A11.1:  Single exponential fit to the data gained when 
carboxyfluorescein leakage is induced by imipramine in a microfluidic 
format........................................................................................................................ 251 
Table A11.2:  Linear regression associated with the data displayed in figure 
A11.1......................................................................................................................... 252 
Table A11.3:  Linear regression associated with the data displayed in figure 
A11.1......................................................................................................................... 252 
Table A12.1: Fitted exponential decay associated with the data displayed in 
figure A12.1.............................................................................................................. 253 
List of Tables 
xxvi 
Table A12.2: Fitted exponential decay associated with the data displayed in 
figure A12.1.............................................................................................................. 254 
Table A13.1: Properties of droplets 1-6.............................................................. 255 
  
 xxvii 
Abbreviations 
 
aDIB  Asymmetric droplet interface bilayers 
ATP  Adenosine triphosphate  
BLM   Black lipid membrane  
CAD   Cationic amphiphilic drug 
CCT  CTP:phosphocholine cytidylyltransferase  
CES  Curvature elastic stress 
CF   Carboxyfluorescein 
CMC  Critical micelle concentration 
DEP  Dielectrophoresis 
DIB   Droplet interface bilayer  
diynePC  Diacetylene phospholipid 
DLPC  1,2-didodecanoyl-sn-glycero-3-phosphocholine 
DNA  Deoxyribonucleic acid 
DOPC  1,2-dioleoyl-sn-glycerolphosphatidylcholine 
DOPE  1,2-dioleoyl-sn-glycerolphosphatidylethanolamine  
DPhPC  1,2-diphytanoyl-sn-glycero-3-phosphocholine 
EWOD Electrowetting on dielectric 
FCC  Face-centred cubic 
FLIM  Fluorescence lifetime microscopy 
FM  Fluorescence microscopy  
FRAP   Fluorescence recovery after photobleaching  
GUV   Giant unilamellar vesicle 
HCP  Hexagonal close-packed  
HEPES  4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
IFT  Interfacial surface tension 
IFTeq  Equilibrium value of the IFT 
Abbreviations 
xxviii 
IPA  Isopropyl alcohol  
LPC  1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine / 
Lyso-phosphatidylcholine 
LUV  Large unilamellar vesicles 
µCP   Microcontact printing 
MDR1  Multidrug resistant protein  
NBD PE  Nitrobenzoxadiazol head group labelled 
phosphatidylethanolamine  
NMR  Nuclear magnetic resonance spectroscopy  
NSB Non-specific binding 
OA  Oleic acid  
PC  Phosphatidylcholine  
PCR   Polymerase chain reaction  
PDMS  Poly(dimethylsiloxane)  
PE  Phosphatidylethanolamine  
PEB  Post exposure bake 
PET Positron emission tomography 
PI  Phosphatidylinositol 
PMMA  Poly(methyl methacrylate) 
PMT  Photomultiplier tube  
PS  Phosphatidylserine  
PTFE  Polytetrafluoroethylene 
QCM-D  Quartz crystal microbalance with dissipation monitoring 
Rh PE 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine 
rhodamine B sulfonyl) (ammonium salt) 
RIE   Reactive ion etching 
ROI  Regions of interest 
SAXS  Small angle X-ray scattering 
SDS  Sodium dodecyl sulphate  
SGLT   Sodium-coupled glucose transporters  
SLB   Supported lipid bilayer 
SML Sterol-modified phospholipid 
Abbreviations 
xxix 
sulfo-SMCC Sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-
carboxylate 
SUV  Small unilamellar vesicle 
TCEP  Tris(2-carboxyethyl)phosphine hydrochloride 
TCSPC  Time-correlated single-photon counting 
TR DHPE  N-(Texas Red sulfonyl)-1,2-dihexandecanoyl-sn-glycero-3-
phosphoethanolamine 
TX-100 Triton X-100 
UV   Ultraviolet  
 
  
 1 
Chapter 1 
 
Introduction 
 
 
 
 
“The process of scientific discovery is, in effect, a continual flight from wonder.” 
Albert Einstein
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1.1 OVERVIEW 
The answer to the following question is fundamental in understanding the 
rationale behind the work detailed in this thesis:  
“Why do we wish to develop high-throughput technologies for the study of drug-membrane 
interactions?” 
Cell membranes are an elementary feature present in every cell of our body, 
acting as a barrier that separates the intra- and intercellular milieux. In order 
for a drug molecule to reach its site of action, it must pass many membranes. 
Therefore understanding how drug molecules interact with lipid membranes is 
crucial, if further insights into the factors affecting their translocation are to be 
gained. In the past, cell membranes were thought to fulfil merely a structural 
role, however lipids in cell membranes are now viewed as more than just 
simple building blocks, aiding the choreography of cellular tasks and 
influencing protein function.1 
It is therefore unsurprising that a wide variety of platforms are being developed 
for the formation of artificial lipid bilayers. Cell membranes are crucial to living 
organisms and so it is important to develop platforms, where studies of a 
biophysical nature can be conducted to probe questions on lipid (and protein) 
function.2 Biophysical assays that are able probe drug-membrane interactions 
in high-throughput will enable a picture to be formed, containing increasing 
levels of complexity using a bottom up approach.   
This chapter provides an overview of cell membranes, where their structure 
and function, as well as biophysical properties, are discussed. The interactions 
of drug molecules with lipid membranes are considered, as too are the current 
technologies available for studying the interactions of small molecules with 
membranes in artificial systems.   
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1.2 CELL MEMBRANES: AN OVERVIEW 
1.2.1 Structure and function of biological membranes 
Cell membranes are ubiquitous in living organisms and are composed primarily 
of a bilayer containing amphiphilic lipids3-6 and sterols,7-9  encompassing 
proteins (integral and peripheral), carbohydrates and a cytoskeletol network, as 
illustrated in figure 1.1. It serves to act not only as a means to 
compartmentalise and regulate the intracellular environment, segregating its 
contents from the outside milieu, but to perform and choreograph multiple 
fundamental tasks via sophisticated mechanisms.10-13 Many of the intricacies 
involved in these mechanisms, including the emergence of dynamic coupling 
between lipids and proteins,5,11 have only recently become better understood. 
For example, recent years have witnessed a large amount of debate and 
controversy within the literature surrounding the existence of lipid rafts in vivo, 
 
 
Figure 1.1: The cell membrane. Key features include the lipid bilayer, which 
possesses embedded proteins and intracellular cytoskeletol filaments.  
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or more pertinently microdomains,14-16 and their ability to confine protein 
binding17-19 thus facilitating processes such as signal transduction.20,21 This is 
one example demonstrating how the interaction of proteins with membranes, 
and vice versa, is an extremely complicated and challenging feat.  
In 1972, Singer and Nicolson expressed a revolutionary concept describing the 
dynamic structure of a cell membrane – The Fluid Mosaic Model.22 This was 
the first model to portray biomembranes as random “two-dimensional 
solutions of orientated globular proteins and lipids”,22 which has since been 
revised.23,24 It was suggested that the lipids must exist in a bilayer motif, with 
the hydrophilic (polar) head groups orientated towards the aqueous 
environment, the hydrophobic (apolar) tails groups orientated towards one 
another and the proteins spanning part (peripheral proteins) or all (integral 
proteins) of the membrane, in order to meet the thermodynamic requirements 
imposed by these amphiphiles (see figure 1.1). This enables the hydrophobic 
and hydrophilic portions of both the lipid and protein moieties to favourably 
arrange, such that their interaction with water is minimised or maximised (i.e. 
to fulfil the hydrophobic25 effect). The rationale behind Singer and Nicolson’s 
approach thus superseded previously reported models of membrane 
structure.26 
1.2.1.1 Membrane lipids 
Phospholipids are major constituents of cellular membranes, being amphiphilic 
in nature.27 There exists a vast diversity in the chemical structure of 
phospholipids, owing to the presence of numerous permutations of ‘head’ and 
‘tail’ assemblages; in fact, the eukaryotic cell generates more than 1000 lipid 
species.28,29 This melange is required in order to govern the numerous 
operations carried out at the molecular level in vivo.30  
There are four main classes of phospholipids present within living systems, 
specifically glycerophospholipids, lysophospholipids, sphingolipids and 
plasmologens.7 Figures 1.2 and 1.3 illustrate the chemical nature of these lipids. 
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It has been postulated by van Meer et al.,29 that the mammalian membrane is 
comprised of glycerolipids, sphingolipids and sterols – another important 
component of cellular membranes – in the following mole percent ratios: 
65 : 10 : 25 mol % respectively. Interestingly, they also provide an estimate as 
to the relative abundances of phospholipids and sterols in the membranes of 
various cell organelles, such as the plasma membrane, endoplasmic reticulum 
and golgi – the plasma membrane is expected to be the most relevant cellular 
membrane to the studies conducted in this thesis. Information concerning the 
identification and quantification of all lipids and their interacting moieties in 
mammalian cells is of great importance, for example with respect to furthering 
our understanding of lipid-based disease mechanisms, and forms a current 
focus of lipidomics. 
A class of enzymes known collectively as the phospholipases, of which there 
are four families (A1, A2, C and D),31-36 act to cleave phospholipids at specific 
sites. For example, lysophospholipids are generated as a result of 
phospholipase A2 catalytically cleaving the sn-2 fatty acyl bond of 
phospholipids (with the corresponding fatty acid also being generated).31 
The general motif of glycerophospholipids includes: i) a lipophilic backbone 
attached to glycerol via the sn-1 and -2 positions,3,4 and ii) a polar head group 
linked to the glycerol moiety via a phosphate group (figure 1.2). If phosphatidic 
acid is esterified at sn-1 and -2 an array of phosphatidyl (or diacylglycerol) lipids 
are produced, including phosphatidylcholine (PC), phosphatidylethanolamine 
(PE), phosphatidylserine (PS) and phosphatidylinositol (PI) (figure 1.2),5 most 
of which are found in varying compositions in different cell types.6 Numerous 
chain lengths can be incorporated at the -1 and -2 positions (a shorter chain 
length, i.e. C16-C18, is normally found in the sn-1 position). The most abundant 
mammalian lipid is phosphatidylcholine (PC),5 with phosphatidylethanolamine 
(PE) being the second most abundant.28,37 Alkylacylglycerols are produced 
when alcohols are incorporated at the sn-1 position, resulting in the production  
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Figure 1.2: Prime chemical motifs of glycerophospholipids. The generic structure 
of a glycerophospholipid is displayed, which consists primarily of a glycerol backbone, 
to which fatty tails and a phosphate carrying head group are attached. 
 
of an ether as opposed to an ester bonded unit. Alternatively, if an unsaturated 
alcohol is introduced at this position, a sub-class of the glycerolipids known as 
plasmalogens (alkenylacylglycerols) are formed.5 Various fatty acids 
incorporating cis double bonds may also be present at sn-2. 
Sphingolipids are a class of phospholipids that contain a sphingoid base, 
normally sphingosine, attached to a fatty acid (via an amide bond) and a 
phosphate-carrying headgroup.5 Figure 1.3 illustrates the chemical nature of the 
sphingolipids. Phosphocholine derived sphingolipids (sphingomyelin) and 
phytosphingosine (possessing an additional OH on C4 of sphinganine) are the 
most frequently found sphingolipids in nature.3 Other derivatives do exist 
including galactosylceramide, glucosylceramide and lactosylceramide. 
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Figure 1.3: Chemical structure of sphingolipids. The generic structure of a 
sphingolipid is displayed, which consists primarily of a glycerol backbone, to which a 
sphingoid base, fatty tail and a phosphate carrying head group are attached. 
 
The biophysical properties of sphingolipids are inherently different to those of 
glycerolipids. In particular, the 2-amide and 3-hydroxyl groups, present in the 
interfacial region of sphingolipids, function as both hydrogen bond donors and 
acceptors, whereas glycerolipids only have hydrogen bond-accepting properties 
in the analogous interfacial region.38 This property enables sphingolipids to 
self-associate with one another and results in the formation of more tightly 
packed lipid membranes that can be up to 30 % thicker than glycerolipids.38 
Additionally, the presence of a very long amide-linked chain, which leads to 
chain asymmetry, has been found to produce unusual phase behaviour, 
including interdigitated phases.39 
Sterols, another important class of molecules found in eukaryotic cell 
membranes, are much more hydrophobic than phospholipids and their rigid 
structure allows them to associate between the chains of adjacent lipid 
molecules in the bilayer.7 Being enriched in the plasma membrane, sterols acts 
to reduce the permeability of the membrane to small molecules due to the 
close packing of the lipids.29 
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Furthermore, sterols, such as cholesterol, play a crucial role in the membrane 
as phase moderators. Sphingolipids possess much higher melting temperatures 
than glycerolipids (generally above physiological temperatures),38 which could 
result in the formation of solid gel phase regions. Cholesterol has been found 
to bind preferentially to sphingolipids and therefore acts to fluidise the 
membrane by disrupting the long range chain order and increasing the 
molecular motion. The chain melting temperatures of the lipids used in this 
investigation have all been below room temperature, thus the temperature at 
which the investigations in this thesis have been conducted does not raise 
cause for concern. 
1.2.1.2 Asymmetrical lipid distribution in cell membranes 
The asymmetric distribution of phospholipids between the two monolayers of 
biological membrane was first recognised by Bretscher more than 30 years 
ago.40 The existence of asymmetrically distributed phospholipids within the 
lipid bilayer is of great importance, as displayed by the prevalent expression in 
eukaryotic and bacterial systems (though the presence of asymmetry in the 
latter case is less certain, most likely attributed to challenging experimental 
procedures). Boon and Smith41 cite numerous examples present in the 
literature detailing possible consequences with regard to loss of asymmetry: 
interruption of signal transduction pathways,42 induction of apoptosis43 and the 
regulation of hemostasis and thrombosis44 are a few examples illustrating the 
need for efficient maintenance of asymmetry across the plasma membrane. 
In order for lipid asymmetry to occur and consequently be maintained, a 
process must exist whereby the lipids have the ability to move from the outer 
leaflet of the lipid bilayer to the inner and vice versa. This translocation, or 
‘flip-flop’,45 is greatly dependent on the nature of the lipid head groups (such as 
the size and charge), possessing a half-life of hours to days.46 The rate of 
translocation however is significantly enhanced by the presence of a specialised 
set of proteins. 
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Aminophospholipid translocases (‘flippases’) specifically aid the stereospecific47 
movement of aminophospholipids from the outer to the inner lipid 
monolayer,44 displaying a high degree of head-group selectivity. Conversely, 
‘floppases’ aid the translocation of both choline- and aminophospholipids in 
the opposing direction to flippases;48 both proteins require the expenditure of 
cellular energy (i.e. they are both adenosine triphosphate (ATP) dependent). 
The third variety of membrane translocases, known as ‘scramblases’, act to 
scramble phospholipids in both the ‘flip’ and ‘flop’ directions thus destroying 
lipid asymmetry41 and has been found to be calcium dependant.49 
In addition to this hypothesis, a second theory regarding the origins of lipid 
asymmetry also exists. This believes that the cytoskeleton proteins interact with 
and influence the positioning of the inner leaflet lipids. It appears that there is 
evidence present in the literature both for and against this latter hypothesis, as 
detailed by Boon and Smith;41 although in hindsight a degree of both 
hypotheses may exist in reality. 
1.2.1.3 Proteins 
As previously mentioned both integral (transmembrane) and peripheral (receptor) 
proteins are key constituents of the cell membrane and are amphiphilic in 
nature. The former often traverse the lipid bilayer as a single α-helix, a β-barrel 
or multiple α-helices, acting as transporters of specific molecules (e.g. anions) 
or signals through the cell membrane.7 The latter may only be half embedded 
into the lipid bilayer or alternatively anchored to the membrane in a number of 
ways, performing tasks of recognition.27 
With respect to the drug development process, membrane proteins are 
important as they constitute the vast majority of drug target receptors. A great 
body of research is aimed at implementing lipidic bicontinuous liquid crystals 
to crystallise proteins,50 thus enabling one to gain an understanding of the 
molecular arrangements of their intrinsic tertiary and quaternary structures. 
Drug molecules can then be designed to specifically target the site of action. 
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However, other factors need to be taken into consideration, including the 
drugs’ ability to traverse biomembranes (such as the blood brain barrier,51,52 in 
the case of drugs targeting the brain and central nervous system). For example, 
our understanding of a drug’s interaction with biomembranes may help to 
elucidate which parameters may influence the degree of non-specific binding 
observed in vivo, thus targeting protein receptors with an increased efficacy.53-55 
 
1.2.2 Membrane biophysics  
The physical properties of biomembranes play a crucial role with respect to the 
regulation of cellular process. For example, the incorporation of certain types 
of lipid molecules can affect the activity of membrane proteins.56 Hence the 
particular composition of lipids present in the bilayer is non-trivial – the 
physical properties of biomembranes are discussed herein. 
1.2.2.1 Lipid mesophases 
Membrane lipid bilayers are biological examples of amphiphilic aggregates 
forming lyotropic liquid crystal mesophases in vivo, their formation driven by the 
hydrophobic effect (see section 1.2.1).25 The fluid lamellar phase, Lα, is 
represented by a one-dimensional stacking of the lipid bilayers in an aqueous 
environment, which is the fundamental foundation of all biological 
membranes.57 Over the years, researchers have studied various lipid-water 
model systems and established that several lipid mesophases can form in the 
presence of water, including the inverse hexagonal and inverse biocontinuous 
cubic phases.58,59 
It is thought that non-lamellar lipid mesophases aid processes such as 
membrane fusion during exocytosis and interbilayer connections; it is 
postulated that the inverse hexagonal and micellar phases aid various steps in 
the fusion of two lamellar bilayer membranes,60-63 which illustrates how cell 
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membrane function can depend upon the ability of biomembranes to adopt 
and negotiate various liquid crystalline mesophases.   
The total free energy of these lipid mesophases is dictated by three major 
factors, specifically: (i) the bending energy per unit area (or curvature elasticity, 
gc), (ii) the packing of the hydrocarbon chains (gp) and (iii) the interaction term 
(a combination of hydration and electrostatic forces, ginter).53,64 The total free 
energy can therefore be described as the sum of these components, as 
indicated by equation 1.1: 
erpctotal gggg int++=   Equation 1.1 
1.2.2.2 Membrane curvature and curvature elasticity (gc) 
The curvature of a membrane can be expressed mathematically, and aims to 
characterise a two-dimensional membrane that exists in three-dimensional 
space.65,66 The two principle curvatures, denoted c1 and c2, are required in order 
to provide a descriptive analysis of the curvature of a membrane and are equal 
to the inverse of their principle radii of curvature, R1 and R2 respectively (see 
figure 1.4).67  
 
Figure 1.4: The principle radii of curvature, R1 and R2 for a given surface. The 
principle curvatures, c1 and c2, can be gained by taking the inverse of R1 and R2 
respectively. The principle curvatures enable a descriptive analysis of the curvature of 
a surface to be made. Image reproduced from Seddon et al.53 
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The mean and Gaussian curvatures for a membrane can therefore be defined, 
as indicated by equations 1.2 and 1.3 respectively:65 
)(
2
1
21 ccH +=    Equation 1.2 
21 ccK ×=     Equation 1.3 
In order to assess the curvature elasticity per unit area of a lipid bilayer, the 
bilayer is first approximated to a single sheet of infinitesimal thickness. The 
deformation of this sheet will have an associated energy cost, which will be 
dependent on the changes in the mean and Gaussian curvatures.53 The 
‘Helfrich ansatz’ (equation 1.4) describes the curvature elastic energy per unit 
area for a membrane, which includes terms associated with the energy cost per 
unit area of changing the mean and Gaussian curvatures (the bending modulus, 
ĸ, and Gaussian modulus, ĸG respectively). The term, H0, describes the 
spontaneous mean curvature when the surface is relaxed. 
   KHHg Gc ×+−= κκ 20 )(2    Equation 1.4 
1.2.2.3 Lateral stress and spontaneous mean curvature 
The concept of lateral stress aims to give an indication as to the forces acting 
upon an amphiphile in the plane parallel to the membrane, thus providing a 
more complete understanding of their tendency to produce curvature. The 
distribution of lateral stresses will ultimately dictate the spontaneous mean 
curvature (H0): the induction of positive and negative spontaneous mean 
curvatures can be attributed to the non-uniform distribution of lateral stresses 
present at different depths within the membrane.1,67 Factors including 
electrostatic repulsions between head groups, hydrogen bonding and steric 
repulsions need to be taken into account in order to generate a good 
understanding of the forces acting upon and between lipids in lipid 
membranes. Figure 1.5 illustrates an example of a lateral pressure profile used 
to describe the attractive and repulsive pressures acting upon an amphiphile (π)  
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Figure 1.5: Lateral pressure profile of a lipid bilayer. The various lateral forces 
acting upon two lipid monolayers (i.e. a bilayer) at different depths in the membrane 
are detailed, as well as a lateral pressure profile demonstrating the attractive and 
repulsive forces present across the two monolayers. Diagram is based on the paper by 
Ces and Mulet.67 
in a membrane at differing depths (z). Importantly, this profile will vary 
depending on the nature of the amphiphiles included in the membrane. In 
order for a monolayer to reach a state of equilibrium, there must be no net 
pressure acting upon the membrane, hence the following equation holds: 
∫ = 0).( dzzπ      Equation 1.5 
Depending on the spontaneous mean curvature exhibited by a particular lipid 
aggregation in aqueous conditions, the lipid may be classed as Type 0, I or II. 
Type I (e.g. lysophospholipids)68 and Type II (e.g. 1,2-dioleoyl-sn-
glycerolphophatidylethanolamine, DOPE) lipids are known collectively as ‘non-
bilayer’ lipids, typically forming micellar and inverse hexagonal phases in water 
respectively (see figure 1.6 for illustration).63,67 Lipid aggregates formed form 
Type I and II lipids curve ‘away from’ or ‘towards’ the water interface 
respectively. This is a direct consequence of the lateral pressures acting upon 
the monolayer: Type I lipids exert a greater pressure in the head region than 
the tail region, with the converse argument being true for Type II lipids.69 Type 
0 lipids possess a spontaneous mean curvature that is approximately zero, 
owing to the exertion of approximately equal pressures in the head and tail 
regions, and are termed ‘bilayer’ lipids (see figure 1.6).   
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Figure 1.6: The spontaneous mean curvature (H 0) exhibited by Type 0, I and II 
lipid aggregates. This diagram illustrates the arrangement of lipid aggregates 
(monolayers) when composed of Type 0, I and II species and the spontaneous mean 
curvature they adopt. Diagram is based on the paper by Ces and Mulet.67 
 
The torque tension, τ, stored in a monolayer is described by the first moment 
of the lateral pressure profile (equation 1.6) and is non-zero.1 This is indicative 
of torque stored in a monolayer due to an imbalance of lateral stresses.1,67 
                ∫ ≠−= 0).(. dzzz πτ     Equation 1.6  
The torque that is stored within a monolayer is referred to as the stored 
curvature elastic stress.  
1.2.2.4 Stored curvature elastic stress 
Biomembranes generally exhibit fluid lamellar behaviour, yet are composed of 
many types of lipid. A packing frustration will inevitably ensue, as each 
monolayer ideally wishes to adopt its spontaneous mean curvature. This 
frustration is known as the stored curvature elastic stress.67,70 Figure 1.7 explains this 
physical phenomenon pictorially.  
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Figure 1.7: Curvature elastic stress (CES). (A) Schematic illustrating two 
monolayers that have adopted their relaxed curvature (theoretical situation). The 
presence of Type II lipids induces a negative spontaneous mean curvature. (B) The 
situation in A is energetically unfavourable, as a vacuum would form or the oily chains 
would be exposed to water. Hence the two monolayers couple back-to-back in order 
to fulfil the hydrophobic effect. The bilayer  possess stored curvature elastic stress as a 
result (b). Image based on reference 67. 
 
Situation ‘A’ represents the two monolayers exhibiting their preferred 
spontaneous mean curvatures. However, the generation of a vacuum and the 
need to maintain back to back coupling of the monolayers result in the 
situation presented in ‘b’; the ideal situation ‘a’ is energetically unachievable.  
There are many examples present in the literature where forces residing in the 
bilayer can influence biological processes.70,71 For example, the degree of 
curvature elastic stress stored within a membrane is important with respect to 
the maintenance of lipid homeostasis. The enzyme CTP:phosphocholine 
cytidylyltransferase (CCT) is regulated as a result of a feedback mechanism 
which senses the change in stored curvature elastic stress present in a 
membrane.1 This highlights the importance of phospholipids, functioning as 
cooperative entities and not mere structural building blocks. 
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1.3 DRUG-MEMBRANE INTERACTIONS 
As discussed in section 1.2.1, the lipid bilayer of cell membranes regulates the 
passage of molecules into and out of the cell. It is important to consider the 
mechanisms by which drug molecules can cross biological membranes. Hence 
this section provides an overview of the various modes of drug translocation, 
including passive and active transport. 
The drug molecules that have been tested in this thesis comprise one of the 
largest groups of drug molecules in the pharmaceutical industry – cationic 
amphiphilic drugs (CADs) – and specifically target the central nervous system. 
Their amphiphilic nature enables them to intercalate and therefore interact 
with biological membranes. The chemical composition of CADs facilitates this 
process; the presence of a secondary / tertiary nitrogen, their flat, planar, 
amphiphilic structures and low molecular weights – qualities closely related to 
Lipinski’s “rule of 5”72 – enables fast and efficient coupling to the membrane.  
Investigations in this thesis have utilised a subset of a group of drug molecules, 
specifically chlorpromazine, imipramine and WAY, which have very good 
specific binding ratios in vivo and well defined physiochemical properties.73 
These drugs have to reach their targets in the brain after translocation across 
many membranes. Their pharmacological targets include D2-dopamine and 5-
HT2 serotonin receptors and malfunctions of such systems have been closely 
linked to several disorders, including Parkinson’s disease, Huntingdon’s chorea, 
progressive supranuclear palsy (PSP), dystonia, tardive dyskinesia, 
schizophrenia and depression.74 
The drug-membrane investigations described in this thesis are fundamental 
studies, as the results of concentration-dependent experiments (Chapters 2 and 
3) do not intend to make physiological assertions. Rather they demonstrate that 
the novel technologies being developed in this thesis are suitable for 
investigating CAD-membrane interactions and drug translocation. The study 
of CAD-membrane interactions is of particular importance as little is known 
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about the molecular basis of non-specific binding of CAD molecules in vivo. 
Further understanding of this phenomenon will enable more accurate in vitro 
models to be developed, therefore reducing the in vitro-in vivo divide and better 
aiding the drug discovery process. 
1.3.1 Passive transport 
Passive transport refers to the mechanisms by which molecules are transported 
across biological membranes without the expenditure of cellular energy. The 
simplest mode of entry into a cell membrane is via simple diffusion, where the 
molecule to be transported travels down a concentration gradient from a 
region of high to low concentration (see figure 1.8). Small, hydrophobic 
molecules, such as oxygen and carbon dioxide, will rapidly traverse lipid 
bilayers. Small, uncharged polar molecules (water and urea for example) will 
permeate lipid bilayers to a lesser extent. Large, uncharged polar molecules (e.g. 
glucose) and those carrying a charge (e.g. ions, cationic drug molecules) will 
possess lower membrane permeabilities.7,53 
The electrical potential difference across a membrane is an additional factor 
that contributes to passive transport, specifically influencing the passive 
transport of molecules carrying a net charge across a biological membrane. 
Most plasma membranes possess an electrical potential difference, with the 
inside of the membrane being negative compared to the outside, thus 
favouring the passage of positively charged ions into the cell.7 The net driving 
force across a membrane can be calculated by coupling contributions due to 
the concentration and electrical gradients, yielding the electrochemical gradient.7 
Passive diffusion may also be facilitated by passive transporters, i.e. membrane 
proteins (section 1.2.1.2), to regulate the entry / exit of less permeable 
molecules. Passive transporters facilitate the transport of molecules down a 
concentration gradient. Transport is spontaneous and can occur through 
membrane channels (channel-mediated) or via a passive carrier-mediated 
transporter (carrier-mediated).7 Figure 1.8 illustrates the aforementioned 
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methods of passive transport. Anti-microbial peptides can be considered as 
passive transporters. They act by inserting themselves into bacterial cell 
membranes, thus creating aqueous pores and increasing membrane 
permeability via channel-mediated passive transport.75 For example, 
Gramicidin A forms β-barrel secondary structures upon insertion into a lipid 
bilayer, aiding the transport of ions and small molecules.75 
 
Figure 1.8: Passive transport. Diagram illustrating the classical modes by which 
molecules are transported across cell membranes in a passive manner. This includes 
simple diffusion, in addition to channel- and carrier-mediated transporters. 
 
Carrier-mediated passive transporters interact with the molecule to be 
transported, binding a specific solute of interest and undergoing a series of 
conformational changes to transfer the molecule across a lipid bilayer. 
 
1.3.2 Active transport 
Active transporters require an expenditure of cellular energy to pump 
compounds against a concentration gradient.7 Adenosine triphosphate (ATP)-
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driven pumps use chemical energy from the hydrolysis of ATP to transport 
molecules against concentration gradients. This process is known as primary 
active transport and transports molecules directly across a lipid bilayer using 
uniporters, as illustrated in figure 1.9. The multidrug resistant protein (MDR1), 
also known as P-glycoprotein, is an example of an ATP-dependant active 
efflux pump.76 This membrane transporter seeks to actively pump molecules, 
often lipophilic drugs directed for action in the brain and central nervous 
system, back into the blood stream.77  
 
Figure 1.9: Active transport. Diagram illustrating the classical modes by which 
molecules are transported across cell membranes in an active manner, i.e. requiring the 
expenditure of cellular energy. This includes facilitated transport of molecules against 
a concentration gradient by uniporters, symporters and antiporters (the former is an 
example of primary active transport, with the latter two being examples of secondary 
active transport). 
 
Secondary active transport involves the coupling of a second species to the 
transport of the primary species, hence providing the energy for the membrane 
transport. The secondary substrate may be translocated in the same direction 
as the primary species by symporters, such as the sodium-coupled glucose 
transporters (SGLTs).78 Proteins that transport secondary species in a direction 
anti to the primary species are called antiporters, such as the sodium-calcium 
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(Na+-Ca2+) exchanger.79 This protein drives calcium from the cell (against the 
concentration gradient) by using the opposing movement of sodium ions. 
Figure 1.9 illustrates the methods of primary and secondary active transport. 
 
1.3.3 Drug translocation via membrane degradation 
Baciu et al.54 have proposed a new mechanism of drug translocation across 
model membranes composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(DOPC). In contrast to both passive and active translocation (sections 1.3.1 
and 1.3.2) this mechanism displays a degradative component. Cationic 
amphiphilic drugs (CADs) have been found to chemically degrade model 
membranes in a catalytic manner to form water soluble micelles carrying drug 
molecules via an acid catalysed ester hydrolysis. 
Experimental studies have investigated the degradation of model DOPC 
membranes by CADs (haloperidol and spiperone) in a physiological buffer 
using several techniques, including: small angle X-ray scattering (SAXS), 
nuclear magnetic resonance spectroscopy (NMR) and fluorescence microscopy 
(FM). In summary, experimental data gained from both SAXS and NMR 
experiments, employing mixtures of buffer, CAD and phospholipid, indicate 
the presence of the degradation products 1-oleoyl-2-hydroxy-sn-glycero-3-
phosphocholine (LPC) and oleic acid (OA). Addition of CADs to 
electroformed giant unilamellar vesicles (GUVs) visually demonstrates the 
degradation of phospholipid membranes to form membranous fragments.  
The experimental data has therefore led to the proposal of the following 
mechanism for the mode of action of CADs on model membranes (depicted 
in figure 1.10). Initially, the CAD is incorporated into the interfacial region of 
the membrane (step 1), as indicated by the SAXS data (and to a certain extent 
the FM data). The chemical composition of CADs facilitates this process; the 
presence of a secondary / tertiary nitrogen, their flat, planar, amphiphilic 
structures and low molecular weights enables fast and efficient coupling to the 
Chapter 1 
21 
membrane. These qualities relate closely to Lipinski’s “rule of 5” – a model 
based on structural features proposed to predict the efficiency of drug 
translocation (with respect to solubility and permeability).72 
The CAD molecules redistribute between both leaflets of the membrane (step 
2), subsequently resulting in an acid catalysed ester hydrolysis of DOPC to 
form LPC and OA (step 3). The formation of LPC and OA thus induces the 
desire to exhibit positive and negative curvatures respectively (section 1.2.2.3), 
resulting in the formation of micellar species / small vesicles carrying CAD 
molecules (step 4).55 Steps 3 and 4 are substantiated by the SAXS and NMR 
spectroscopy data, which indicate the presence of both micellar and inverse 
hexagonal phases.80 It is postulated that these micelles are then able to fuse into 
further membranous species, where the process is repeated. 
 
 
Figure 1.10: Diagram illustrating the mechanistic implications of membrane 
degradation. Drug molecules are incorporated into the interfacial region of the 
membrane (step 1) and redistribute between both leaflets of the membrane (step 2). 
This results in an acid catalysed ester hydrolysis of DOPC to form the degradation 
products LPC and OA (step 3). Consequently, micellar species / small vesicles are 
formed that carry drug molecules (step 4). Images reproduced from paper by Sebai et 
al.54 
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1.4 HIGH-THROUGHPUT TECHNOLOGIES FOR THE STUDY OF 
DRUG-MEMBRANE INTERACTIONS 
Within the scope of this thesis, the careful manipulation of fluids on the 
microscale (i.e. microfluidics) and droplet interface bilayer (DIB) technologies 
provide platforms upon which the interaction of pharmaceutical agents with 
model lipid membranes may be investigated. It is the further use of 
microfluidic technologies, coupled with the interfacing of DIB technologies 
with microfluidic systems, which will lead to the aspiration of producing high-
throughput drug-membrane assays, a premise which is at present highly 
desirable in relation to the pharmaceutical industry. Herein, the major 
technologies that are currently available for the study of drug-membrane 
interactions in a high-throughput format are reviewed, including microfluidic, 
supported lipid bilayer and DIB technologies.  
 
1.4.1 Microfluidics 
1.4.1.1 Introduction 
Over the last two decades microfluidic manipulation of fluids on the micro-
scale (i.e. 10-9 to 10-18 litres) has become highly desirable in the biological, 
chemical and medical sciences.81-92 Development of microfluidic technologies 
has continued, owing to the desirable features that are afforded with system 
miniaturisation. For example, microfluidic technologies enable small fluid 
volumes to be manipulated with ease, are associated with low production costs, 
yield reduced instrumental footprints owing to their small size, afford 
enhanced analytical performances and enable thousands of samples to be 
sampled per second.93 Droplet-based microfluidics offers further advantages, 
as discrete and monodisperse experimental compartments are afforded.94 
Therefore the opportunity to perform quantitative analyses on single molecules 
and cells is presented, as is the opportunity to perform large numbers of 
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experiments. Furthermore, high-throughput analysis of systems in parallel have 
emerged as a direct consequence, enabling DNA analysis and the possibility for 
pharmaceutical screening and drug discovery to be conducted on a single 
microfluidic chip.95,96 Figure 1.11 illustrates an example of a microfluidic 
device.88,97 
 
 
Figure 1.11: An example of a microfluidic device. The device has been 
photographed next to a one dime coin in order to provide an indication of its relative 
size. Image reproduced from the papers by Balagaddé et al.97 and Whitesides et al.88 
 
Microfluidic devices are typically made from poly(dimethylsiloxane) (PDMS). 
PDMS is often used as it has many desirable characteristics. These include the 
following:  
(i) It is a low cost material;85 
(ii) It is gas permeable and therefore oxygen can be supplied to cells 
contained within PDMS devices, for example;98 
(iii) It can successfully translate features, with a resolution of less than 100 
nm;99 
(iv) It is optically transparent between 240-1100 nm;99 
(v) It is chemically inert and nontoxic;99,100 
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(vi) It can be bonded reversibly and irreversibly to glass and PDMS substrates 
(irreversible bonding is achieved by subjecting the PDMS to an air or 
oxygen plasma);101-103  
(vii) It can be deformed easily and reversibly, as it is an elastomeric material, 
therefore enabling valves and pumps to be incorporated into device 
designs.104,105 
1.4.1.2 Laminar flow in microfluidic systems 
Within microfluidic systems, the underlying physics is quite different to that on 
the macroscale. Devices on the micro-scale exhibit primarily laminar flow 
qualities, controlled diffusion and high surface area / volume ratios.106 The 
distinction between turbulent and laminar flow can be characterised by use of 
the Reynold’s number, Re, which defines the ratio of inertial to viscous forces. 
Equation 1.7 is used to calculate the Reynold’s number, which is dependent 
upon the following parameters: the fluid density (ρ), velocity (υ), viscosity (µ) 
and the hydraulic diameter (Dh).106,107 
µ
ρν h
e
D
R =     Equation 1.7 
Importantly, when Re < 2300, viscous forces will dominate and the transition 
from turbulent to laminar flow will occur. Figure 1.12 A and B illustrate 
examples of systems dominated by laminar (Re < 2300) and turbulent (Re > 
2300) flow regimes respectively.106,108 Laminar flow is often advantageous, as 
multiple streams flowing parallel to one another will not mix in a turbulent 
fashion, hence inter-stream mixing will only occur by controlled diffusion. 
Droplet generators often use multiple laminar streams to vary the composition 
of the aqueous phase in a controlled manner, meaning that the contents of 
each discrete droplet produced is controlled and flexibility is afforded by the 
microfluidic platform. The combination of multiple laminar flows in this 
manner, however, may appear detrimental, as mixing can only occur slowly via 
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diffusive transport. The introduction of snake-like channels ensures that rapid 
mixing ensues by chaotic advection.109 
 
 
Figure 1.12: Laminar and turbulent flow. The diagrams illustrate examples of 
systems dominated by: (A) laminar (Re < 2300) and (B) turbulent flow regimes (Re > 
2300).110 
 
1.4.1.3 Segmented flows 
Rather than flowing fluids through microfluidic channels using a single-phase, 
continuous format, a segmented flow is often adopted in order to eliminate 
problems associated with dispersion of the reaction mixture.111-113 Figure 1.13 A 
illustrates the occurrence of this spreading effect. Segmented flow is achieved 
by creating discrete microdroplets that are carried by an immiscible “carrier 
fluid” through a microchannel. Each droplet acts as an individual experimental 
vessel, with the interaction of each discrete droplet with the walls of the 
microchannel being minimised, hence reducing loss of reagents and cross-
contamination. Figure 1.13 A and B illustrate the differences between 
continuous and segmented flow microfluidics. 
Droplet formation is also advantageous as it enables rapid, efficient and 
reproducible mixing to occur inside each microdroplet.111 Furthermore, as 
thousands of droplets may be produced per second using this technique, it also 
means that large data sets can be collected therefore enabling more 
sophisticated statistical analyses to be performed.  
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Figure 1.13: Continuous versus segmented flow. (A) Continuous flow format, 
comprised of reagents carried in a miscible phase (i.e. a single phase). It can be 
observed that the two reagents (1 and 2) suffer from Taylor dispersion (see the box 
labelled “spreading effect”), consequently mixing and forming a new compound (3). 
Additionally, the channel edges become spoiled by both reagents, resulting in cross-
contamination as well as loss of reagent (represented by the green lines). (B) 
Segmented flow format, comprised of discrete microdroplets carried in an immiscible 
phase (i.e. two phases). As microdroplets are discrete reaction vessels they do not 
suffer from Taylor dispersion nor is cross-contamination / loss of reagent to the 
microchannel an issue. Image reproduced from the paper by Casadevall i Solvas et 
al.112 
 
 
1.4.1.4 Methods for forming microfluidic droplets 
This section will consider the formation of water-in-oil droplets only, as this is 
the format most relevant to this thesis. Other types of droplet systems can be 
created, for example oil-in-water and gas-liquid dispersions.114 
It should be noted that the first realisation of segmented flow was achieved 
using a capillary flow.112,115 However, the major methods used to generate 
water-in-oil droplet formation in a planar chip format include: (i) T-
junction113,116,117 and (ii) flow focusing.118 
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Figure 1.14 A illustrates the T-junction method.113,116,117 The name originates 
from the fact that oil and aqueous streams are brought into contact with one 
another at a “T” junction. Depending on the delicate balance between the oil 
and aqueous flow rates, the two phases will meet and the aqueous phase 
segmented. Consequently, water-in-oil droplets are formed. Importantly, 
surfactant molecules are incorporated into in the oil stream (carrier fluid) to 
stabilise the oil-aqueous interface and hence prevent the droplets from 
coalescing.  
 
 
Figure 1.14: T-junction technique for the formation of microdroplets in a planar 
chip format (i.e. segmented flow). (A) A generic representation of the set up, where 
channels, carrying oil and aqueous streams, meet at a “T” junction. At this point the 
aqueous flow can be segmented. (B) An example of a microfluidic device possessing a 
T-junction for droplet formation. Several aqueous streams can be focussed onto the 
oil stream by making use of laminar flow. Winding, snake-like channels are 
incorporated to aid mixing of the droplet contents. This image has been reproduced 
by the paper by Bringer et al.119 
 
More than one aqueous stream can be brought into contact with the oil carrier 
fluid if desired, as illustrated in figure 1.14 B. Here the properties of laminar 
flow have been exploited to control the composition of the aqueous input. 
Often snake-like channels are incorporated into the channel design shortly 
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after the point at which droplet formation occurs to aid mixing of the droplet 
contents via chaotic advection. The device displayed in figure 1.14 B illustrates 
an example of the mixing process. 
The second method that can be used to create a segmented aqueous flow of 
water-in-oil droplets is the flow focusing technique.118 The basic principle 
behind this technique is illustrated by figure 1.15 A. Three microchannels 
(labelled 1-3, figure 1.15 A) convene at a central point in the device. Fluids 
flowing through these microchannels, towards the meeting point, then exit  
 
 
Figure 1.15: Flow focusing technique for the formation of microdroplets in a 
planar chip format (i.e. segmented flow). (A) Schematic illustrating the general 
setup that is required in order to form a segmented flow using the flow-focusing 
technique. (B) An example of a real microfluidic chip that is designed to enable 
droplet formation using the flow focusing technique. (C) A series of images illustrating 
the formation of a single droplet using the device detailed in B. Images B and C have 
been reproduced by the paper by Anna et al.118 
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through an orifice into a fourth microchannel (labelled 4 in figure 1.15). 
Specifically, two oil streams (denoted by 2 and 3 in figure 1.15 A) flow towards 
the central point, i.e. in opposing directions to one another. These are used to 
‘focus’ a third stream – the aqueous stream (denoted by 1 in figure 1.15 A) – 
that meets two oil streams flowing through channels 2 and 3 (figure 1.15 A). 
As a result, the focussed aqueous stream flows through the orifice and into 
channel 4 (figure 1.15 A), where the aqueous stream is segmented and forms 
discrete microdroplets (again under optimum conditions). Figure 1.15 B 
illustrates a real example of a microfluidic chip that utilises the flow focusing 
technique for droplet generation: the three channels, that are to contain the oil 
and water streams, are denoted and the central point, where the trajectories of 
each flow meet, can be viewed. Figure 1.15 C provides a series of successive 
images, illustrating how a single droplet is formed using the flow focusing 
technique (using the device depicted in figure 1.15 B).  
1.4.1.5 Droplet manipulation 
After having generated a series of microdroplets, either by using the T-junction 
or flow focusing techniques in a planar chip format, there may be other 
operations that the researcher may wish to perform. The following operations 
are currently available and can be used to manipulate droplets, forming the 
extremely handy droplet “tool kit”: 
 
(i) Droplet merging. Either “active” processes (such as electrocoalescence, 
see figure 1.16 A)120 or passive processes (see figure 1.16 B)121 can be used 
to control the fusion of droplets. The passive process cleverly uses 
strategic variations in channel geometry to control fluid flow and hence 
droplet merging;  
(ii) Droplet splitting.122 As a result of introducing droplets to a T-junction 
(figure 1.16 C), droplets can be broken up in a passive manner. It can be 
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observed from figure 1.16 C that each initial plug is subsequently split up 
into eight smaller droplets. 
(iii) Droplet storage. Droplets may be stored for a period of time in delay 
channels,123 traps124,125 and reservoirs,126 as illustrated in figure 1.15 D, E 
and F respectively;  
(iv) Droplet sorting.127,128 Figure 1.16 G illustrates that droplets can be sorted 
by applying an electric field, which generates a dielectrophoretic force and 
attracts the droplets (1 = no electric field applied, 2 = electric field 
applied). 
 
Figure 1.16: Operations that can be performed on droplets after having been 
generated. (A) Active droplet merging, e.g. by electrocoalescence.120 (B) Passive 
droplet merging.121 (C) Droplet splitting.122 (D) Storage of droplets in microfluidic 
channels.123 (E) Storage of droplets in trapping devices.124,125 (F) Storage of droplets in 
reservoirs.126 (G) Sorting of droplets, by using dielectrophoretic manipulation.127 
Images have been reproduced from the respective papers. 
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1.4.1.6 Microfluidic technologies amenable for investigating drug-membrane 
interactions 
The preparation of homogenous populations of small unilamellar vesicles 
(SUVs, 50-200 nm in diameter) using manual methods (e.g. extrusion methods) 
can be achieved very easily and is a popular choice of assay format for the 
investigation of exogenous species upon model lipid membranes. More 
recently, however, there have been developments in microfluidic technology 
that allow the generation of SUVs using flow focusing techniques.129,130 These 
techniques are advantageous as the ability to control the diameter of a 
monodisperse population of SUVs in a precise manner is highly desirable (for 
example, to investigate the effect of membrane curvature on a system).67 
Moreover, such developments will enable both SUV synthesis and 
measurement to be conducted simultaneously on a single chip, thus increasing 
the high-throughput capabilities of the technique. Notably, SUV assays have 
not been performed in a microfluidic format to date. Hence part of the work 
presented in this thesis has sought to demonstrate that SUV assays can be 
translated into a microfluidic format, as detailed in chapters 2 and 3.  
Giant unilamellar vesicles (GUVs, on the order of 1-200 µm in diameter) are 
also popular model systems for investigating an expansive range of biological 
events in real time.131,132 The formation of GUVs, however, is a much more 
elusive process: traditional methods for forming GUVs, which includes 
swelling of dried lipid films with aqueous solutions,133,134 solvent evaporation135 
and electroformation136,137 rarely produce sufficient numbers of vesicles in the 
micrometer range and do not yield monodisperse populations. Attempts have 
been made to use microfluidic technologies for the formation of GUVs, via 
the electroformation technique.138,139 These attempts have been successful in 
generating a plentiful supply of GUVs in solutions of high ionic strength, 
which is important if physiological conditions are required and often difficult 
to achieve in non fluidic systems. However, the major problems associated 
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with each of these techniques include the inability to control the 
monodispersity and lamellarity of the GUVs.  
Several methods exist for the formation of monodisperse populations of giant 
unilamellar vesicles, which include: (i) the “lipid-coated ice droplet hydration 
method”,140 (ii) GUV formation by inkjet printing141,142 and (iii) GUV formation  
 
 
Figure 1.17: High-throughput formation of monodisperse, unilamellar GUVs 
using microfluidics. (A) The steps involved in generating a GUV. First a plug of 
water, followed by a plug of oil (containing lipids), followed by another plug of water 
are introduced into a microchannel and flow over small chambers that form T-
junctions with the main channel (1) – the air is squeezed out of the small chambers 
during this process through the PDMS walls (2). A lipid monolayer forms at the first 
interface (water-oil, see 3), with a second monolayer forming at the second interface 
(oil-water, see 4). The fluid stream that crosses each of the T-junctions draws the lipid 
film out of the small chamber (5), further thinning the bilayer as it protrudes (6). A 
small PDMS post aids vesicle formation (7). An air bubble is generated in a large 
chamber (connected to the small chambers), using a laser spot, in order to aid the 
gentle outward flow of the protruding bilayer film (8). (B) Images 1-3 illustrate the 
formation of a single GUV that contains fluorescent calcein. (C) Fluorescence image 
of several GUVs generated using this technique. Note that the scale bars in B and C 
represent 20 µm. Images reproduced from Ota et al.143 
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using microfluidic T-junctions (figure 1.17).143 The latter two techniques are 
highly advantageous, as populations of unilamellar GUVs can be produced (i.e. 
those that consist of a single-walled lipid bilayer) in a high-throughput manner. 
Frequencies of up to 200 Hz can be attained using these two methods,141 
though only the method by Ota et al.143 uses microfluidics for GUV formation. 
Figure 1.17 illustrates the process that is undertaken to produce single-walled, 
monodisperse solutions of GUVs in high-throughput. 
Importantly, microfluidic devices have also been used to investigate the 
permeability of drug- and other biomolecules across more complex membrane 
systems. For example, researchers have looked at drug permeability across the 
endothelium, where cells have either been trapped in microhole arrays144 or cell 
cultures grown in the actual device.145 The latter study highlights the 
importance of simulating experimental conditions that represent the natural 
environment, accounting for factors such as the shear-stress, which affects 
drug uptake across cardiovascular endothelial cells.145 
More recently, researchers at Harvard University have developed a novel 
device, coined a “lung-on-a-chip” device.146 The device is made from 
micropatterned PDMS and consists of three layers sandwiched together: a 
porous membrane and upper / lower layers, as illustrated in figure 1.18 A and 
B. Human epithelial and endothelial cells are cultured on either side of the 
porous membrane, which is coated with extracellular matrix, and supplied with 
nutrients / cells using directed microfluidic flow. In order to simulate the 
breathing action imposed on the cells by the action of the lung, a vacuum 
pump is used; importantly, the inherent elasticity of PDMS means that it is able 
to withstand the change in pressure and hence replicate the process of 
‘breathing’ in an analogous manner to a lung (see figure 1.18 C). This research 
demonstrates that immune responses can be triggered upon the introduction 
of bacteria, as well as the induction of inflammation upon the introduction of 
toxins, and importantly suggests that such platforms can be used to screen for 
drug-responses and efficacy on the cellular level.146 This research will no doubt  
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Figure 1.18: Development of “lung-on-a-chip” devices. (A) Here the nature of the 
device is illustrated, which is comprised of three PDMS layers, one of which contains 
micropores. The scale bar represents 200 µm. (B) Illustrates a photograph of the 
device. (C) These images demonstrate how the device is able to ‘breath’ upon the 
application/removal of a vacuum, thus mimicking the environment found in a lung. 
Epithelial cells are cultured on one side of the porous membrane and endothelial cells 
on the other. The images have been reproduced from Huh et al.146 
 
lead the way in the development of more sophisticated “organ-on-a-chip” 
devices, resulting in advances in drug discovery. 
Notably, the advent of droplet-based microfluidics has also enabled the 
polymerase chain reaction (PCR) to be performed in a microfluidic format, 
which is highly desirable to the pharmaceutical industry.123 Ultimately, one can 
envisage amplifying a specific region of DNA, encoding for a specific protein 
of interest, coupled with the online in vitro expression of that protein. If one 
could amplify numerous mutated versions of the DNA sequence in parallel, 
thus inducing random mutations in the expressed protein structures, one could 
also screen for potential inhibitors / promoters of that protein. Droplet-based, 
high-throughput technologies have also played an important role in controlling 
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protein crystallisation, crucial for structure based drug-discovery, as well as 
furthering our understanding of the variables involved in the process.147 
Additionally, kinetic measurements can be easily performed using droplet 
technologies, which in turn can reveal important information about a drug’s 
behaviour.148  
In summary, this section has introduced the topic of microfluidics and has 
highlighted many examples of current microfluidic platforms that can be used 
to monitor the effect of drug-membrane interactions and are applicable to the 
pharmaceutical industry. The following section will consider a relatively new 
technology, namely supported lipid bilayers (or SLBs), which has created 
further opportunities for probing the interaction of various species with model 
membranes.149 
 
1.4.2 Supported lipid bilayers (SLBs) 
A supported lipid bilayer (SLB) can be defined as “a single, continuous 
phospholipid bilayer” that is supported on a substrate of choice,150 such as 
glass,151,152  mica,153 titanium dioxide154 or PDMS,155-158 via physical interactions 
existing between the support and bilayer.159 Figure 1.19 illustrates the nature of 
an SLB, formed by introducing a vesicle population to a solid support. 
 
Figure 1.19: Supported lipid bilayer. (A) Population of vesicles. (B) Supported lipid 
bilayer (SLB) formed by introducing vesicles to a solid support. 
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SLBs have been used extensively to model biological membranes in milieux 
that can be manipulated and designed to suit the problem at hand; an 
intriguing example involves using SLBs to aid the design of biointeractive 
interfaces on titanium oxide, a biocompatible material often used in implant 
technology.160  
1.4.2.1 Formation of supported lipid bilayers 
Section 1.4.2.2 will consider solely solid-supported lipid bilayers, although a 
variety of surface confined membrane models exist:161-163 polymer-cushioned 
lipid bilayers,164-168 hybrid bilayers (i.e. a self-assembled monolayer coupled to a 
lipid monolayer),169,170 tethered lipid bilayers,171 freely suspended lipid bilayers172 
and supported/tethered vesicular layers173,174 are the major examples detailed in 
the literature (see figure 1.20). Polymer-supported bilayers incorporate a  
 
 
Figure 1.20: Approaches used to deposit fluid phospholipid bilayers upon a 
substrate. (A) solid-supported lipid bilayer, (B) polymer-cushioned lipid bilayer, (C) 
hybrid bilayer (consisting of a self-assembled monolayer and a lipid monolayer), (D) 
tethered lipid bilayer, (E) freely suspended lipid bilayer, (F) and (G) supported 
vesicular bilayers. Diagram reproduced from Richter et al.161 
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polymer film that is deposited onto the substrate to act as a soft cushion and 
functioning in an analogous manner to that of the cytoskeletal network.175 
Interestingly, Johnson et al.165 have employed both solid supported and 
tethered egg phosphatidylcholine monolayers, incorporating the protein 
ponticulin, to assemble an in vitro actin cytoskeletal scaffold upon the 
supported lipid bilayer. Deposition of polymeric material onto substrates to 
support phospholipid bilayers is particularly advantageous if transmembrane 
proteins are to be reconstituted into lipid bilayers. Often proteins can become 
immobilised and thus denatured, as a result of unfavourable protein-substrate 
interactions, if solely water is the medium residing between the supported 
bilayer and substrate.166 
Importantly, the lipid bilayer must retain its fluid nature after deposition onto a 
solid support, thus maintaining the dynamic and structural properties of a 
biomembrane. Typically a thin layer of water, 10-20 Å in thickness (as 
determined by specular reflection of neutrons),176 resides between the substrate 
and bilayer, to exclude the occurrence of inhibiting interactions. Fluorescence 
recovery after photobleaching (FRAP) measurements are often used to assess 
the lateral fluidity of the deposited lipid bilayers.177 
In 1984, Brian and McConnell instigated a method to deposit a single 
supported lipid bilayer upon a hydrophilic solid support; their technique 
involved flowing a solution of small unilamellar lipid vesicles (SUVs) over the 
substrate of choice.178 The formation of an SLB is generally considered to 
comprise of two main steps: (i) adhesion of SUVs to the substrate followed by 
spontaneous rupture and (ii) coalescence of these bilayers to form the 
SLB.161,179 Understanding the mechanisms of and factors influencing vesicle 
adsorption and rupture, to form a single continuous bilayer, has contributed 
largely to the advancement of SLB technologies over the last 10 years; a 
coherent review is afforded by Richter et al. and should be consulted for 
further information.161 In summary, the lipid deposition pathway chosen to 
form SLBs is largely governed by the interplay between: (i) the bilayer and 
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substrate, (ii) interbilayer interactions and (iii) intrabilayer interactions. The 
contribution provided by each of these effects to enable successful bilayer 
deposition is greatly dependent upon numerous parameters, including: the 
nature of the substrate;161 vesicle composition, charge, size, physical state and 
concentration;180 the aqueous environment;181 and, the presence of ions.182,183 
Quartz crystal microbalance with dissipation monitoring (QCM-D) is a 
powerful technique, which has enabled the determination of the lipid 
deposition pathways of vesicles and hence furthers the understanding of 
vesicle rupture mechanisms and SLB formation. For example, if the adsorbed 
vesicle remains intact, a high dissipation is observed. Conversely, if the 
adsorbed vesicle has ruptured, resulting in SLB deposition, a low dissipation is 
observed.161 Figure 1.21 illustrates the various mechanisms of vesicle rupture 
that result in SLB formation, as determined using this method. 
 
 
Figure 1.21: Diagram illustrating the various mechanisms of vesicle rupture to 
yield SLB formation. (A) The spontaneous rupture of alone vesicle, (B) adjacent 
vesicle fusion followed by vesicle rupture, (C) induced vesicle rupture by the active 
edge of an SLB, (D) vesicle fusion occurrence at critical vesicular coverage 
cooperative action. Note that the illustration is not to scale and is based on the figure 
detailed in the paper by Richter et al.161 
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Cremer and Boxer have noted that the spreading of lipid bilayers, after 
deposition, halts when the amount of lipid residing on a substrate is fixed.181 
This phenomenon is self-limiting, due to the highly unfavourable 
intermolecular interactions that phospholipid molecules would otherwise 
experience.184 The lateral expansion has been found to be restricted when the 
lipid area exudes ca. 106% of its initial size (for egg phosphatidylcholine 
bilayers); this is termed the self-limiting lateral expansion of lipid bilayers181 and 
proves to be an important feature with regard to the patterning of SLBs. Its 
application is discussed further in section 1.4.2.2. 
1.4.2.2 Patterning supported lipid bilayers 
It is desirable to pattern solid-supported lipid bilayers in order to create a series 
of regions that are distinct and separate from one another, thus enabling more 
than one investigation to be conducted at any one time, i.e. increasing the high-
throughput capabilities associated with this technique. This has therefore led to 
the introduction of ‘barriers’, to create corralled regions. Lipids can diffuse 
laterally within the corralled regions, with diffusion between the corrals being 
prevented.150 Several methods exist that enable one to incorporate barriers to 
lateral diffusion within the SLBs and these are reviewed herein. The majority 
do not require the presence of physical barriers to confine lateral diffusion to 
specific regions, exploiting the characteristic self-limited lateral expansion of 
lipids and eliminating the presence of unfavourable lipid-barrier interactions 
that are poorly understood. Methods for patterned SLB formation include the 
following: 
(i) Mechanical scratching of glass 
(ii) Blotting and stamping by microcontact printing (µCP) 
(iii) Polymer lift-off technique 
(iv) Aluminium lift-off technique 
(v) Patterning by polymerisation 
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(vi) Hydrogel stamping 
Mechanical scratching 
Mechanical scratching of glass substrates (for example using a sharp metal rod) 
affords the simplest method of creating such a barrier,150,185,186 albeit the least 
controllable. In this instance a topological barrier is produced that discourages 
the expansion of the deposited lipid bilayer. 
Blotting and stamping by microcontact printing (µCP) 
The process of “blotting and stamping”, using microcontact printing (μCP), 
provides an alternative option for the creation of patterned SLBs, as illustrated 
by figure 1.22.177,187-191 This methodology relies on using a pre-patterned PDMS 
stamp either: (i) to “blot” and hence remove specific regions of a preformed 
SLB or (ii) to “stamp” the SLBs attached to the pre-patterned PDMS stamp 
onto a fresh substrate, as illustrated by figure 1.22 A and B respectively. The 
latter process must be performed under aqueous conditions in order to prevent 
removal of the SLBs from the PDMS stamp. Alternatively, SLBs may be 
stamped onto clean substrates by first creating SLBs on the microscale features 
of patterned PDMS stamps by subjecting the oxidised stamp to a solution of 
small unilamellar vesicles, as illustrated in figure 1.22 C. The excess lipid is 
removed by shaking the stamp in the aqueous solution and the PDMS-bilayer 
ensemble positioned onto a clean substrate. This method is more reliable than 
the blotting method for SLB deposition and provides the most efficient 
transfer of lipid bilayer.190 
Visualisation of the patterned SLB via the blotting and stamping method has 
been achieved by incorporating 1 mol % N-(Texas Red sulfonyl)-1,2-
dihexandeconoyl-sn-glycero-3-phosphoethanolamine (Texas Red DHPE) into 
small unilamellar vesicles and monitoring the fluorescence of the fluorophore 
using fluorescence microscopy. Images D and E in figure 1.22 illustrate that 
specific regions of the SLB were successfully removed using this technique and 
distinct corralled regions are evident. 
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Figure 1.22: Diagrams illustrating the “blotting” and “stamping” techniques 
developed by Hovis and Boxer to create patterned, supported lipid bilayers. (A) 
A pre-patterned PDMS stamp is oxidised and then used to remove or “blot-out” 
regions of a pre formed, solid-supported SLB. (B) The PDMS stamp can also be used 
to transfer blotted SLBs onto a fresh glass substrate. (C) An alternative method for 
stamping a SLB onto a glass substrate, where the PDMS stamp is subjected to a 
solution of small unilamellar vesicles after oxidation followed by a rinsing stage. (D) 
Epifluorescent images of the solid-SLB, doped with 1 mol % N-(Texas Red sulfonyl)-
1,2-dihexandeconoyl-sn-glycero-3-phosphoethanolamine (Texas Red DHPE), after 
blotting and (E) after application of an electric field gradient parallel to the plane of 
the bilayer. Diagrams have been reproduced from the paper by Hovis et al.187,190 
 
Image E in figure 1.22 illustrates that Texas Red DHPE lipids, attracted to the 
anode upon the application of an electric field parallel to the plane of the 
bilayer (thus generating a concentration gradient), are confined to the corralled 
regions i.e. that the areas of lipid bilayer removed by blotting act as effective 
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barriers to lateral diffusion between adjacent corrals. Additionally, removal of 
the electric field gradient and fluorescent recovery after photobleaching 
(FRAP) measurements both indicate that the diffusion coefficients of the 
labelled lipids (1.21 μm2 / s) are consistent with reported values in the literature 
under analogous conditions,190 a feature crucial for studies on lipid membranes. 
In addition to forming barriers by removing portions of the SLB via the 
blotting methodology, barriers to lipid lateral diffusion may be gained by 
stamping down barriers comprised of protein onto substrates. Kung et al. 
describe two ways in which this may be achieved.177 Firstly, the protein barrier 
may be stamped onto a glass substrate using a pre-patterned PDMS stamp, in 
an analogous manner to what has been described previously for lipids. A 
solution of small unilamellar vesicles is then flowed over the stamped protein 
barriers and patterned SLB formation is achieved. Figure 1.23 A-C illustrates 
this approach. 
Secondly, specific portions of the SLB may be removed by blotting, after 
which protein is ‘caulked’ into areas where lipid has been removed; protein 
caulking is illustrated by Figure 1.23 D-F. Figure 1.23 G and H represent false 
colour images of fluorescent protein (Texas Red bovine serum albumin, TR 
BSA, red) and lipid (labelled with 2 mol % nitrobenzoxadiazol head group 
labelled phosphatidylethanolamine, NBD PE) that have been transferred onto 
the glass substrate via the method of either protein stamping or protein 
caulking respectively. It can be observed that the authors have created 
patterned SLBs that are very uniform in nature and vary in size. A major 
advantage of incorporating protein into the patterned SLB design, i.e. acting as 
a barrier to lateral diffusion, is that cell attachment can ensue – for example, 
barriers comprised of fibronectin can act as a point for attachment of 
endothelial cells.191 
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Figure 1.23: Protein stamping and caulking for patterned SLB formation. (A)-
(C) illustrate the protein stamping method for barrier formation: (A) fluorescently 
labelled protein is initially attached to the PDMS stamp, (B) the protein is transferred 
to the glass substrate via stamping and (C) small unilamaller vesicles (doped with a 
fluorescent tag) are introduced to backfill the non-stamped regions. (D)-(E) represent 
the protein caulking method for barrier formation: (D) a patterned PDMS stamp is 
used to remove regions of a pre-formed SLB, (E) a patterned region now ensues 
where SLB has been removed and (F) protein is introduced and binds to the exposed 
regions of glass. (G) and (H) illustrate an example of the types of patterned SLBs that 
can be generated: the protein and lipid are represented by the red and green regions 
respectively. The scale bars in G and H represent 20 and 50 µm respectively. The 
illustration is based on figures in the paper by Kung et al.177 
 
Polymer lift-off technique. 
The fabrication processes involved in the polymer lift-off technique for the 
patterning of SLBs, developed by Orth et al.,192 are detailed in figure 1.24 A. 
The polymer lift-off technique relies on the deposition of both photoresist and 
Parylene to pattern an SLB. Specifically, photoresist is deposited onto 
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Parylene-coated silicon substrates, after which the photoresist is patterned 
using photolithography and the exposed Parylene surfaces removed using 
reactive ion etching (RIE). The RIE step serves two purposes; firstly to remove 
areas of exposed Parylene, but more importantly to afford a surface that is 
more favourable for lipid assembly (i.e. the newly exposed silicon surface is 
more hydrophilic than Parylene). Small unilamellar vesicles are then delivered 
to the surface to form a SLB (on both the silicon substrate and Parylene). 
Peeling of the Parylene results in the formation of a patterned lipid bilayer. An 
example of the type of patterned SLBs that can be attained using this technique 
is displayed in figure 1.24 B.  
This technique is advantageous, when compared to the stamping and blotting 
techniques, as sharp boundaries are produced in the patterned SLBs and many  
 
 
 
Figure 1.24: Polymer lift-off technique for the formation of patterned SLBs. (A) 
Illustration of the steps involved in the fabrication process. First the photoresist is 
patterned using photolithographical techniques (1), after which the exposed 
photoresist and Parylene are removed using developer and reactive ion etching 
respectively (2). Small unilamellar vesicles are then introduced to the Parylene and 
silicon substrate and a SLB is formed (3). Patterning of the SLB results when the 
Parylene sheet is stripped from the substrate (4). (B) An example of a patterned SLB 
gained using this technique (scale bar = 70 μm). Images are based on the paper by 
Orth et al.192 
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of the disadvantages associated with deformation of the PDMS stamps are 
eliminated. Moreover, this technique enables the production of higher 
resolution patterned SLBs, where features in the region of 1 μm have been 
reported. The success of the technique is largely owed to the chemical nature 
of Parylene, which binds weakly to the substrate in question, so is easily 
removed in one step, and is also chemically inert.192 
Aluminium lift-off. 
The aluminium lift-off approach utilises a layer of aluminium that is deposited 
onto a silicon substrate and subsequently patterned using traditional 
lithographical methods (photolithography or electron beam lithography), in 
order to produce patterned SLBs. The first stage in figure 1.25 (1) includes a 
side-on depiction of the patterned aluminium template. The patterned  
aluminium template is then treated with 3-aminopropyltriethoxysilane in dry 
acetone to yield amine-terminated glass, after which sulfosuccinimidyl-4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC) is introduced in 
order to yield succinimidyl attachment to the surface amines. Monomeric 
fibronectin (fluorescently labelled), formed by treating fibronectin with tris(2-
carboxyethyl)phosphine hydrochloride (TCEP) to reduce disulphide bonds, is 
covalently attached to a pre-patterned and pre-treated silicon surface to define 
barriers to lateral diffusion (stage 2 in figure 1.25 and the enlarged box for 
further details relating to the chemisty).193 Upon dissolution of the aluminium 
in alkaline solution (stage 3 in figure 1.25), small unilamellar vesicles are 
introduced to the patterned substrate affording a patterned SLB (stage 4 in 
figure 1.25).  
Disadvantages associated with this technique include the need for highly 
alkaline conditions to remove the deposited aluminium, which raises concerns 
relating to the biocompatibility of the covalently attached protein. 
Furthermore, economic considerations do not favour this technique; each  
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Figure 1.25: Aluminium lift-off technique for patterned SLB formation. Stages 1-
4 illustrate the steps involved in patterning a SLB using this methodology, specifically: 
(1) patterning of the aluminium coated silicon using lithographical techniques, (2) 
introduction of protein barriers by covalent attachment of fibronectin chemically 
treated silicon (see the enlarged box for details of the chemistry), (3) chemical “lift-
off” of the deposited aluminium and (4) formation of patterned SLBs by the 
introduction of small unilamellar vesicles. Image reproduced from the paper by 
Jackson et al.193  
 
patterned SLB may only be used once. However, high-quality patterns can be 
produced relatively quickly using this technique. 
Patterning by polymerisation 
Patterning by polymerisation utilises phospholipids that are able to polymerise 
upon the introduction of light as barriers to lipid diffusion between corrals. In 
the example described by Okazaki et al.,194 a bilayer comprised of diacetylene 
phospholipid (diynePC) are assembled onto solid supports (stage 1 in figure 
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1.26) and polymerised using photolithographical methods (stages 2 and 3 in 
figure 1.26). The non-polymerised material can then be removed using sodium 
dodecyl sulphate (SDS) solution (stage 4 in figure 1.26). A solution of small 
unilamellar vesicles can then be introduced to the pre-patterned substrate, 
where rupture and SLB formation results, as illustrated in stage 5 of figure 
1.26. 
 
 
Figure 1.26: Patterned SLB formation via lipid polymerisation. Diacetylene 
phospholipid (diynePC) bilayer are assembled onto a solid support (stage 1) and 
specific regions polymerised by using a photo mask to direct UV light (stages 2 & 3). 
The regions that are not polymerised are removed (stage 4) and the exposed regions 
backfilled with a solution of small unilamellar vesicles (stage 5). The diagram is based 
on the paper by Okazaki et al.194 
 
One advantage associated with this technique is that hybrid patterned bilayers 
remove the existence of energetically unfavourable environments, i.e. the 
‘edges’ of the supported lipid bilayer. The process of SLB formation was found 
to be enhanced using this process. Therefore regions that may possess 
anomalous characteristics, when compared to the bulk SLB, are removed, such 
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as regions possessing heightened levels of membrane curvature. This allows 
experiments of a biophysical nature to be conducted upon lipid bilayers that 
are more ‘controlled’ in biophysical terms.  
Hydrogel stamping.  
Madj and Mayer have developed a very effective technique for the deposition 
of patterned SLBs, which contrasts largely to those discussed hitherto.195,196 
They have demonstrated that stamps comprised of hydrogel, specifically high-
gel strength agarose (4 % w/v), inked with solutions of small unilamellar 
vesicles enable a patterned SLB to be printed onto a substrate ca. 100 times 
without the need for re-inking. Figure 1.27 illustrates the stages required to 
produce patterned supported bilayers using the hydrogel stamping technique. 
Specifically, a PDMS cast is produced (stage 1 in figure 1.27 A) and the 
hydrogel then poured on top of this cast and allowed to set (stage 2 in figure 
1.27 A). After the hydrogel has set, it may then be peeled away from the 
PDMS cast (stage 3 in figure 1.27 A). Vesicle solutions may then be 
administered to the raised features (“posts”) of the agarose gel, which over a 
short period of time are taken up by the gel (figure 1.27 B). The pore size, 
determined by the agarose gel, allows liposomes to diffuse throughout the 
stamp. As the stamp comes into contact with the substrate, liposomes at the 
stamp-substrate interface are thought to fuse to form an SLB in a similar 
manner to that of vesicular fusion from solution (figure 1.27 C).196 
With respect to determining the reproducibility of SLB deposition, FRAP 
experiments have revealed that diffusion coefficients for the 6th and 100th 
stamped array are consistent to within 5 % of each other. The mean 
fluorescent intensity reduced by only ca. 10 % from the 6th to the 100th array, a 
feature which is very desirable for bilayer deposition and suggests that 
reproducibility of this method is amenable for high-throughput capabilities in 
the future. Furthermore, Madj and Mayer have demonstrated the applicability  
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Figure 1.27: Hydrogel stamping for the creation of patterned supported lipid 
bilayers. (A) Initially a PDMS cast is produced (stage 1), after which a solution of 
high-strength agarose gel is poured on top of the PDMS cast and allowed to set (stage 
2). Once the hydrogel has set, it may be peeled away from the cast (stage 3). (B) The 
agarose gel is then doped with vesicle solution and allowed to absorb the solutions. 
(C) The loaded agarose stamp is then placed into contact with a substrate, which is 
then transferred into an aqueous environment. Patterned supported lipid bilayers 
result. Images in the figure are based on the information provided by Madj and Mayer 
(Supporting Information).196 
 
of such a technique to biophysical studies, where they have conducted 
investigations probing both drug- and protein-membrane interactions. 
 1.4.2.3 Production of composition arrays 
The previous section has reviewed the various methods that are available to 
produce patterned supported lipid bilayers. This is extremely important if 
numerous experiments are required to be conducted in parallel (i.e. to increase 
the number of experimental repeats) and in high-throughput (i.e. in order to 
increase the speed with which a great volume of data is collected). However, in 
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order to conduct high-throughput investigations of a biophysical nature, it is 
desirable to create single arrays that vary in lipid composition. Madj and Mayer 
touched upon the ability of their hydrogel stamping technique for producing 
composition arrays; however, the approach described is not high-throughput in 
nature as each post on the hydrogel has to be individually addressed by manual 
pipetting. However robotic technologies could be viewed as a way in which to 
bridge this gap, as Castellana and Cremer have envisaged as a result of the 
investigations that they have conducted.197,198 Specifically, they state that 
although spatially addressing each experimental area is slow, it enables the lipid 
composition in each unit to be controlled more rigorously.  
The main methods detailed in the literature that enable the creation of 
patterned SLB composition arrays in high-throughput include the following: 
(i) Controlled mixing and surface capture,199 a technique that utilises 
microcontact printing (to form barriers) interfaced with microfluidics to 
produce lipid composition arrays. Laminar flow is used in order to ensure 
that mixing and surface capture is controlled (see figure 1.28 A for further 
information); 
(ii) Stamping by microcontact printing,190 where the PDMS stamp is designed 
such that it is able to print areas of SLB that vary in size and where the 
unstamped regions may then be ‘backfilled’ using a second vesicle solution 
to create composition arrays (see figure 1.28 B for further information); 
(iii) Spatially selective manipulation by laminar flow,200 where lipid in a SLB 
can be ‘stripped’ and then ‘replaced’ using laminar flow (see figure 1.28 C 
for further information); and finally, 
(iv) Scanning probe lithography,201 where a pre-patterned substrate is doped 
with small unilamellar vesicles and the resulting SLB then patterned using 
the ‘tip’ of a scanning probe for composition array formation (see figure 
1.28 D). 
Chapter 1 
51 
 
Figure 1.28: Methods for forming supported lipid bilayer composition arrays. 
(A) Controlled mixing and surface capture. This method relies on using laminar flow 
to create lipid composition arrays.199 (B) Stamping by microcontact printing. Oxidised 
PDMS stamps, pre patterned using photolithographic methods and subjected to 
vesicle suspensions, are able to print SLBs of different areas onto substrates. The 
unstamped regions can then be ‘backfilled’ with a different vesicle suspension.190 (C) 
Spatially selective manipulation by laminar flow. Here a laminar stream containing a 
stripping solution is scanning across the desired section of SLB to be removed. A 
second batch of new vesicles is then introduced to enable composition array 
formation.200 (D) Scanning probe lithography. In this instance the tip of a scanning 
probe is used to remove specific regions of deposited SLB – new vesicles can be 
introduced thereafter.201 Images are reproduced from the references provided. 
 
1.4.2.4 Problems associated with the SLB technique 
Having personally attempted to deposit supported lipid bilayers onto solid 
supports, using the microcontact printing technique, it can be confirmed the 
process can be extremely difficult to master. First of all, it was found that the 
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quality of printing was particularly poor when using a PDMS stamp, which was 
attributed to the deformation of the PDMS upon the application of pressure. 
Hovis et al. noted that the predicted thickness of the grid lines after 106 % 
lateral self expansion of the remaining bilayer was not achieved, which they 
attribute to the deformation of the PDMS stamp.187 Secondly, sophisticated 
stamping devices are required in order to print complex composition arrays. 
Thirdly, as the technique requires a single SLB to be transferred under aqueous 
conditions, and within a time period dictated by the oxidised PDMS stamp, the 
transferral process has to be conducted relatively quickly and is therefore 
difficult to execute. Furthermore, it is felt that the transferral of a single 
supported lipid bilayer is extremely difficult to achieve, owing to the fact that 
there will always be an excess of small unilamellar vesicles present in the 
aqueous solution (unless a flow system can be implemented where washing 
stages take place). Even still, it is felt that the deposition of a single supported 
bilayer is far from trivial. Hower, Hovis et al.190 feel that both leaflets of the 
lipid bilayer are removed during the blotting process, when assessing the 
fluorescence intensities of the blotted regions. They also indicate that in order 
to enhance transfer efficiencies using microcontact printing, the following 
guidelines should be followed, in order to gain transfer efficiencies of greater 
than 80 %: 
 
(i) Use extruded vesicles and cleaned / baked glass substrates within three 
days of preparation; 
(ii) Use a buffer solution (e.g. 10 mM Tris, 100 mM NaCl, pH 8) as 
opposed to Millipore water; 
(iii) Design the pattern to be printed in a grid-like system containing large 
corralled regions separated by small barriers; 
(iv) Use Sylgard 182 (instead of 184) for PDMS stamp manufacture; and, 
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(v) Complete the printing procedure in less than 15 s. 
 
In conclusion, it is felt that this technique is not the easiest to grasp and would 
require several years for a lab to set up the process successfully. In general, a 
major limitation of the SLB methodology surrounds the fact that the lipid 
bilayers are supported. Therefore controversies persist, with opinions suggesting 
that substrate-membrane interactions may impact upon the physical nature of 
the bilayer, even if polymer-cushioned SLBs are utilised. Furthermore, as the 
distance between the SLB and substrate is so small, i.e. on the order of 10 Å 
(as detailed in section 1.4.2.1), the ability to manipulate this water volume is 
virtually impossible. Additionally, it is believed no published articles exist, 
surrounding the formation of asymmetric bilayers using the SLB technique to 
date, which coupled with the difficulties associated with mastering the 
technique do not suggest that it is the most suitable approach to build upon. A 
methodology that has recently taken hold in the scientific world is associated 
with droplet interface bilayers (DIBs), which addresses and overcomes each of 
the aforementioned problems. 
 
1.4.3 Droplet interface bilayers 
Droplet Interface Bilayers (DIBs) are a new and emerging technology that have 
surfaced as a major alternative to traditional methods for creating single lipid 
bilayers for probing the interaction of drug molecules and proteins with 
artificial lipid membranes. 2006 saw the emergence of the very first droplet 
interface bilayer, developed concomitantly by the labs of Takeuchi202 and 
Bayley.203  
1.4.3.1 Definition  
The term, “Droplet Interface Bilayer”, relates to the formation of a lipid bilayer, 
as a result of forming an interface between two aqueous droplets in an oil 
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environment. Importantly, the aqueous droplets contain surfactant molecules 
in order to stabilise the oil-aqueous interface, hence ensuring that the water 
droplets do not merge. Each droplet is therefore surrounded by a surfactant 
monolayer. The surfactant of choice in this instance is a biological amphiphile, 
i.e. a phospholipid, and the interface that forms between two aqueous droplets 
is a lipid bilayer. Figure 1.29 illustrates how droplet interface bilayers are 
formed.  
 
 
Figure 1.29: Droplet Interface Bilayer (DIB) definition. (A) Two aqueous 
droplets, whose interfaces are stabilised using surfactant molecules (i.e. amphiphilic 
phospholipids), are submersed in an oil environment. As a result, lipid monolayers 
reside at the droplets’ oil-aqueous interface. (B) Upon bringing the two droplets into 
contact with one another, a droplet interface bilayer is formed.   
 
DIBs can be formed by incorporating the lipid into either the oil or aqueous 
phase (as they are amphiphilic molecules), termed the “lipid-out” and “lipid-in” 
approaches respectively. However the latter method is often favoured, where 
extruded vesicle suspensions are utilised, as this reduces lipid consumption and 
generally results in faster DIB production.204  
Chapter 1 
55 
1.4.3.2 Advantages of the DIB system 
The major advantage of the DIB system, over other technologies such as 
supported lipid bilayers (as discussed in section 1.4.2) for example, is that it is 
extremely easy to implement. All that is required to successfully make a droplet 
interface bilayer is the following: some oil, water, lipid and a chamber to hold 
the sample in. The technique is extremely quick to pick up and within a few 
hours the researcher can observe the formation of their first DIB. This process 
is fascinating, whereby the “zipping-up” of two monolayers to form a single 
lipid bilayer can be observed in real time using a microscope. It is felt that the 
ease with which DIB formation can be achieved will appeal to many 
researchers in the fields of biophysics and biochemistry, and as such, will 
prevail to become a major technology for research conducted within these 
disciplines. Hence this is one of the reasons why the latter part of this thesis 
concentrates on the development of DIB technologies. 
Other factors that make this method very advantageous include: the stability of 
the platform once formed and the nature of the aqueous compartments that 
are created during DIB formation. When a DIB is formed, it possesses a 
lifetime that exists on the order of days to weeks. This is highly desirable and 
contrasts largely to classical techniques of artificial bilayer formation, such as 
the Montal-Mueller method for example, where only very fragile lipid 
membranes can be created and are stable for up to an hour at best. Unlike the 
supported lipid bilayer method, the aqueous compartments that are present on 
either side of a lipid membrane created using the DIB methodology may be 
manipulated with ease. This is extremely advantageous, providing the 
researcher with the option to tune the aqueous composition on either side of 
the lipid bilayer.   
Further advantages of the DIB technology include the ability to form 
asymmetric droplet interface bilayers (aDIBs)205 with ease, thus producing a  
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Figure 1.30: Asymmetric droplet interface bilayer (aDIB) formation and the 
formation of droplet interface bilayer networks. (A) Illustration of a droplet 
interface bilayer, formed with the lipid in the aqueous phase initially (as vesicles). 
Here, the lipid composition on either side of the bilayer is the same. (B) Formation of 
an asymmetric droplet interface bilayer (aDIB). Different lipid compositions are used 
to form the vesicle populations in each droplet. (C) A linear sequence of droplets that 
forms a DIB network possessing multiple DIBs. (D) An example of a more advanced 
DIB network, where each droplets forms two DIBs with its neighbours. (E) A key to 
indicate that the small doughnut-shaped features represent small unilamellar vesicles.  
 
system that has the potential to mimic nature more closely. Figure 1.30 A and 
B illustrate how asymmetric DIBs differ from the most basic of DIB systems. 
In order to create an asymmetric DIB, a second vesicle suspension has to be 
extruded that is comprised of an alternative lipid composition (c.f. the first 
vesicle suspension). A droplet from each of two different vesicle suspensions is 
then pipetted into an oil environment – after a period of time the two droplets 
are brought into contact with one another resulting in the formation of an 
asymmetric DIB. 
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It can also be observed that the concept of DIBs can be extended to produce 
DIB networks that contain more than one DIB, as established by Holden et al. 
and Hwang et al.203,206 Figure 1.30 C and D illustrate how linear sequences of 
DIBs, as well as more complicated DIB arrangements, can be achieved. The 
ability to form more than one bilayer per experimental unit will enable 
advanced systems to be explored. 
1.4.3.3 High throughput lipid bilayer formation 
To date, there has been very little development with respect to techniques that 
are able to produce lipid bilayers, or DIBs, in a high-throughput, automated 
manner. This is most probably because the suspension of lipid bilayers can be 
challenging and that the concept of DIBs has only been established very 
recently. However there are now a few examples present in the literature that 
describe methods able to conduct experiments across several lipid bilayers, 
with the major application of these methods having been to monitor 
transmembrane ion channel currents. This includes the following methods: 
(i) Falling drop method 
(ii) Black lipid membrane (BLM) approach 
(iii) Hanging droplet screening chip using droplet interface bilayers (DIBs) 
Falling drop method 
The falling drop method207,208 relies on using gravity to deposit a small droplet 
(containing lipid vesicles, and hence possessing a lipid monolayer at the droplet 
interface) onto a monolayer-containing surface, where a lipid bilayer is formed 
in a horizontal plane. Figure 1.31 A and B illustrate how the falling drop 
process works and the scale of assay that may be achieved when using a liquid-
handling robot respectively. 
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Figure 1.31: The falling drop method for high-throughput lipid bilayer 
formation. (A) Illustration of how the falling drop method works. An aqueous, lipid-
containing droplet is deposited into a well and falls on top of a lipid monolayer, 
formed at the interface between an aqueous and oil phase (stage 1). A second 
electrode may then be incorporated into the droplet to enable electrical measurements 
to be conducted (stage 2). Image 3 illustrates a photograph of the electrode 
incorporated into the droplet and image 4 illustrates where DIB formation occurs. (B) 
The capability of performing high-throughput measurements using this method is 
demonstrated, where droplets have been dispensed into 96-well plates. (C) An 
example of the type of experiment that may be conducted; here, the incorporation of 
alpha hemolysin pores into the membrane has been investigated. Images reproduced 
from Poulos et al.207 
 
Figure 1.31 C illustrates the type of measurement that may be conducted using 
this setup; specifically, the incorporation of alpha-hemolysin pores into 1,2-
diphytanoyl-sn-glycero-3-phosphocholine (DPhPC) bilayers has been 
investigated. 
Although this has been an important development, with respect to initiating 
research into the high-throughput capabilities of artificial lipid bilayer systems, 
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there are still limitations in the methodology. For example a major limitation of 
this technique is due to the orientation of the lipid bilayer – the fact that the 
bilayer is orientated in the horizontal plane means that the lifetime of the 
bilayer is far reduced when compared to those assembled in the vertical 
plane.207 This is thought to be due to the effect of gravity acting upon the 
dispensed droplet. Additionally, this technique does not enable more advanced 
experiments to be conducted, perhaps those concerned with cooperativity, i.e. 
where more than one bilayer is required.  
Black lipid membrane (BLM) approach 
This method utilises black lipid membranes, i.e. membranes that are suspended 
across apertures, as opposed to bilayers interfaces that are formed between 
droplets.209-211 Figure 1.32 A illustrates a device that can be used to create 
numerous lipid bilayers, which are suspended across apertures present in a 
Parylene sheet. Microfluidic channels are used to deliver both lipid and buffer 
solution for lipid bilayer assembly via an inlet to the bottom channel. The 
device possesses nine recording wells (see image 2 in figure 1.32 A); electrodes 
are placed in each of the recording wells, as well as a common electrode that is 
placed in the bottom channel, in order to measure membrane current. Image 3 
in figure 1.32 A illustrates an image taken on a scanning electron microscope 
(SEM) of the microfabricated apertures present in the Parylene sheet (situated 
in each recording well). 
A disadvantage associated with this technique is associated with the complexity 
of the device. The microfabrication procedures, which are required in order to 
pattern the Parylene sheet, are depicted in figure 1.32 B. Therefore, specialist 
technologies and clean rooms will be required in order to pattern the Parylene. 
Secondly, the device design is quite complicated, as can be observed from 
figure 1.32 C. Here it is apparent that several layers are required in order to 
assemble the device. Therefore, great care will be required during device 
construction to ensure proper alignment and good sealing.  
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Figure 1.32: Black lipid membrane (BLM) approach for high-throughput lipid 
bilayer formation. (A) Device design used to create numerous lipid bilayers 
suspended across apertures fabricated in a Parylene sheet (1). An enlarged image of a 
single upper recording well is displayed in 2. Image 3 represents an image of the 
patterned Parylene sheet, taken on a scanning electron microscope (SEM). (B) Steps 
involved in the microfabrication of the Parylene sheet. First, Parylene and aluminium 
are deposited onto a silicon substrate (1). The aluminium is patterned using 
photolithographic procedures (2). An oxygen plasma is then used to etch the Parylene, 
using the aluminium as a mask (3). The residual aluminium is then removed (4) and 
the Parylene substrate peeled off (5). (C) Here the various layers used in order to 
construct the device are detailed. Images reproduced from the paper by Le Pioufle et 
al.209 
 
Hanging droplet screening chip using droplet interface bilayers (DIBs)  
Syeda et al.212 have recently developed an approach in order to probe the effect 
of a number of drug molecules as potential blockers of the pore, α-hemolysin. 
This technique utilises a droplet suspended from a Ag/AgCl electrode that is  
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Figure 1.33: Hanging droplet screening chip using droplet interface bilayers 
(DIBs). (A) An illustration of the 16-well assay plate for investigating the potential 
blocking ability of drugs molecules on the pore, α-hemolysin. 16 wells that contain 
lipid and the drug of interest are submersed in an oil environment in order to enable 
monolayer formation at the oil-aqueous interface. (B) Enlarged image that depicts 
four wells and the formation of a DIB between the suspended droplet and well (each 
of which are coated with a lipid monolayer at the oil-aqueous interface). Incorporation 
of electrodes into the chip design enables electrical measurements to be conducted. 
Images are reproduced from the paper by Syeda et al.212 
 
also mobile. They have produced a 16-well assay plate, which contains 16 wells 
filled with lipid as well as the drug to be tested (and a pure lipid-buffer well to 
act a control), as illustrated in figure 1.33 A. The 16-well assay plate is then 
filled with oil, which thus enables lipid monolayers to form at the oil-aqueous 
interface of each well after a period of time. The droplet that is suspended 
from the electrode contains the pore of interest (cleverly synthesised in situ), 
and can be brought into contact with a well manually. A DIB is formed as a 
result (see figure 1.33 B), with the pores then incorporating themselves into the 
bilayer - an electrical measurement recorded. The suspended droplet is then 
disconnected from the well and connected to the next – the process is repeated 
until an electrical measurement for each of the wells has been taken.  
In addition to issues that may surface due to contamination of the chip, for 
example, if the assay design is expanded to enable more than 16 units per assay 
to be investigated, this technique, as with the others detailed in this section, is 
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limited by the fact that the format is only able to afford one lipid bilayer per 
experimental unit, hence limiting its application to more advanced situations.  
 
1.5 CONCLUDING REMARKS AND THESIS AIM  
In summary, it is extremely important to further our understanding of how 
small molecules interact with lipid membranes. We yearn to learn more, as it is 
imperative to discover how drug molecules interact with our body at the 
molecular level – often little consideration is given to drug-lipid interactions 
within the pharmaceutical industry, for example. The major aim of this thesis 
has therefore been to develop new technologies, able to be used in screening 
drug-membrane interactions.  
Artificial membranes have long been employed as a means to investigate the 
effect of exogenous species (such as proteins) on lipid membranes. 
Carboxyfluorescein leakage assays in particular have been effective in revealing 
how such species perturb the membrane and consequently influence the efflux 
kinetics. Chapter 2 details the steps taken to develop a carboxyfluorescein 
leakage assay for the study of drug-membrane interactions, where the 
reproducibility of the assay and the effect of lipid composition on the rate of 
carboxyfluorescein leakage are investigated. Chapter 3 builds on the work 
detailed in chapter 2, demonstrating that the carboxyfluorescein leakage assay 
can be performed in a microfluidic format and hence offers the possibility to 
rapidly screen drug- and protein-membrane interactions in high-throughput.  
As discussed in section 1.4.3, DIBs are an extremely advantageous platform for 
probing the interaction of small molecules upon artificial membranes. Upon 
reviewing the literature, it is apparent that only a handful of examples have 
exploited the high-throughput aspect of DIB technologies. Opportunities 
therefore exist to produce platforms for the generation and manipulation and 
droplets in a high-throughput and automated fashion. 
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Chapter 4 demonstrates that DIB formation is easily reproduced using the lipid 
1,2‐diphytanoyl‐sn‐glycero‐3‐phosphocholine (DPhPC) and details the 
successful formation of DIBs comprised of the more biologically relevant lipid, 
1,2‐dioleoyl‐sn‐glycero‐3‐phosphocholine (DOPC) for the first time. 
Furthermore, a proof-of-concept leakage assay across DIBs, that uses pH 
gradients to potentially assess drug-membrane interactions, has been detailed. 
The problems associated with the manual manipulation of droplets have also 
been highlighted, hence justifying the need for an approach able to form DIBs 
reliably and in a uniform manner.  
Chapter 5 presents work that has been published recently in Chemical 
Communications,213 detailing the development of a microfluidic approach for 
the formation of DIB networks in a high-throughput and controlled manner. 
An automated system has been set up, where the size of water-in-oil droplets 
participating in DIB formation is uniform and tuneable. Additionally the ability 
to form three dimensional DIB networks, where droplets are able to fill 
predefined structures of any desired shape or size, and the possibility for 
asymmetric DIB formation has been demonstrated.  
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Chapter 2 
 
A carboxyfluorescein leakage assay for the study of 
drug-membrane interactions 
 
 
 
“If we knew what it was we were doing, it would not be called research, would it?” 
Albert Einstein  
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2.1 OVERVIEW 
Drug discovery is often focussed largely around investigating the interaction of 
pharmaceutically active agents, i.e. small drug molecules, with the target 
protein(s) of interest. However, little consideration is given to the interaction 
of such molecules with the fabric of our cell membranes – lipids. Often they 
are viewed merely to possess structural qualities, acting in passive manner, 
whereas it is now apparent that their function is more significant.214,215 
Artificial membranes have long been employed as a means to investigate the 
effect of exogenous species (such as proteins) on lipid membranes. 
Carboxyfluorescein (CF) leakage assays in particular have been effective in 
revealing how such species perturb the membrane and consequently influence 
the efflux kinetics. This chapter details the steps taken to develop a CF leakage 
assay for the study of drug-membrane interactions, where the reproducibility 
of the assay and the effect of lipid composition on the rate of CF leakage are 
investigated. 
 
2.2 INTRODUCTION 
2.2.1 Properties of carboxyfluorescein 
CF, a derivative of the well known fluorescein family, is a molecule that 
exhibits an unusual fluorescence behaviour. Its structure differs to that of 
fluorescein due to the possession of an extra carboxyl group, situated at either 
the 5- or 6-position, as displayed in figure 2.1 A. This feature is advantageous, 
reducing the ability of CF molecules to partition into hydrophobic 
environments by up to three orders of magnitude (c.f. fluorescein)216,217 and 
thus resulting in enhanced retention of the molecule within vesicular species. 
Notably, the most soluble and highly fluorescent form of CF is the trivalent 
anion, in the pH range 7-11.216  
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Figure 2.1: Molecular structure and excitation / emission spectra of 5(6)-
carboxyfluorescein. (A) Illustration of the molecular structure of CF. (B) Graph 
showing the excitation / emission spectra of 5(6)-CF, where the maximum emission 
and excitation wavelengths are 490 and 520 nm respectively for a 0.2 mM CF sample. 
 
When excited by blue light, the molecule emits green radiation; more 
specifically, CF has excitation and emission maxima of approximately 490 nm 
and 520 nm respectively as illustrated in figure 2.1 B. Moreover, at particularly 
high concentrations (in the region of 1-100 mM), the fluorescence emission is 
effectively quenched. This phenomenon, known as ‘self-quenching’, is believed 
to arise predominantly due to the formation of non-fluorescent CF-CF dimers 
and energy transfer between these dimers.218 
The fluorescence spectra in figure 2.2 reveal how the fluorescence spectra of 
CF change with concentration. A combined plot of both excitation and 
emission spectra for various CF concentrations is included, in addition to a 
graph of the fluorescence intensity values (gained using an excitation of 516 
nm) versus concentration. Upon dilution of a self-quenched sample of CF (i.e. 
50 mM), an increase in the fluorescence output is observed. A maximum in the 
fluorescence intensity occurs at ca. 1.0E-05 M CF (see figure 2.2 B, “self-
quenching regime”). Upon dilution, the fluorescence intensity decreases as 
illustrated in figure 2.2 B and is represented by the region labelled the “dilution 
regime”. 
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Figure 2.2: Fluorescence properties of carboxyfluorescein (CF). (A) Excitation 
and emission spectra for different concentrations of CF in solution. (B) Graph 
indicating the dependence of CF fluorescence emission on concentration, constructed 
by taking the value attained at 516 nm for each CF concentration measured. (C) An 
image illustrating the nature of the samples used to construct the calibration. (D) 
Table indicating the concentration of the CF samples tested. (E) Key illustrating 
which sample, in the image displayed in C, refers to which CF concentration.   
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A photograph of the CF samples utilised in the serial dilution study is displayed 
in figure 3.2 C. The self-quenched dye is a deep red, with the sample exhibiting 
the greatest fluorescence output possessing a faint green / yellow colour (i.e. 
sample 7 in figure 2.2 C, D and E).  
 
2.2.2 Carboxyfluorescein in liposomes 
The encapsulation of fluorescent markers, such as CF, at self-quenched 
concentrations and within phospholipid shells has been a popular assay format 
over the last few decades.219 There are numerous examples of membrane-
leakage assays detailed within the literature and it appears that the main 
applications of such an assay seek to probe the interaction of exogenous 
species upon a membrane,220-226 to monitor fusion events or to act as a vehicle 
to investigate intracellular delivery.227-229 This investigation has exploited the 
former application in order to indirectly monitor drug-membrane interactions. 
CF-containing vesicles can be prepared, where dye molecules are present 
within the interior region of the vesicle (i.e. contained within the vesicle 
lumens). Crucially, the underlying principle of this assay relies on the fact that 
there is little contribution to the output fluorescence intensity when the dye is 
spatially confined within liposomes, at self-quenched concentrations (i.e. 50 
mM for the experiments conducted within this investigation). Therefore unless 
a distinct event takes place on or at the lipid bilayer, that is able to perturb the 
membrane in such a way to allow the release of dye molecules, there will be no 
observed change in the observed fluorescence intensity. Figure 2.3 clearly 
demonstrates this principle. A vesicular solution, containing 300 μM dioleoyl 
phosphatidylcholine and encapsulating 200 mM CF, when excited with 
ultraviolet (UV) does not fluoresce (see figure 2.3 A). Once the membrane 
disrupting detergent Triton X-100 (TX-100) is introduced into  
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Figure 2.3: Visualisation of carboxyfluorescein (CF) release from liposomes 
contained within a cuvette and viewed under an ultraviolet (UV) lamp. (A) 
Vesicles containing 200 mM of encapsulated CF. (B) Partial dye release upon the 
addition of Triton-X 100. (C) Release of the internalised dye, resulting in a final CF 
concentration of ca. 70 μM and 20-fold fluorescent enhancement. Image reproduced 
from Weinstein et al.216 
 
the sample, however, partial release of CF can be detected, as displayed in 
figure 2.3 B. Complete disruption results in release of the internalised dye into 
the total cuvette volume (see figure 2.3 C) – this lysis results in a final CF 
concentration of ca. 70 μM and a 20-fold enhancement in fluorescence 
intensity.216 In summary this method can therefore distinguish between 
material that has been released from vesicles and that which is still retained. 
 
2.2.3 Summary and chapter aims 
As detailed in section 2.2.2, CF leakage assays have been a popular choice of 
assay format, where information about the effect of membrane active species 
may be investigated. Importantly, this exploits the fluorescence properties of 
CF, as discussed in section 2.2.1. In summary, the experiments detailed in this 
chapter aim to: 
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1. Indicate the steps taken to develop the CF leakage assay. 
2. Investigate the reproducibility of the assay and the dependence of CF 
leakage, using drugs such as chlorpromazine, WAY and imipramine. 
3. Investigate the dependency of efflux rate on DOPE content in a 
DOPC membrane. 
 
2.3 MATERIALS AND METHODS 
The following section details the materials required and methods employed in 
order to perform each of the experiments described in this chapter. 
2.3.1 Materials 
2.3.1.1 Vesicle preparation 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (ammonium salt) 
(Rh PE) were purchased from Avanti® Polar Lipids, Inc. and used to prepare 
large unilamellar vesicles (LUVs). Lipids were lyophilised initially in 
cyclohexane (Sigma-Aldrich).  
2.3.1.2 Dye and buffer solutions 
The fluorescent dye 5(6)-CF (CF), Trizma® hydrochloride (TRIS-HCl), 
sodium chloride (NaCl) and sodium hydroxide (NaOH), all purchased from 
Sigma-Aldrich, were the main components of the buffers used in these 
experiments. An aqueous CF stock solution (internal buffer, solution 2.1), 
incorporating 50 mM CF, 10 mM TRIS-HCl, 10 mM NaCl and adjusted to pH 
7. 4 with ca. 135 mM NaOH (to aid CF solubilisation) at room temperature, 
was used for vesicle formation. An elution buffer (solution 2.2) was also 
prepared and consisted of 10 mM TRIS-HCl, 107 mM NaCl – approximately 5 
mM NaOH was required to adjust to pH 7.4 at room temperature. Solution 2.1 
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was covered in foil and kept in the dark at all times, and all buffers stored at 4 
oC when not in use. The two solutions used are summarised as follows: 
 
Solution 2.1:  50 mM CF, 10 mM TRIS-HCl, 10 mM NaCl, pH 7.4 
Solution 2.2:  10 mM TRIS-HCl, 107 mM NaCl, pH 7.4 
 
2.3.1.3 Drugs 
The following drugs were utilised in the experiments detailed within this 
chapter: chlorpromazine, WAY-100635 and imipramine (all purchased from 
Sigma-Aldrich). Aqueous stock solutions were prepared using the elution 
buffer (solution 2.2, see section 2.3.1.2) and diluted to provide the desired drug 
concentration. All aqueous stock solutions were stored at 4 oC when not in use.  
2.3.1.4 Gel filtration column 
SephadexTM G25m (GE Heathcare) is a medium suitable for the separation of 
molecules with a molecular weight, Mr, of greater than 30,000 g/mol from 
those with Mr < 1,500 g/mol and was therefore chosen to separate vesicles 
containing entrapped CF from free dye. The SephadexTM G25 medium was 
bought pre-prepared and stored at 4 oC when not in use.  
 
2.3.2 Methods 
2.3.2.1 Encapsulation of carboxyfluorescein 
Stock solutions of DOPC (25 mg / ml, 786.15 g / mol) and DOPE (25 mg / 
ml, 744.03 g / mol) were prepared in chloroform. Subsequently, the correct 
volumes were pipetted into a 10 ml round bottomed flask (for each specific 
experiment) to yield a final concentration of 12.5 mM in 500 μl (6.3E-06 
moles). Using a stream of nitrogen, the solvent was removed gently, hence 
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resulting in the formation of a thin lipid film. The sample was then placed in a 
dessicator (under vacuum) for a minimum of one hour to ensure removal of 
residual solvent molecules. The lipid film was hydrated with 500 μl of the CF 
stock solution (solution 2.2, section 2.3.1.2) and left for 5-10 minutes, after 
which the sample was vortexed to ensure removal of lipid from the glass 
vessel. Five freeze-thaw cycles were performed with liquid nitrogen to aid the 
disruption of multilamellar species and the sample extruded 21 times through a 
polycarbonate membrane (100 nm diameter pore size) to form large 
unilamellar vesicles.230 See steps A-E of figure 2.4 for an illustrative 
representation of this procedure.  
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Figure 2.4: Illustration of the steps involved in producing CF-encapsulated vesicles. (A) A lipid film is formed by depositing the lipid of 
interest into a round bottom flask and removing the solvent under a stream of nitrogen, after which the film is hydrated with the CF-containing 
buffer. (B) The sample is then vortexed and freeze-thawed, resulting in the formation of multilamellar species (C). Extrusion of the sample 
through a polycarbonate membrane (D) yields unilamellar vesicles (E). The unencapsulated dye is then removed, using a Sephadex column (F, 
image reproduced from GE Healthcare’s Gel Filtration Handbook),231 to afford CF-encapsulated vesicles (G).   
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2.3.2.2 Exclusion of external dye by gel filtration 
After extrusion, CF will be present in the interior and exterior milieux of the 
vesicles. The external dye was removed using a gel filtration column, via the 
principle of size exclusion.232,233 First, the column was prepared by passing 5-10 
column volumes of Milli-Q water through the gel. The column was then 
equilibrated with three column volumes of the elution buffer (solution 2.2). A 
300 μl aliquot of the extruded vesicle sample was loaded onto the column and 
consequently separated from the free dye, as illustrated in figure 2.5 A and B 
respectively. Fresh vesicle samples were prepared for each day of experiments 
and the column washed with copious amounts of Milli-Q water between 
experiments. See steps F-G of figure 2.4 for an illustrative representation of 
this procedure. The collected vesicle suspension post-elution contained a lipid 
concentration of ca. 2 mM, which was subsequently diluted to a concentration 
of 0.2 mM for use in efflux measurements.  
 
 
Figure 2.5: Separation of free carboxyfluorescein (CF) dye from CF-containing 
vesicles via the principle of size exclusion. (A) 300 μl of CF-encapsulated vesicles 
was deposited onto a Sephadex columnTM; one can immediately observe dilution of 
the free CF (depicted by yellow band). The red band represents the CF-containing 
vesicles. (B) Upon elution of the sample with elution buffer (solution 2.2), it is 
apparent that the free dye is retained within the column whereas the vesicle 
population clearly moves preferentially along the column (highlighted in B, by 1 and 2 
respectively). 
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2.3.2.3 Column calibration  
The SephadexTM column, used to exclude unencapsulated dye from the CF 
containing vesicles, was calibrated to confirm the lipid concentration gained 
post elution (ca. 2 mM). Note that section 2.4.1.2 describes and discusses this 
in detail, as it was an important step in assay development. In order to conduct 
these experiments, the following lipid mixture was utilised: DOPC, doped with 
the lipid Rh PE (1 mg / ml, 1318.75 g / mol) in a 99.5 : 0.5 mol % ratio. 
Fluorescence measurements were conducted using a Cary Eclipse (Varian) 
Fluorescence Spectrophotometer (Varian, Inc.). All measurements involving 
Rh PE utilised an excitation wavelength of 557 nm, with fluorescence emission 
collected from 570 – 700 nm. Excitation and emission slits were both set to 5 
nm, and a medium scan rate and a photomultiplier tube (PMT) detector 
voltage of 500 V utilised. The fluorescence experiments described within this 
chapter were conducted utilising Microwell plates (Microplate 96 well, Fisher 
Scientific Ltd), which are able to contain a total volume of 400 µl. 
2.3.2.4 Efflux measurements 
For all efflux measurements, conducted with CF, an excitation wavelength of 
490 nm was employed. Where kinetic experiments were conducted, an 
emission wavelength of 516 nm was chosen. Excitation and emission slits were 
both set to 5 nm, and a medium scan rate and a photomultiplier tube (PMT) 
detector voltage of 500 V utilised.  
The general format of the experiments involved introducing a 150 μl aliquot of 
drug solution (or buffer, for control experiments) to a 150 μl sample of dye-
loaded vesicles (lipid concentration equal to 0.2 mM) residing in one of the 
Microplate wells. The final lipid and drug concentration are therefore half that 
of their initial concentrations; the lipid concentration was always maintained at 
0.1 mM (final concentration) with the concentration of the exogenous species 
being varied. Efflux of the dye from the vesicles was then monitored by 
measuring the fluorescence intensity at 516 nm at specific intervals over time. 
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Addition of 1 % (v/v) of Triton X-100 achieved disruption of the vesicles, 
hence releasing entrapped dye into the total sample volume (303 μl) and 
enabling the final fluorescence intensity (at t → ∞) to be determined. All efflux 
measurements were conducted at room temperature.  
2.3.2.5 Critical micelle concentration (CMC) measurements 
Interfacial surface tension (IFT) measurements were conducted using an Easy 
Drop tensiometer (Krüss), for the determination of the critical micelle 
concentration (CMC) for various of drug molecules. A 0.5 ml glass syringe 
(Hamiliton, bore inner diameter = 3.256 mm), equipped with a disposable 
needle (Krüss, diameter = 1.830 mm), was used to dose and hence interrogate 
the solution of interest. The Easy Drop tensiometer and syringe mounting 
stage can be viewed in figure 2.6 A and B respectively. Note, that as water-in-
air IFT measurements were utilised in these experiments, it is crucial to ensure 
that the hanging droplet does not lose volume over time (i.e. over a 
measurement period of 10 minutes). Hence to maintain a constant volume, the 
droplet was suspended within a closed environment, i.e. a chamber, comprised 
of a glass cuvette (Starna Scientific Ltd., Type 3 (2 cm x 1 cm x 5 cm) and 
cover plate (Krüss), containing a few millilitres of buffer solution (as illustrated 
in figure 2.6 C).  
The graphs illustrated in figure 2.6 D, E and F illustrate the effect upon the 
IFT, droplet area and volume in the presence and absence of a closed 
environment. The use of a chamber (a cuvette with a few millilitres of buffer 
and a cover plate) was found to prevent droplet evaporation. 
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Figure 2.6: Apparatus used to conduct interfacial surface tension (IFT) 
measurements. (A) Easy Drop tensiometer; the red box indicates the location of the 
dosing mechanism and syringe housing. (B) An enlarged version of the motorised 
dosing syringe. (C) The specific experimental setup utilised; importantly, a cuvette 
containing a few millilitres of buffer and capped with a cover plate are used to 
minimise evaporation of the droplets under investigation. (D) Graph indicating the 
change in the IFT, area and volume of a droplet (sample is an aqueous solution of 1 
mM DOPC vesicles) without the use of a chamber (i.e. cuvette and cover plate). (E) 
The same experiments as presented in D, but in the presence of a chamber (i.e. 
cuvette and cover plate). (F) Comparison of the IFT results gained in the presence and 
absence of a chamber. 
 
All data were collected using the software programme “Drop Shape Analysis”. 
Specifically, the Trackerman programme was utilised to determine an 
equilibrium value of the IFT (IFTeq). This programme was set up to record an 
IFT measurement every 10 s, for a total duration of 10 minutes. After 
approximately 6-7 minutes the system reached equilibrium and the remaining 
data points were used to ascertain the IFTeq. Each data point represents an 
average of three or more IFTeqs, quoting an error equal to plus or minus one 
standard deviation. See figure 2.7, which illustrates the type of trace 
 
Chapter 2 
78 
 
 
Figure 2.7: Determining equilibrium values for the interfacial surface tension 
(IFTeq). (A) Example of an interfacial tension (IFT) curve gained over time using the 
Trackerman programme for a sample containing 0.2 mM WAY. The shaded region 
depicts the data used to ascertain the equilibrium value of the IFT (IFTeq) for one 
measurement. The inset image illustrates the hanging droplet from which the 
measurement was gained. (B) The graph illustrates that a constant area and volume are 
maintained throughout the duration of the experiment. 
 
gained from the Trackerman programme (for 0.2 mM WAY) and the region 
used to determine the IFTeq. 
In order to determine the CMC for a drug of interest, the IFTeq for several 
drug concentrations is determined. A plot of the IFT versus concentration can 
then be constructed. The CMC is defined as the concentration at which further 
addition of drug molecules leads to the formation of more micelles (i.e. the air-
water interface is saturated with drug monomers).234 The expected relationship 
between IFT and drug concentration is displayed in figure 2.8. Linear 
extrapolation of the data contributing to (i) the decrease in the IFT (possessing 
a negative gradient) and (ii) the point at which the IFT no longer changes will 
yield a value for the CMC. All experiments were conducted at room 
temperature. The lights in the vicinity of the tensiometer were turned off to 
ensure that good contrast was gained between the drop circumference and 
background.  
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Figure 2.8: Determination of the critical micelle concentration (CMC). The 
graph illustrates the nature of a theoretical plot of the interfacial surface tension versus 
concentration for a surfactant (i.e. drug molecule). The data is then extrapolated to 
determine the CMC, as indicated on the diagram. At low surfactant concentrations, 
relatively few monomers reside at the air-water interface. However upon increasing 
the concentration of surfactant, more and more monomers incorporate themselves at 
the interface, thus resulting in a decrease in the interfacial surface tension (IFT). At a 
critical concentration, i.e. the CMC, the air-water interface becomes saturated with 
monomers. Further increases in the surfactant concentration thus results in the 
aggregation of monomers to form increased numbers of micelles. 
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2.4 RESULTS AND DISCUSSION 
2.4.1 Assay development 
The various steps involved in the development of the CF assay are detailed in 
this section. Specifically, the assay format is addressed, as well as the steps 
taken in order to calibrate the SephadexTM column and important control 
measurements. 
2.4.1.1 Assay format 
The bulk fluorescence measurements conducted during this investigation 
utilised a well plate and followed a specific format, illustrated by figure 2.9. The 
experimental format consisted of placing 150 μl of pre-prepared vesicle sample 
loaded with dye into a well (figure 2.9 (i)), followed by a further 150 μl of drug 
or solely buffer (control) solution (figure 2.9 (ii)). The fluorescence intensity 
(f(t)) at 516 nm was monitored at 10 s time intervals after this addition and the 
system was completely disrupted with 1 % (v/v) Triton-X 100 to yield the final 
fluorescence intensity (finf, figure 2.9 (iii)). This information can also be 
represented graphically, as illustrated by the example efflux curve displayed in 
figure 2.9. 
As CF possesses a unique fluorescence fingerprint, it means that this property 
can be exploited when utilising dye-leakage assays. As described previously 
(section 2.2.1), CF is self-quenched at very high CF concentrations, which 
subsides, upon dilution, to yield an increase in the fluorescence intensity (until 
a maximum value is reached). Hence, the experiment can be tuned such that 
the complete disruption of vesicles, encapsulating 50 mM CF, results in a final 
CF concentration that is close to this maximum output intensity (i.e. a 
fluorescence intensity of ca. 700 a.u. is gained, for a given set of experimental 
conditions, when a CF concentration of at ca. 10 μM is present, see the CF 
calibration curve displayed in figure 2.10).  
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Figure 2.9: Assay format. Pictorial representation of the basic experimental format 
practised during this investigation, including a typical time-course curve monitoring 
the rate of efflux of self-quenched CF from encapsulated vesicles. Initially, 150 µl of 
the dye-loaded vesicle suspension is placed into the well (i). Upon inclusion of a 
membrane disrupting entity (ii), the increase in fluorescence intensity at specific time 
points (f(t)) can be monitored i.e. efflux of dye from vesicles. Addition of 1 % (v/v) 
Triton-X 100 yields the final fluorescence intensity (finf) after complete vesicle 
disruption (iii). Note that the initial fluorescence intensity (f0) is gained by measuring a 
sample comprised of 150 µl of the dye-loaded vesicle suspension and 150 µl of buffer 
solution (iv). 
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The total volume of aqueous solution held in the well during the experiment 
(300 μl) is known and the approximate concentration of lipid required in order 
to achieve this maximum intensity (i.e. after disruption of vesicles) may 
therefore be calculated. Each vesicle (with a diameter taken to be 100 nm) will 
contain approximately 5E-04 fl of 50 mM CF. The number of vesicles can be 
calculated and hence the molarity of lipid required, achieving the optimum 
dilution. 
For example, if a final concentration of ca. 10 μM CF is desired (ca. -5 on the 
log scale using units of mol / dm3, see figure 2.10), which should possess a 
fluorescence intensity of ca. 700 a.u. according to the calibration curve, then 
the dilution factor going from a 50 mM to a 10 μM solution would be 5000. 
Therefore the total internal vesicle volume present in the system would have to 
encapsulate ca. 0.1 μl of 50 mM CF in order for this to be achieved. 
 
Figure 2.10: Carboxyfluorescein (CF) calibration curve. The dependence of 
fluorescence intensity (490 nm excitation, 516 nm emission) upon CF concentration is 
demonstrated and several repeats of the data included (error is equal to ± 1 s.d.). 
Ideally, 100% leakage of CF from vesicle lumens would result in a final CF 
concentration that yields a fluorescence value close to the fluorescence maximum. 
 
The number of vesicles (ves) that could encapsulate 0.1 μl, calculated using a 
total internal vesicle volume of 5E-13 μl, is ca. 2E+11. The number of moles 
per vesicle, 2.5E-20 mol/ves (the value of which assumes a cross sectional area 
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of a lipid head group to be ca. 0.66 nm2 235 and a bilayer to thus contain ca. 9E-
04 lipids), can be utilised to determine the moles of lipid required, 3E-08 mol, 
and hence molarity, 1E-04 M (0.1 mM). This lipid concentration was used in all 
vesicle experiments. 
In order to normalise the data and therefore enable direct comparison between 
each experimental data set, an efflux function (see equation 2.1) can be 
implemented. This yields a result where 0 < E(t) > 1 holds,236 where E(t) is 
defined as follows: 
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f0 = the fluorescence intensity of the sample in the absence of membrane 
perturbing agent 
f(t) = the fluorescence intensity of the sample at a specific time point, t, 
after having introduced the membrane perturbing agent. 
finf = the fluorescence intensity of the sample after having introduced 1 % 
v/v Triton-X 100 
 
The percent of CF leakage is thus defined as: 
 
   %100).(1% tEleakageCF −=   Equation 2.2 
 
2.4.1.2 Calibration of column 
The first step involved calibrating the SephadexTM column, used to separate the 
CF-containing vesicles from the free dye, in order to determine the lipid 
concentration of the sample collected. Initial experiments involved preparing 
SephadexTM columns by hand; however it was found that pre-packed 
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SephadexTM columns afforded better reproducibility between column changes 
and hence less variation in the final lipid concentration collected.  
The graph displayed in figure 2.11 A indicates the percentage of lipid collected 
in each fraction, after having eluted an extruded aliquot of 12.5 mM DOPC 
(300 µl), doped with RhPE (DOPC : Rh PE, 99.5 : 0.5 mol %), through the 
column. Each fraction was found to contain 475 µl of elutant, equivalent to 
five “drops”. Fractions 6-9 were then combined, yielding a total lipid 
concentration of 2.0 ± 0.2 M (see Appendix 1). Although lipid is present in 
fraction 10, as observed in figure 2.11 A, this was not combined with fractions 
6-9. This is because fraction 10 was found to contain the first traces of the free 
dye, as determined by running a 300 µl aliquot of the CF stock solution 
through the column. 
 
 
Figure 2.11: Column calibration. (A) Graph indicating the fractions into which the 
lipid, i.e. DOPC doped with Rh PE (99.5 : 0.5 mol %), is eluted. The fluorescence 
intensities of each fraction at 591 nm were measured and the percentage of lipid in 
each calculated accordingly. Fractions 6-9 were combined and used to perform efflux 
measurements. (B) The lipid concentration of the elutant (combined fractions 6-9) 
was thought to be ca. 2.0 mM. In order to confirm this, the sample was diluted to 
form numerous solutions of different lipid concentration (DOPC : RhPE column), 
and the fluorescence intensities of each compared to a vesicle sample prepared in an 
analogous manner, which had not been eluted through a SephadexTM column prior to 
dilution (DOPC : RhPE no column). It can also be observed that a 10 fold dilution of 
the combined vesicle fractions, as is performed during each experiment, successfully 
yields a lipid concentration of 0.2 mM within error (“diluted by a factor of 10”). 
Errors represent ± 1 s.d. (n > 3). 
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Furthermore, the total lipid concentration of the combined fractions was 
confirmed by performing an examination with an external standard of known 
lipid concentration. First, the vesicle suspension assumed to be ca. 2 mM, i.e. 
the elutant comprised of the combined fractions (numbers 6-9), was diluted in 
order to yield numerous solutions of different lipid concentration. The 
fluorescence intensities of these samples (at 591 nm) were then plotted and 
displayed in figure 2.11 B. These data were then compared to an external 
standard of known concentration, where, for example, loss of lipid to the 
column could not have occurred. Specifically, a 12.5 mM DOPC : RhPE  
(99.5 : 0.5 mol %) lipid sample was extruded, diluted to form solutions of 
various lipid concentration and the fluorescence intensities measured. It can be 
observed, from figure 2.11 B, that the results from the two experiments are in 
good agreement with one another, i.e. they are within error, hence confirming 
that lipid is not lost to the column and that the lipid concentration can be 
taken to be ca. 2.0 mM. A dilution of the combined elutant fractions “by a 
factor of 10” was also included, in order to mimic the exact dilution conditions 
that occur during experiments. The results are displayed in figure 2.11 B and 
indicate that dilution falls within the remit of the external standard.   
2.4.1.3 Control measurements 
The control measurements relevant to all experiments have been included in 
this section. Those more specific to a particular experiment (such as drug-dye 
interactions) have been integrated within the relevant sections. 
Evidence for vesicle formation and encapsulation of carboxyfluorescein 
The first question one may wish to ask is what evidence can be collected to 
prove that these CF-encapsulating vesicles have indeed been produced and the 
external dye removed? A key observation that has been made certainly 
supports their formation. After fractions 6-9 have been collected from the 
column and collated (containing ca. 2.0 mM lipid and appearing red/orange in 
colour), the solution is then diluted to form a lipid concentration of 
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approximately 0.2 mM. In order to achieve this, 160 μl of the 2.0 mM lipid 
suspension is pipetted into 1440 μl of the elution buffer to yield a total volume 
of 1600 μl. Crucially, there is no change in the colour of the solution upon 
dilution, indicating that: (i) the external dye has been successfully removed and 
(ii) the vesicles maintain their form, i.e. they do not burst. Additionally, 
dynamic light scattering experiments have been conducted, revealing that the 
average diameter of the vesicle population post elution is 115 ± 4 nm. 
Effects due to scattering from vesicles alone (at a concentration of 0.1 mM) 
One may expect phospholipid vesicles to scatter light, being spherical entities. 
As these assays utilise 490 nm light to excite the samples, it is important to 
investigate to what extent it is dispersed. A control has been performed with 
solely DOPC vesicles, where the final concentration of lipid ranges from 12.5 
mM to 4 μM. The data are displayed in figure 2.12 A. It can be seen that at the 
concentrations employed in this investigation (0.1 mM final), only a very small 
contribution to the fluorescence intensity will arise due to scattering in the 
region of interest (500-600 nm).  
Assessing leakage of CF from vesicles over time 
An important control includes assessing the rate of leakage of encapsulated CF 
from the interior of a vesicle, i.e. when the vesicles are present in buffer alone 
and no membrane perturbing species have been introduced. This has been 
assessed over 1 hour time periods, with the CF containing vesicles being used 
no longer than 1 hour after production. Figure 2.12 B illustrates that CF 
leakage from vesicles in the absence of membrane perturbing species is 
minimal, over a one hour time period.  
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Figure 2.12: Control measurements. (A) Influence on the fluorescence intensity due 
to scattering from vesicles alone (using different lipid concentrations), where an 
excitation wavelength of 490 nm is employed. (B) Graph illustrating the extent of CF 
leakage from vesicles over a one hour time frame. It can be observed that the addition 
of Triton-X 100 results in the release of the internalised dye. (C) Effect of Triton-X 
100 addition on the fluorescence intensity of CF over a wide concentration range.  
 
Triton-X 100 and carboxyfluorescein control 
The effect of Triton-X 100 on the fluorescence intensity of CF has also been 
investigated over a range of concentrations, as illustrated by the graph 
presented in figure 2.12 C. Within error, it can be ascertained that Triton-X 
100 does not affect the final fluorescence intensity. Every attempt was made to 
ensure the amount of Triton-X 100 introduced was equivalent, though this was 
often difficult due to the viscous nature of the surfactant.  
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2.4.2 Reproducibility of assay: investigations with chlorpromazine, WAY and 
imipramine 
The first experiments included investigating the reproducibility of the assay. In 
order to achieve this, three water soluble drugs were chosen, namely 
imipramine, WAY and chlorpromazine. The effect of drug concentration on 
the efflux of CF from vesicle lumens was investigated, the results of which are 
displayed in figure 2.13. Note that each repeat comprised freshly made vesicle 
and drug suspensions. 
 
 
 
Figure 2.13: Effects of three drugs (three repeats for each) on the efflux of 
carboxyfluorescein from DOPC vesicles (buffer only). (A-C) Imipramine, (D-F) 
WAY, (G-I) chlorpromazine. Drug concentrations employed (final) are represented as 
follows: 1.6 mM (●), 0.8 mM (●), 0.4 mM (●), 0.2 mM (●), 0.1 mM (●), 0.05 mM (●), 
0 mM (●). 
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Visual inspection of the efflux curves displayed in figure 2.13 reveals that there 
is a good level of reproducibility from experiment to experiment (for each drug 
investigated). It was important to utilise drug and vesicle suspensions that were 
freshly made in each instance, in order to introduce as much variation as 
possible into the experimental data gained. It can also be observed that efflux 
of CF is dependent upon the concentration of drug present. Generally 
speaking, the more drug molecules present per set volume, the faster the rate 
of CF release. In simple terms, this can be understood by considering the 
amount of amphiphilic drug molecules available to intercalate at the polar / 
apolar interface of the lipid membrane - the more drug molecules that are 
present, the more likely it is that they are able to incorporate themselves within 
the amphiphilic lipid environment. The chemical motifs of imipramine, 
chlorpromazine and WAY are displayed in figure 2.14 for reference. 
 
 
Figure 2.14: The chemical motifs of imipramine, chlorpromazine and WAY. (A) 
imipramine, (B) chlorpromazine and (C) WAY. 
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In order to gain quantitative information from the data presented in figure 
2.13, the efflux curves were fitted using an exponential decay model to 
ascertain the initial rate of CF release (see Appendix 2 for further information). 
The dependency of the initial rate of CF release on drug concentration (with 
regards to chlorpromazine, WAY and imipramine) has been summarised 
graphically and is displayed in figure 2.15 A.  
Not only can it be observed that the rate of CF release is linked to changes in 
drug concentration (where the final lipid concentration remains constant), the 
assay is able to distinguish between relative initial rates of CF release due to the 
introduction of different drug samples present at different concentrations in 
solution. For example, it can be observed from figure 2.15 A that the initial 
percent of CF release per minute (initial % CF release / min) is more 
prominent for chlorpromazine, than for WAY or imipramine and hence the 
ability of these drugs to induce CF release can be ranked in the following 
order: 
 
chlorpromazine > WAY > imipramine  
 
This is easily visualised if the initial % CF release / min for a specific drug 
concentration is monitored (e.g. 0.4 mM). 
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Figure 2.15: Dependency of carboxyfluorescein (CF) leakage upon the 
introduction of chlorpromazine, WAY and imipramine. (A) Dependency of the 
initial rate of CF release on the concentration of chlorpromazine, WAY and 
imipramine. (B) The percentage of CF released after 50 minutes in the presence of 
different concentrations of chlorpromazine, WAY and imipramine. Reported errors 
represent ± 1 s.d. (where n ≥ 3). 
 
 
These results are consistent with those previously reported in the literature. It 
has been shown, using surface plasmon resonance (SPR) techniques, that 
chlorpromazine exerts more pronounced effects on DOPC bilayers than 
imipramine.214 Chlorpromazine is thought to bind more to DOPC bilayers, 
compared to imipramine, due to the fact that chlorpromazine is more 
hydrophobic.214,237 Hence the degree of drug interaction with the hydrophobic 
lipid bilayer is enhanced, causing increased levels of molecular disorganisation 
and resulting in increased levels of CF release. The water solubility of 
imipramine is twice that of WAY (50 and 25 mg / ml respectively238,239), which 
may provide one explanation as to why WAY induces a greater effect on CF 
leakage than imipramine.   
A graph illustrating the percent of CF released from vesicle lumens, fifty 
minutes after introducing chlorpromazine, WAY and imipramine, has also 
been constructed (see figure 2.15 B). This provides information about the 
extent of CF released at later time points (as t → ∞) with different drug 
concentrations. Naturally, the data displayed in figure 2.15 B mirrors the 
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information represented in figure 2.15 A: a higher drug concentration leads to 
a higher initial rate of release, which in turn will lead to a greater percent of CF 
release, if capturing the data at a specific time point. It can be observed that the 
data could be represented by a sigmoidal function, where the percent of CF 
released after 50 minutes begins to approach a plateau as the drug 
concentration is increased. However, upon looking at the traces for 
chlorpromazine and WAY, in figure 2.15 B, it can observed that the percent of 
CF released after 50 minutes appears to decrease after the introduction of 
certain drug concentrations (i.e. drug concentrations at the higher end of the 
spectrum utilised). The reason why this feature occurs is due to the presence of 
drug-dye interactions. More specifically, the apparent decrease in the 
percentage of CF released after 50 minutes observed in the presence of 
chlorpromazine and WAY (figure 2.13 and 2.15 B) is due to the dye interacting 
with drug micelles, which is a well known phenomenon.240 Hence, the use of a 
dye that internalises within surfactant micelles is one way in which to 
determine the critical micelle concentration (CMC) for a drug.241,242 CMC 
measurements have been undertaken in order to confirm this finding using a 
drop tensiometer (see section 2.3.2.4 for further information). The dependence 
of the interfacial surface tension on the concentration of chlorpromazine, 
WAY and imipramine has been determined, and is displayed in figure 2.16 G, 
H and I. The leakage data (initial percentage of CF release per minute and 
percentage of CF release after 50 mins) have also been included in figure 2.16 
for each drug investigated.  
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Figure 2.16: Comparison of the leakage data for chlorpromazine, WAY and 
imipramine with the data gained from interfacial surface tension 
measurements. (A), (B) and (C) illustrate the dependence of the initial percentage of 
CF release per minute upon the introduction of different concentrations of 
chlorpromazine, WAY and imipramine respectively. (D), (E) and (F) illustrate the 
dependence of the percentage of CF released after 50 minutes upon the introduction 
of different concentrations of chlorpromazine, WAY and imipramine respectively. 
(G), (H) and (I) illustrate the dependence of the interfacial surface tension (IFT) on 
the concentration of chlorpromazine, WAY and imipramine respectively. Reported 
errors represent ± 1 s.d. (where n ≥ 3). 
 
Inspection of the data presented in figure 2.16 H, shows that the interfacial 
surface tension (IFT) reaches a plateau at relatively low concentrations of 
WAY (i.e. at concentrations approximately equal to or greater than 0.2 M). 
Hence the CMC, in the case of WAY, is obtained at a relatively low 
concentration (ca. 0.2 mM). The CMC for chlorpromazine is much higher than 
for WAY. It can be observed from the plot of IFT versus concentration, in 
figure 2.16 G, that the reduction in the IFT from 0.8 to 1.6 mM deviates from 
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linearity, indicating that the CMC is fast being approached but has not yet been 
achieved. Imipramine has a comparatively high CMC; figure 2.16 I illustrates 
that a linear relationship between the IFT and drug concentration still exists up 
to concentrations of 1.6 mM. 
Importantly the results discussed previously and illustrated in figure 2.16 G, H 
and I corroborate the trends observed in the leakage data. Firstly, as the CMC 
for imipramine is the highest of the three drugs examined and has not been 
reached at the highest concentration employed in these experiments, the 
presence of the drug will have a minimal effect on the dye. However, 
chlorpromazine and WAY affect the dye at higher drug concentrations. 
Discrepancies in the CF efflux data, owing to the presence of these drugs, can 
be observed in figure 2.16 D and E. Specifically, the percentage of CF released 
is found to decrease and hence based on the experiments described previously, 
this phenomenon can be attributed to the presence of drug micelles. Moreover, 
a greater percentage of CF appears to have been “removed” from the system 
when 1.6 mM WAY is introduced to CF-containing vesicles c.f. 1.6 mM 
chlorpromazine. It is thought that this is due to the presence of a greater 
number of drug micelles comprised of WAY at this concentration, c.f. 
chlorpromazine, when taking the IFT data for these drugs into consideration. 
Hence more dye can be sequestered by WAY drug micelles at this 
concentration. Perhaps therefore the CF assay may also present an interesting 
way in which to determine the CMC for drugs of interest. As an aside, it was 
also found that drug-dye controls, performed in the absence of lipid vesicles, 
mirror the CMC data (Appendix 2 for confirmation of drug-dye interaction). 
The degree by which the IFT is reduced by chlorpromazine, WAY and 
imipramine (figure 2.16 G, H and I) appears to correlate with the initial rate of 
release (figure 2.16 A, B and C), i.e. chlorpromazine molecules seem to cause a 
larger drop in the IFT compared to WAY, with WAY resulting in a larger 
change in the IFT than impramine, for a set concentration. A larger decrease in 
the IFT reveals that the drug molecules interact more favourably with the air-
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water interface. Hence, these data appear to reflect the drugs’ abilities to bind 
to and consequently disrupt the membrane (i.e. their amphiphilicity).    
Additionally, the data presented in figure 2.16 A and B, indicate that the initial 
rate of CF release starts to reduce and plateaus as the CMC of the drug is 
approached. This is an important result as it suggests that increasing the drug 
concentration above its CMC does not act in a beneficial manner in terms of 
the rate of CF release. This result can be understood when considering the 
relative concentrations of drug monomers in solution above and below the 
CMC. Below the CMC the number drug monomers in solution will increase 
with concentration, hence higher drug monomer concentrations will result in a 
higher degree of membrane perturbation. Above the CMC, however, the drug 
monomer concentration in solution will plateau, as the additional drug 
monomers participate in forming micelles; this therefore explains why 
increasing the drug concentration above its CMC does not further increase the 
rate of CF release. 
 
2.4.3 Dependency of efflux rate on DOPE content 
In order to demonstrate the flexibility of the CF assay and to provide an 
example of the type of biophysical measurements that can be conducted, the 
effect of increasing the level of DOPE in a DOPC bilayer on drug-induced CF 
leakage was monitored. This has not knowingly been investigated or published 
to date for chlorpromazine, WAY and imipramine.  
The reason for considering PC bilayers, doped with different amounts of PE, 
is that these lipids are both predominant in mammalian membranes, both in 
the plasma membrane and membranes of cell organelles.37 Biophysical studies 
aim to understand how incremental changes in one parameter at a time effect 
the overall system, thus building a picture containing increasing levels of 
complexity (i.e. using a bottom up approach). 
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It was hypothesised that the rate of CF release would increase, upon increasing 
the mole percent of DOPE in a DOPC bilayer. DOPE is a non-bilayer 
forming lipid, classed as Type II (see chapter 1, section 1.2.2.3) and as such 
DOPC bilayers containing DOPE possess higher levels of curvature elastic 
stress (as discussed in chapter 1, section 1.2.2.4). Hence, one would expect 
CADs to bind more avidly to such membranes in order to release this stress.243  
2.4.3.1 Calibration of column using vesicles comprised of DOPC : DOPE 
The first step involved calibrating the SephadexTM column to ensure that 
vesicles comprised of DOPC : DOPE are eluted into the same fractions. 
Figure 2.17 A illustrates that the majority of vesicles were eluted into fractions 
6-9, which is consistent with the results gained previously; the lipid 
concentration of the combined eluted fractions (6-9) for a 12.5 mM DOPC : 
DOPE : RhPE (79.5 : 20 : 0.5  mol % respectively) sample was found to be 2.1 
± 0.3 mM (see Appendix 3). Note that it was also possible to easily check 
which fractions the lipid sample was eluted into by visually inspecting the 
fractions. Specifically, the fractions containing the eluted vesicle suspension 
(i.e. 6-9) appeared red/orange in colour. No discrepancies were found with 
respect to the fractions into which the various DOPC : DOPE vesicle samples 
used in this investigation were eluted.  
Experiments were performed as described previously (section 2.3.2.3) in order 
to determine the lipid concentration after dilution. Figure 2.17 B illustrates that 
the concentration of the collated fractions when diluted (DOPC : DOPE : 
RhPE column; 79.5 : 20 : 0.5 mol % respectively): (i) is consistent with the 
measured external standard (DOPC : DOPE : RhPE no column), (ii) is 
consistent with the DOPC measurements acquired previously (DOPC : RhPE 
column and DOPC : RhPE no column) and (iii) successfully yields a lipid 
concentration of 0.2 mM, within error, upon diluting the combined fractions 
by a factor of ten (“diluted by a factor of 10”, figure 2.17 B), as is performed 
during each experiment.  
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Figure 2.17: Calibration of column 2. (A) Graph indicating the fractions into which 
the lipid, i.e. DOPC doped with DOPE and Rh PE (79.5 : 20 : 0.5 mol % 
respectively), is eluted. The fluorescence intensities of each fraction at 591 nm were 
measured and the percentage of lipid in each calculated accordingly. Fractions 6-9 
were combined and used to perform efflux measurements. (B) The lipid concentration 
of the elutant (combined fractions 6-9) was thought to be ca. 2 mM. In order to 
confirm this, the sample was diluted to form numerous solutions of different lipid 
concentration (DOPC : DOPE : RhPE column), and the fluorescence intensities of 
each compared to a vesicle sample prepared in an analogous manner, which had not 
been eluted through a SephadexTM column prior to dilution (DOPC : DOPE : RhPE 
no column). The data gained after having calibrated the column with solely DOPC : 
RhPE has been included for comparison (DOPC : RhPE column and DOPC : RhPE 
no column). Additionally it can be observed that a 10 fold dilution of the combined 
vesicle fractions, as is performed during each experiment, successfully yields a lipid 
concentration of 0.2 mM within error (“diluted by a factor of 10”). Errors represent ± 
1 s.d. (n > 3). 
 
2.4.3.2 Control for CF vs DOPC : DOPE samples 
A further control involved investigating the effect of introducing DOPE into a 
DOPC bilayer upon the final fluorescence intensity, gained after adding 
Triton-X 100. For example, it is important to determine whether there may be 
any substantial effects due to the introduction of differing amounts of a second 
lipid into the system. Upon the addition of Triton-X 100 (1 % v/v) to 0.1 mM 
vesicle suspensions, comprised of varying amounts of DOPE in a DOPC 
bilayer (specifically 0, 20, 40 and 60 mol % DOPE), it was determined that 
there is very little effect on the final fluorescence intensity after disruption 
when 20 and 40 mol percent of DOPE is included (compared to the pure 
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DOPC sample). There does appear, however, to be a slight reduction in the 
final fluorescence intensity as the percentage of DOPE is increased to high 
levels, i.e. 60 mol %, although this does not greatly affect the line of best fit 
(linear regression, gradient equal to -0.2 ± 0.3 fluorescence units / DOPE mol 
%). The results of this experiment can be viewed in figure 2.18.  
 
Figure 2.18: Control investigating the effect of introducing DOPE into a DOPC 
bilayer upon the final fluorescence intensity. The final fluorescence intensity has 
been measured (■) for a series of CF-containing vesicle suspensions upon the 
introduction of Triton-X 100 (1 % v/v). Specifically, the lipid systems investigated 
involve using DOPC : DOPE with the respective mol % equal to 100 : 0, 80 : 20, 60 : 
40 or 40 : 60. The fluorescence intensity of the vesicle suspensions prior to the 
addition of Triton-X 100 has also been included (●). Errors represent ± 1 s.d. (n > 3). 
 
2.4.3.3 Results for DOPC : DOPE samples 
Figure 2.19 illustrates the results of experiments conducted with 
chlorpromazine, WAY and imipramine, to determine the effect on the rate of 
CF leakage upon introducing varying amounts of DOPE into the lipid system. 
The dependence of both the initial rate of CF release and the percentage of CF 
released after 50 minutes upon drug concentration was investigated and 
compared to the results gained in section 2.4.2. 
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Figure 2.19: Effect of introducing DOPE, into DOPC bilayers, upon the rate of 
carboxyfluorescein leakage. (A), (C) and (E) illustrate the dependence of the initial 
percentage of CF release per minute upon the introduction of varying mol percents of 
DOPE within a DOPC bilayer, as well as different concentrations of chlorpromazine, 
WAY and imipramine respectively. (B), (D) and (F) illustrate the dependence of the 
percentage of CF released after 50 minutes upon the introduction of varying mol 
percents of DOPE within a DOPC bilayer, as well as different concentrations of 
chlorpromazine, WAY and imipramine respectively. Errors represent ± 1 s.d. (n > 3). 
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The results displayed in figure 2.19 A, C and E (also consult Appendices 4, 5 
and 6) indicate that the initial rate of CF release is dependent upon the mole 
percent of DOPE incorporated into a DOPC bilayer (as well as the drug 
concentration, as previously established). It can be observed that the initial rate 
of CF release in fact decreases as the DOPE content increases, which opposes 
the original hypothesis; there exists a consistent decrease in the initial rate of 
CF release for each of the three drugs. 
It is thought that a decrease in the initial rate of CF release with increasing 
DOPE content prevails due to the presence of hydrogen bonding between the 
DOPE head groups and drug molecules. In contrast to DOPC, the head group 
of DOPE consists of an -NH3+ group (for DOPC, the head group is –NMe3+). 
Figure 2.20 illustrates the chemical nature of DOPC and DOPE. The 
formation of hydrogen bonds between drug and lipid head groups will 
therefore prevent drug molecules from intercalating at the polar / apolar 
interface, thus essentially being sequestered at a position farther away from this 
interface and reducing membrane disruption and the extent of CF leakage. It 
therefore follows that the greater the DOPE content, the more pronounced 
the observed effect, which can be observed in the graphs presented in figure 
2.19 A, C and E. One point to note is that the fits to the 100 % DOPC efflux 
curves, used to gain the initial rate of CF release, yield less satisfactory results 
when the highest measureable drug concentrations are used (0.4 mM for 
chlorpromazine and 1.6 mM for WAY and imipramine). Essentially an 
underestimate of the initial rate of CF release is afforded due to the fact that 
these experimental conditions yield very fast rates of CF efflux. Consequently, 
it is very difficult to capture the first few data points using this experimental 
format making it difficult to realise a true representation. 
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Figure 2.20: Chemical motifs of DOPC and DOPE. The chemistry of the head 
groups for DOPC and DOPE are displayed in (A) and (B) respectively (grey boxes). 
 
The data presented in figure 2.19 B, D, and F again mirror the information 
gained in figure 2.19 A, C and E. Generally speaking, the data indicate that the 
percent of CF released at a specific point in time, i.e. 50 minutes after having 
introduced the drug to the dye loaded vesicles, is very much dependent on the 
mole percent of DOPE present. This is true for chlorpromazine, WAY and 
imipramine up to concentrations of 0.4, 0.8 and 1.6 mM respectively. However 
above a drug concentration of 0.4 and 0.8 mM, for chlorpromazine and WAY 
respectively, the percent of CF released after 50 mins is approximately equal, 
suggesting that virtually all of CF has been released.  
Additionally, the inclusion of only 20 mol % DOPE appears to have a bigger 
effect on the initial rate of the release for WAY, in comparison to 
chlorpromazine and imipramine. This suggests that WAY molecules are 
sequestered more avidly by the lipid membrane. Upon examining the chemical 
motif of WAY, it can be observed that the number of potential regions where 
hydrogen bonding can occur is greater than for chlorpromazine and 
imipramine (see figure 2.14, section 2.4.2 for chemical motifs). Hence it is 
postulated that WAY can participate in more hydrogen bonding events with 
the lipid membrane, or more specifically with DOPE. This explains the 
reduction in the initial rate of release. Furthermore, this observation provides 
more evidence to support the aforementioned rationale: that it is the presence 
of DOPE which leads to the reduction in the initial rate of CF release. 
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2.5 CHAPTER SUMMARY 
The studies presented demonstrate that the CF leakage assay has been 
successfully set up, affording reproducible data comparable with trends 
observed in the literature. Additionally, studies highlight the fact that this 
methodology is able to afford important information about the interaction of 
drug molecules with model lipid membranes. For example, the influence of 
increasing the mole percent of DOPE in a DOPC bilayer has been 
investigated, which was found to reduce the rate of leakage. Hence this assay 
provides the means to gain further insight into the interaction of drug 
molecules with lipid membranes at the molecular level.  
However, in order to elucidate the effects of different drug compounds on 
many lipid compositions, where changes in lipid head and tail groups can be 
investigated, substantial data sets need to be gained – not only in terms of 
probing different parameters that affect drug-membrane interactions, but also 
with respect to affording reliability in the data from numerous repeat 
measurements. In turn this will require significant amounts of reagents, as well 
as time. Accordingly, the use of microfluidic technologies offers a solution to 
this problem, where the opportunity to perform numerous experiments in 
quick succession is possible. Additionally, microfluidic technologies only 
require very small amounts of reagent, i.e. drug, which will also result in these 
experiments becoming more economically viable. Chapter 3 details the steps 
taken in order to translate the CF leakage assay into a high-throughput format 
using microfluidic technologies. 
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Chapter 3 
 
Translation of carboxyfluorescein leakage assay into 
a microfluidic format 
 
 
 
“Anybody who has been seriously engaged in scientific work of any kind realizes that over the 
entrance to the gates of the temple of science are written the words: ‘Ye must have faith.’” 
Max Planck 
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3.1 OVERVIEW 
Chapter 3 builds on the work detailed in chapter 2, demonstrating that the 
carboxyfluorescein (CF) leakage assay can be performed in a microfluidic 
format and hence offers the possibility to rapidly screen drug- and protein-
membrane interactions in high-throughput.  
Initial attempts involved using fluorescence intensity measurements to perform 
the leakage assay in a microfluidic format. Unfortunately, calibration of 
experiments proved problematic and it was therefore decided to utilise time-
resolved fluorescence measurements. Preliminary results suggest that this 
technique offers a potential solution to the problems encountered with the 
fluorescence intensity measurements. 
 
3.2 INTRODUCTION 
3.2.1 Droplet microfluidics 
As detailed in chapter 1, section 1.4.1, microfluidic droplet technologies are 
emerging as a real alternative for use in high-throughput screening. Segmented 
flow in microchannels, i.e. the formation of water-in-oil droplets via the T-
junction or flow-focusing methods (section 1.4.1.3), is highly advantageous.  
Not only does this technology enable rapid, efficient and reproducible mixing 
to occur inside each microdroplet,111 segmented flow also ensures that uniform 
mixing is achieved. As thousands of droplets may be produced per second 
using this technique, acting as individual experimental vessels, it also means 
that large data sets can be collected therefore enabling more sophisticated 
statistical analyses to be performed. Hence it can be observed that droplet 
microfluidics offers many advantages over conventional technologies for 
performing assays, such as 96-well plate assays in fluorescence 
spectrophotometers. 
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The work described in this chapter utilises droplet-based microfluidics, owing 
to the format of the experiment being conducted. Specifically, the drug-
dependent leakage of CF, from phospholipid vesicle lumens, is monitored over 
time. Such an assay, able to probe the interactions of drug molecules with a 
specific membrane of choice, has not previously been performed in a 
microfluidic device. The major technique used in the experiments described in 
this chapter was time-resolved fluorescence spectroscopy. Fluorescence 
lifetime imaging microscopy (FLIM) was also employed. Hence an 
introduction to the topic of the fluorescence lifetime has been afforded for the 
reader.  
 
3.2.2 Fluorescence lifetime measurements 
The fluorescence lifetime, denoted by τ, describes the average time that an 
fluorophore remains in its excited state before emitting a photon and hence 
returning to its ground state.244 This emission is not fixed and occurs randomly; 
hence the fluorescence lifetime is a statistical average, described by the time 
constant in an exponential decay function such as that detailed in figure 3.1. A 
typical intensity versus time plot that one would collect during a lifetime 
experiment is illustrated in figure 3.1. 
The lifetime, which can be gained by measuring the gradient of a plot of ln I(t) 
versus t for fits to single exponential decays, is equivalent to the inverse of the 
total decay rate (i.e. the sum of the emissive rate, k, and the non-radiative decay 
rate, knr) and is often ascertained using specialist software packages. The 
fluorescence lifetime of a fluorophore can range from the order of a few 
picoseconds to the microsecond regime. 
There are several measurements that can be utilised to determine the 
fluorescence lifetime. These involve using time- or frequency-domain 
measurements.244 Time-domain measurements have been used in the 
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Figure 3.1: A typical plot of intensity versus time gained during a fluorescence 
lifetime experiment. The short excitation pulse and subsequent fluorescence decay 
are represented by the green and red traces respectively. The exponential decay 
function used for a single exponential fit is included and the time constant, i.e. the 
fluorescence lifetime (τ) can be extracted.  
 
experiments described within this chapter, specifically time-correlated single-
photon counting (TCSPC), as this was the technique available. 
The basic principle of TCSPC is demonstrated in figure 3.2 A-C. A laser pulse 
of light is used to excite the sample of interest, which results in a photon being 
emitted at a specific time after excitation. Figure 3.2 A illustrates this principle, 
where three excitation pulses result in the emission of three photons, but with 
each photon emitted at a different time after excitation. The use of a pulsed 
laser, having a pulse repetition rate of 80 MHz, means that 80E-06 pulses 
occur per second. Hence a large number of photons can be sampled, if a data 
collection window of 5 minutes is used for example. A histogram of their 
respective times can be collated and the data then fit to an exponential decay. 
Figure 3.2 B illustrates how the time for photon emission to occur can vary for 
a hypothetical sample of eight photons, after having excited the sample with 
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Figure 3.2: Principle of time-correlated single-photon counting (TCSPC) used 
to extract information about the fluorescence lifetime. (A) This image illustrates 
how the time taken for an excited sample to emit a photon can vary, hence being a 
random process. The blue waveforms represent the laser pulse used to excite the 
sample and the red waveforms the emitted photons. (B) If one excites the sample 
several times, one can begin to build up a ‘picture’ of how many photons correlate to a 
specific emission time, as shown in this image. (C) After collecting a sufficient amount 
of data, a histogram can therefore be constructed and an exponential decay curved 
fitted in order to extract the fluorescence lifetime. (D) This image illustrates the data 
one may gain if using fluorescence lifetime microscopy. Each pixel gives a value of the 
fluorescence lifetime, meaning that information about the lifetime in a specific 
environment can be gained. The six colours each represent a different value of the 
fluorescence lifetime (τ1 - τ6). Images revised from Lakowicz244 and Leica website.245  
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eight pulses of light. Subsequently, the registered number of photons that 
possess specific emission times are collated, after which a histogram can be 
constructed, such as that illustrated in Figure 3.2 C, and a decay curve fitted.  
Fluorescence lifetime measurements can also be conducted using microscopy, 
where an image can be constructed that describes the change in the 
fluorescence lifetime of a region of interest. This method is known as 
fluorescence lifetime microscopy (FLIM) and has been used to conduct the 
microfluidic experiments described in this chapter. Figure 3.2 D illustrates an 
example of an image that one might expect to gain using FLIM. Importantly, 
the image reports any changes in the fluorescence lifetime observed in the 
environment probed. 
 
3.2.3 Summary and chapter aims 
Microfluidic droplet technologies offer many advantages over conventional 
assay formats. Therefore, the ability to translate the CF assay, detailed in 
chapter 2, into a high-throughput, microfluidic format is highly desirable. In 
summary, the experiments detailed in this chapter aim to:  
 
1. Demonstrate that it is feasible to translate the CF leakage assay into a 
microfluidic format, using microfluidic droplet technologies.  
2. Indicate that fluorescence intensity measurements are not suitable for 
assaying leakage in a quantitative manner. 
3. Demonstrate that fluorescence lifetime measurements allow the leakage 
assay to be performed in a quantitative fashion and in high-throughput. 
4. Demonstrate the potential for translating other assays into a high-
throughput format, which involves performing fluorescence 
measurements on bulk vesicle populations.  
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3.3 MATERIALS AND METHODS 
3.3.1 Materials 
3.3.1.1 Dye and buffer solutions 
The dye solutions and buffers required in order to conduct the experiments 
detailed in this chapter incorporated the following: Trizma® hydrochloride 
(TRIS-HCl), sodium chloride (NaCl), sodium hydroxide (NaOH) and CF, all 
of which were purchased from Sigma-Aldrich®. 
3.3.1.2 Photomasks 
Photomasks, required for the production of photolithographical features, were 
designed using the design software package AutoCAD 2005. The masks were 
sent to and generated by JD Photo-Tools (Photodata Test Services Ltd, 
Oldham). Specifications are as detailed herein: 
 
• Mask type: emulsion on polyester film 
• Size: 10’’ x 12’’ 
• Polarity: darkfield 
• View side: design is viewed from chrome/emulsion side 
• Resolution: high 
 
3.3.1.3 Soft-lithography and substrate materials 
Materials required for production of microfabricated structures via soft-
lithography include the following: 100 mm silicon-wafers (thickness 525 ± 25 
μm & single sided polish, IDB Technologies UK Ltd.), Su-8 50 photoresist 
(Chestech Ltd.), Microposit EC-Solvent (Chestech Ltd.) and Sylguard 184 
Elastomer Kit (VWR). A UV lamp was used to irradiate the exposed 
photoresist. Silicon wafers and glass slides (VWR) were cleaned prior to use 
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with a 1:2 mixture of hydrogen peroxide and concentrated sulphuric acid 
(‘piranha’ solution) (Sigma-Aldrich). Distilled water and isopropylalcohol (IPA, 
Sigma-Aldrich) were used for rinsing.  
Polytetrafluoroethylene (PTFE) ultramicrobore tubing (0.004” ID, 
Cole‐Parmer Instrument), a hole punch (able to punch holes possessing a 
diameter slightly smaller than 0.004”), plastic syringes (disposable BD Plastipak 
Syringes) and needles (BD Microlance 25G 1” – Nr. 18, 0.5 × 25 mm) were 
used as a means to inject fluid into microfluidic devices. 
3.3.1.4 Performing measurements in microfluidic devices 
In order to generate water-in-oil droplets and hence perform experiments in 
microfluidic devices, one requires several syringe pumps in order to control 
fluid manipulation through microfluidic channels. Specifically, three syringe 
pumps (PHD 2000, Harvard Apparatus) were required to control the flow of 
two aqueous solutions and one oil carrier fluid. The surfactant / oil mixture 
utilised in the experiments detailed in this chapter was 1.8 % E2KO660126 (a 
kind gift from Raindance Technologies, USA) in FC40 (Sigma-Aldrich®). 
3.3.1.5 Carboxyfluorescein leakage assay 
DOPC (Avanti Polar Lipids), was used to form vesicle suspensions for the 
leakage experiments detailed in this chapter. PD-10 columns containing 
SephadexTM G25m media (GE Heathcare) were used to remove external dye 
from the vesicle suspensions, after which the collated vesicle fractions were 
diluted to yield a final lipid concentration of 0.2 mM (see chapter 2, section 
2.3.2.2 for further information). Imipramine HCl (Sigma-Aldrich®) was chosen 
to induce CF leakage in the preliminary experiments described within this 
chapter. Microwell plates (Microplate 96 well, Fisher Scientific Ltd.) and a 
quartz cuvette (Fisher Scientific Ltd., path length 10 mm) were required to 
conduct both fluorescence intensity and lifetime measurements in a non-
microfluidic format.  
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3.3.2 Methods 
3.3.2.1 Dye and buffer preparation 
Solutions 2.1 and 2.2 (as detailed in chapter 2, section 2.3.1.2) were prepared 
and used in the experiments described in this chapter. 
 
3.3.2.2 Creation of photomask 
Photomasks were created using the software package, AutoCAD 2005. A 
screen shot of the software interface is depicted in figure 3.3 A, where 
examples of the types of features and designs that can be generated in 
AutoCAD, to produce a photomask, are displayed. Figure 3.3 B illustrates the 
actual photomask used to create the devices described in the experiments 
conducted in this chapter. The document “Design Rules for Photomask 
Generation”,246 produced by JD Photo-Tools, was consulted for advice with 
respect to drawing designs in AutoCAD. Note that white features in the 
computer design correspond to areas of transparency in the resulting 
photomask film (and thus raised features in the patterned photoresist).  
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Figure 3.3: Software used to create photomask designs. (A) A screenshot of the 
software package, AutoCAD 2005, used to compose photomask designs; the enlarged 
area (highlighted by the red boxes) illustrates examples of designs that can be 
generated. The photomask displayed in (B) represents the design used to create the 
microfluidic chip detailed in the CF leakage experiments on chip (note that the width 
of the channels are ca. 300 μm, with a depth of 50 μm).  
 
3.3.2.3 PDMS preparation 
Sylguard 184 Elastomer Kit, composed of PDMS (poly(dimethylsiloxane)) 
elastomer and curing agent, was mixed in a 10:1 ratio respectively to yield a 
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total weight of ca. 30 g (a suitable volume to cover the 100 mm patterned 
silicon wafer with ca. 3 mm PDMS). A plastic stirrer was used to mix the two 
components efficiently. After thorough mixing, the PDMS was degassed to 
remove remnant air bubbles; the PDMS was placed in a dessicator attached to 
a vacuum pump for approximately 30 minutes to achieve this. 
3.3.2.4 Procedure for microfluidic device assembly 
After thorough washing of the silicon wafer(s) in piranha solution (see section 
3.3.1.3), rinsing with IPA and then drying with compressed air, the wafer was 
allowed to dry on a hotplate at 200 oC for 5-10 minutes. SU-8 50 photoresist 
was then spin coated onto the clean wafer to yield a 50 µm thick layer (single 
coat) as illustrated in figure 3.4. Coating of the wafer required a spread cycle 
(ramp to 500 rpm at 100 rpm / s, hold for 10 s) and a spin cycle (ramp to 2000 
rpm at 300 rpm / s, hold for 30 s). 
Several procedures then follow in order to process the photoresist to form a 
micropatterned substrate. The spin coated photoresist was subjected to a soft 
bake, composed of two baking steps: (i) pre-bake at 65 oC for 6 minutes and 
(ii) soft bake at 95 oC for 20 minutes. The photomask is then placed on top of 
the soft baked photo resist film and exposed to UV irradiation, as illustrated by 
step (i) in figure 3.4. MicroChem’s processing guidelines should be consulted 
for further information concerning exposure optimisation / exposure energies 
etc.).246 A post exposure bake (PEB) is performed to afford selective cross-
linking of the exposed SU-8 film; a two-step increase in heating is required in 
order to avoid creating unnecessary stresses within the film. Specifically, post 
exposure bakes at i) 65 oC for 1 minute and ii) 95 oC for 5 minutes were 
performed. Finally the SU-8 was developed, as shown by step (ii) in figure 3.4, 
using Microposit EC-Solvent (following optimum developing times), rinsed 
with IPA and dried in a stream of air after allowing the wafer to cool slowly. 
Pre-prepared PDMS (see section 3.3.2.3 for PDMS preparation) was then  
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Figure 3.4: Processes involved in PDMS chip manufacture, using 
photolithography techniques. The steps specifically involve: (i) irradiating a thin 
layer of photoresist (spin coated onto a silicon wafer) with UV light through a 
photomask, (ii) removing the exposed photoresist with developer, (iii) pouring pre-
prepared PDMS over the patterned microstructures in the photoresist and allowing 
the PDMS to set, (iv) carefully peeling the PDMS off the silicon wafer and (v) 
assembly of chip by bonding the patterned PDMS to glass slides (the photograph 
illustrates an example of a microfluidic device). 
 
poured over the patterned SU-8 photoresist and left to set overnight on a level 
surface (step (iii) in figure 3.4). Note: all chip fabrication was carried out in a 
specialised clean room. 
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Once the desired features have been translated to the PDMS substrate via soft-
lithography, the microfluidic chip can be assembled. Firstly, the set PDMS is 
carefully removed from patterned photoresist in order to ensure that the 
microfabricated features remain intact, as illustrated by step (iv) in figure 3.4. 
Holes are then punched into the patterned PDMS substrate at the appropriate 
positions (i.e. where one desires fluid to enter / exit the devices) using a hole 
punch producing holes with a diameter slightly smaller than that of the PTFE 
tubing to be inserted (see figure 3.5 A, B, C and figure 3.6 A). The PDMS 
substrate is then adhered to a clean glass slide (or PDMS) to produce a sealed 
system (see step (v) in figure 3.4); sonication of the substrates, i.e. both PDMS 
and glass, prior to device assembly in 0.5 M NaOH, followed by ethanol, 
distilled water, thorough drying on a hot plate and exposure to an oxygen 
plasma for 20 seconds (resulting in oxidation of the surfaces) affords good 
bonding. Note that a microscope slide was placed onto the reverse side of 
PDMS substrates (i.e. the side containing no microfabricated structures) in 
order to act as a guide during the bonding process; the microscopy slide is held 
in place naturally (by suction) and can be removed easily. This is especially 
important when bonding larger microfabricated PDMS substrates to glass / 
PDMS substrates in order to ensure that even bonding is gained and the 
microfabricated structures are conserved.  
PTFE tubing (each piece approximately 30 cm in length, or an adequate 
amount such that your device can be mounted easily onto the microscope 
stage and connected to the syringe pumps with ease) is carefully inserted into 
the pre-punched holes in the microfabricated PDMS substrate using a pair of 
tweezers. Care has to be taken, particularly when thin glass microscopy cover 
slides are bonded to the microfabricated PDMS substrate, and insertion of the 
PTFE tubing should be conducted on a flat surface, as otherwise the glass can 
easily be broken. The PTFE tubing that has been connected to the punched 
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Figure 3.5: Microfluidic chip assembly 1. (A) Illustration demonstrating how 
microfabricated PDMS substrates can be bonded to glass to form microfluidic 
channels; the top and side projections of an example microfluidic device are shown in 
(B) and (C) respectively for clarity. 
 
 
holes in the microfabricated PDMS, now has to be connected to the 
removable needles attached to the disposable plastic syringes thus enabling 
fluid to be introduced into the device in a controlled manner. Specifically, 
disposable needles are inserted into the tubing to afford a pressure-tight system 
to which plastic syringes are attached (as illustrated in figure 3.6 B). Syringe 
pumps are used to house the syringes and mechanically drive both aqueous and 
oil solutions into the devices (see figure 3.6 A). The outlet capillary is 
connected to a glass vial via PTFE tubing in order to collect waste fluid; this is 
illustrated in figure 3.6 C for clarity. 
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Figure 3.6:  Interfacing of the microfluidic chip with syringes. (A) Indication of 
how the PTFE tubing is used to connect the device to syringes housed in syringe 
pumps; here, an example of the actual device used in the experiments detailed in this 
chapter is displayed. The illustration in (B) clarifies how the removable needles, which 
are attached to the syringes, connect to the PTFE tubing thus producing a good seal. 
Finally, (C) details how the waste material is collected, after having been produced in a 
microfluidic device during an experiment. 
 
 
3.3.2.5 Carboxyfluorescein leakage assay 
The experimental format detailed in chapter 2, section 2.3.2.3, was used to 
prepare and perform the CF leakage assays detailed in this chapter. All leakage 
experiments involved using the drug, impramine HCl, as it is highly water 
soluble (50 mg / ml)239 and its effect on CF leakage from DOPC vesicles has 
been established previously in chapter 2, section 2.4.2. The volumetric ratio of 
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drug solution introduced to vesicle solution is always 1:1; the final 
concentration of imipramine in solution was either 1.6 mM or 0.8 mM 
(specified in the appropriate sections) and the final lipid concentration of 
DOPC always 0.1 mM. Note that whenever a leakage assay was performed 
using a different detection system, or in a different experimental environment 
(i.e. a microfluidic format), an experiment was run in parallel on the 
fluorescence spectrophotometer (in a well plate format, as described previously 
in chapter 2, section 2.4.1.1). This was undertaken in order to act as a control 
for that day’s experiments, thus ensuring that the leakage assay was taking place 
in the expected manner. Additionally, CF-containing vesicles in buffer alone 
(i.e. in the absence of drug) were monitored over the time course of each 
kinetic experiment to act as a further control. Fluorescence intensity 
measurements were conducted using a Cary Eclipse (Varian) Fluorescence 
Spectrophotometer (Varian, Inc.) with excitation at 490 nm and emission at 
516 nm; 96-well plates (Fisher Scientific Ltd.) were employed to contain the 
sample to be measured. 
3.3.2.6 Fluorescence intensity measurements in a microfluidic format 
The fluorescence intensity measurements that were conducted in a microfluidic 
format involved using a confocal fluorescence detection system, specifically an 
Olympus microscope equipped with a 488 nm diode laser and Avalanche 
photodiode detector. The samples were excited at 488 nm. A 488 nm dichroic 
mirror and a 505 nm long pass emission filter were utilised, as well as a second 
emission filter (500-580 nm bandpass) situated in front of the detector (all 
Olympus). 
3.3.2.7 Fluorescence lifetime measurements in bulk 
The fluorescence lifetime measurements conducted in a bulk format were 
performed using a home-built, time-resolved fluorimeter utilising TCSPC. A 
quartz cuvette (path length = 1 mm) was used to contain the sample of 
interest. A pulsed laser was used to excite these samples, namely a titanium 
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sapphire laser (Mai Tai, Spectra-Physics, Mountain View, CA, USA); an 
excitation wavelength of 450 nm and a 460 nm long pass emission filter were 
utilised. Initially, the laser is passed through a piece of quartz which reflects a 
small portion of the light onto a photodiode. The signal is then amplified and 
connected to the TCSPC card, informing the card how long it took each 
photon to arrive at the detector after the excitation pulse. Data acquisition for 
each data point took ca. 1 s, resulting in just less than 65000 counts / second in 
the peak decay (with 65000 counts being the maximum that the card can 
collect).  
The fluorescence lifetimes of ten CF samples, the concentrations of which are 
displayed in table 3.1, were ascertained in order to generate a calibration curve. 
The results are presented and discussed in the results and discussion section 
(section 3.4.2.1, also see Appendix 7). Additionally, CF leakage experiments 
with DOPC vesicles and imipramine HCl were performed using this setup, as 
described in section 3.4.2.2. Measurements were recorded every two minutes 
for total period of thirty minutes (see Appendices 8 and 9).   
 
 
 
 
 
Table 3.1: The ten samples of carboxyfluorescein used to construct the 
calibration curves. 
 
3.3.2.8 Fluorescence lifetime measurements in a microfluidic format 
The calibration and fluorescence leakage experiments, performed in a 
microfluidic format, involved flowing fluids through microfluidic devices. In 
order to perform the calibration experiment, the ten CF solutions (detailed in 
Sample [CF] (M) Sample [CF] (M) 
1 5.0E-02 6 1.0E-04 
2 2.5E-02 7 2.0E-05 
3 6.3E-03 8 6.0E-06 
4 1.6E-03 9 2.0E-06 
5 3.9E-04 10 4.0E-07 
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table 3.1), were flowed through the microfluidic channels independently at a 
total flow rate of 1.6 μl / min. 
In order to perform the leakage assay, both the vesicle suspension (loaded with 
CF, denoted as Aqueous1 or Aq1) and the imipramine solution (Aqueous2 or 
Aq2) were brought into contact with one another using equal flow rates for 
each aqueous inlet, thus ensuring that 1:1 mixing of the two samples occurred 
(and hence a 50 % dilution). In order to form oil-in-water droplets, the two 
aqueous streams (Aq1 and Aq2) were brought into contact with an oil stream; 
droplet formation was achieved using the flow focussing approach (see chapter 
1, section 1.4.1.4). Figure 3.7 displays the configuration used. Note that the 
photograph displayed in figure 3.6 A (section 3.3.2.4) depicts the actual 
experimental setup, where the device and various aqueous inlets / outlets etc. 
are highlighted. Figure 3.3 B (section 3.3.2.2) informs one of the device design; 
the major channels possessed a width and depth of 300 and 50 μm 
respectively. Experiments were conducted to ascertain the optimum conditions 
required for stable droplet generation in the device, the results of which are 
detailed in section 3.4.2.4.  
An SP5 confocal microscope (Leica) was used to measure fluorescence 
lifetimes during experiments performed in a microfluidic format. For FLIM 
acquisition, a pulsed, titanium sapphire laser (Broadband Mai Tai, Spectra-
Physics, Mountain View, CA, USA) was used as the excitation source. An 
excitation wavelength of 475 nm was utilised and fluorescence emission 
collected from 490 to 600 nm. The light used to illuminate the sample, as well 
as the wavelengths of light consequently emitted upon excitation, were 
distributed and collected respectively through an objective lens via scanning 
mirrors in the scan head of the microscope.  
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Figure 3.7: Device configuration for droplet formation. The flow-focussing 
approach was utilised for droplet formation – one can see that the two aqueous 
streams flowing through inlets 1 and 2 (Aq1 and Aq2) are focussed onto a ‘cross-
shaped’ junction (indicated by the red box), where they meet the oil carrier fluid. Here 
droplet generation ensues.  
 
Fluorescence emission was detected using a photomultiplier tube (PMT) and 
the PMT signal was recorded using TCSPC electronics (SPC-830, Becker & 
Hickl). Data were acquired at either a single, or various, point(s) along the 
device in order to construct a calibration curve or kinetic traces for leakage 
experiments respectively. In the latter case, four channels were analysed per 
acquisition (i.e. in the field of view), consequently resulting in a value for the 
average fluorescence lifetime in that region. Data were acquired for a total of 5 
minutes for each data point included in the graphs in Appendices 10 and 11. 
3.3.2.9 Data analysis of lifetime measurements 
The software package, SPC Image, was used to analyse the data and extract 
values for the fluorescence lifetime. Figure 3.8 displays a screen dump of the 
main software window. 
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Figure 3.8: Screen dump of the software package, SPC Image, used to analyse 
the fluorescence lifetime data. An example has been included of an image to be 
analysed. It can be observed that SPC Image enables one to view the distribution of 
fluorescence lifetimes in the image sampled, by means of a false colour image and 
histogram. One can also view the fit to the decay data for a specific pixel, as well as 
the residuals, χ2 value and fit parameters associated with that fit. 
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3.4 RESULTS AND DISCUSSION 
3.4.1 Fluorescence intensity measurements 
The initial step taken in order to translate the bulk assay into a high-throughput 
droplet format involved measuring the fluorescence response of CF at 
different concentrations using a microfluidic format. Ten samples, spanning 
the concentration range of interest (50 mM - 1 µM, see section 3.3.2.7) were 
prepared in order to ascertain if the output concurs with what was observed 
for the experiments conducted on the fluorescence spectrophotometer. Several 
experiments have been conducted, where the fluorescence response for each 
of the ten CF samples has been measured and assembled into a calibration 
graph. These are described as follows.  
The first experiment involved flowing the ten samples through a microfluidic 
device in a droplet format (each sample separately). The fluorescence intensity 
of each sample was then measured at a specific point in the channel. 
Surprisingly, it was found that the calibration curve was shifted to higher 
concentration when compared to the results gained using the fluorescence 
spectrophotometer, as illustrated in figure 3.9 below.  
 
 
Figure 3.9: Carboxyfluorescein calibration curve gained using intensity 
measurements in a microfluidic format. (A) Calibration curve gained using 
droplets formed in a microfluidic device (each sample tested separately) and (B) 
calibration curve gained using fluorescence intensity measurements in the fluorescence 
spectrophotometer. 
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It was thought that the observed shift in the calibration curve may be due to 
loss of CF molecules to the oil-aqueous interface. A loss of dye in this manner 
would therefore result in an effective decrease in the concentration, thus 
resulting in an increase in the observed fluorescence intensity. However, each 
solution was also assessed using a bulk measurement on the same experimental 
set up, where an oil-aqueous interface is excluded. An aliquot of each CF 
solution was pipetted onto a glass side and the relevant fluorescence intensities 
of the ten CF samples were measured. The results of this experiment are 
illustrated in figure 3.10 A. However, a shifted calibration curve still persisted. 
The same measurement was also conducted using a flow format, where the 
samples are flowed solely through the microfluidic channels and are thus in the 
absence of droplets and of an oil-aqueous interface, as the use of a flow format 
reduces any effects that may have affected the static samples due to 
photobleaching. Again the calibration curve was still shifted with respect to 
that observed using intensity measurements on the fluorescence 
spectrophotometer (data displayed in figure 3.10 B). Hence this indicates that 
the primary cause of the shift in the calibration curve is not due to a loss of CF 
molecules to the oil-aqueous interface. Additionally there is no reason why CF 
would wish to reside at this interface, as its structure possesses two hydroxyl 
groups and an acid group that are all deprotonated at the pH used in these 
experiments (pH 7.4), and hence is content residing in an aqueous 
environment.  
For completion, controls were also performed whereby the effect of changing 
the oil and the total flow rate of the aqueous / oil streams used during droplet 
generation were investigated. The results of these experiments are illustrated in 
figure 3.10 B and C respectively, where it is apparent that the same feature 
persists. Figure 3.10 D provides a summary of the results displayed in figure 
3.10 A-C. 
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Figure 3.10: The various control measurements conducted to ascertain which 
parameters, if any, may explain the shifted calibration curve. (A) Results of the 
calibration conducted off-chip, i.e. the ten samples measured using the same set up 
but aliquots of each are pipetted onto a microscopy slide. (B) Results of the 
calibration, conducted by flowing each sample through the microfluidic channels, i.e. 
in the absence of droplets. The results of experiments conducted with two different 
oils are also included (in the presence of droplets), where oil 2 = FC3283 and oil 3 = 
oleic acid; note that only two measurements were made, i.e. where the maximum and 
minimum points were expected to be gained, due to time restraints. (C) This graph 
indicates the effect of the calibration curve on the total flow rate of the aqueous / oil 
streams used. (D) Summary of the results displayed in A-C; the indicated errors 
represent ± 1 s.d (n ≥ 6). 
 
 
To conclude, the experiments detailed in this section reveal that the calibration 
curve is shifted to higher concentrations, when compared to the calibration 
curve gained using the fluorescence spectrophotometer. A summary of the 
overall result that these findings portray is detailed in figure 3.11.  
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Figure 3.11: Summary of findings conducted using intensity measurements in a 
microfluidic format (“on-chip”) and compared to the measurements 
conducted on the fluorescence spectrophotometer. 
 
Although several controls have been performed, these do not help to explain 
the origins of the observed differences. It is expected that this feature is due to 
inherent artefacts associated with intensity based measurements. Additionally, 
it would not have been feasible to conduct the leakage experiment in a 
microfluidic format, using the calibration curve gained for this set up. As a 
result of a shift in the curve to higher concentrations, the sensitivity of the 
leakage assay is reduced, i.e. a far greater number of vesicles containing CF per 
set volume are required in order to reach this maximum (or, to afford a smaller 
dilution). However, it is not sensible to use lipid concentrations above 1 mM, 
i.e. increasing the vesicle density per droplet, which would be required to use 
the assay in this format. Nor is it practical to encapsulate higher concentrations 
of CF within vesicle lumens, in attempt to increase the sensitivity of the 
leakage assay. Therefore it was decided to move away from intensity 
measurements and attempt to use fluorescence lifetime measurements. 
3.4.2 Fluorescence lifetime experiments 
It was expected that solutions of CF present at high concentrations, for 
example at concentrations corresponding to approximately 50 mM (where the 
dye participates in concentration-quenching events, as described previously in 
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chapter 2, section 2.2.1), would yield substantially different fluorescence 
lifetimes compared to solutions containing CF present at much lower 
concentrations (approximately 1E-05 M). Therefore it was proposed that this 
particular property, exhibited by CF solutions, could be exploited and in turn 
used as an alternative means to investigate the leakage of CF from liposomes 
upon the addition of drug molecules, for example.  
3.4.2.1 Carboxyfluorescein calibration experiment performed in a cuvette 
format  
The first experiments to be conducted involved determining the fluorescence 
lifetime of ten different CF solutions, each of which is present at a different 
concentration, thus creating a calibration graph indicating the dependency of 
the fluorescence lifetime on concentration. The results of the calibration 
experiment are displayed in figure 3.12 A, where data for two experimental 
repeats are provided (see Appendix 7 for tabulated data with χ2 values).  
 
Figure 3.12: Carboxyfluorescein calibration experiment performed in a cuvette 
format (fluorescence lifetime). (A) The fluorescence lifetime gained for each of the 
ten solutions of CF, present at different concentrations, performed in a cuvette 
format. Two repeats are displayed and indicated by the symbols □ and ○. (B) 
Literature data for CF, which indicates the relationship between the concentration of 
the dye in solution and its fluorescence lifetime. Image reproduced from Chen et al.218  
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It is apparent that the data gained experimentally agrees in part with that 
detailed in the literature (see figure 3.12 B for literature data), particularly in the 
regions where the concentration of CF in solution is greater than ca. 1E-02 M 
and less than ca. 1E-05 M. The fluorescence lifetime gained experimentally for 
CF-containing solutions, possessing a concentration of less than 1E-05 M, is in 
the region of 4.5 ± 0.1 ns (n = 6), agrees well with the literature value of 
approximately 4.5 ns (see figure 3.12 B and Appendix 7).218 The fluorescence 
lifetime of more concentrated CF samples, e.g. 50 mM, are noticeably shorter – 
a value of ca. 0.3 ns was gained experimentally (see figure 3.12 A and Appendix 
7) and is in agreement with the value presented in figure 3.12 B.218 
As Chen et al. describe,218 the decrease in the fluorescence lifetime (associated 
with an increase in the concentration of CF in solution) is unexpected if 
dimerisation of CF molecules is the only factor contributing to quenching 
events, as usually the fluorescence lifetime is not found to decrease in static 
quenching. However, they state that dimerisation is crucial for the observed 
decrease in the fluorescence lifetime, based on experiments conducted with 
propylene glycol and highly concentrated solutions of CF. The addition of 
propylene glycol essentially removes the potential for CF molecules to 
dimerise. Hence, as the percentage by volume of propylene glycol is increased, 
in concentrated CF solutions of a fixed concentration (i.e. 0.04 M), the lifetime 
increases due to the effective increase in the monomer-monomer spacing. 
Additionally, if the concentration of propylene glycol in solution is kept 
constant and the CF concentration is altered, the values for the fluorescence 
lifetime are longer than for the equivalent CF solution in buffer alone. Table 
3.2 displays the results of the experiments conducted with propylene glycol. 
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Table 3.2: The effect of propylene glycol on lifetimes of concentrated 
carboxyfluorescein. The data is reproduced from the paper published by Chen et 
al.218 
  
It is believed that the observed shortening of the fluorescence lifetime, upon 
increasing the dye concentration in solution, is due to energy transfer from 
monomers to non-fluorescent dimers. The dimers are able to act as energy 
sinks, and the phenomenon arises due to a large overlap in the excitation and 
emission spectra. For a detailed discussion of the evidence to support this 
theory, one should consult the paper by Chen et al.218 
Discrepancies between the fluorescence lifetime data gained experimentally 
and that described in the literature, illustrated previously in figure 3.12 A, do 
exist. Notably, it can be observed that significant differences reside in the 
region between 1E-02 to 1E-04 M CF. As the concentration of CF in solution 
is increased, from approximately 1E-04 M to 1E-03 M, a significant increase in 
the fluorescence lifetime was observed (compared to the literature data). It is 
thought that this may be due to reabsorption of the emitted fluorescence 
intensity, as this phenomenon is known to cause increases the fluorescence 
lifetime.247,248 A cuvette possessing a pathlength of 1 cm was used to conduct 
these experiments, therefore it is possible that this may afford an environment 
whereby emitted light maybe reabsorbed and emitted in a cyclic manner, within 
this particular concentration range, hence lengthening the value of the 
fluorescence lifetime. It is thought that the optimum conditions for this 
% (v/v) propylene glycol [CF] (M) τ (ns) 
0 0.04 0.43 
20 0.04 0.92 
40 0.04 1.71 
60 0.04 2.13 
40 0.01 5.23 
40 0.02 3.85 
40 0.06 0.80 
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phenomenon occur at ca. 1E-03 M, where the maximum lifetime value is 
reached (ca. 10 ns), after which the lifetime decreases rapidly. Interestingly, the 
concentration at which this decrease in the fluorescence lifetime commences 
coincides with that of the literature data, i.e. at ca. 3E-03 M CF, suggesting that 
the same mechanism is responsible for the decrease in the fluorescence 
lifetime. Note that Chen et al. do not disclose the nature of the cells used to 
conduct the fluorescence lifetime measurements described in their paper.  
3.4.2.2 Carboxyfluorescein leakage assay performed using imipramine in a 
cuvette format 
Having determined the dependency of the fluorescence lifetime on the 
concentration of CF in solution for the cuvette based system, a leakage assay 
was performed using the drug, imipramine, in the same system. Imipramine 
was chosen as the drug of choice, for use in the fluorescence lifetime 
experiments described in this chapter, as it is readily soluble in aqueous 
solutions and very economical. 
The results of the leakage assay are present in figure 3.13. Specifically, the 
lifetime results for the addition of imipramine to a vesicle suspension loaded 
with CF in the interior of the vesicles are displayed in figure 3.13 A (yielding 
final concentrations of imipramine and DOPC equal to 1.6 and 0.1 mM 
respectively), as well as the data for the control experiment (figure 3.13 B), 
where the lifetime of the vesicular solution alone, i.e. with no addition of drug, 
is measured concurrently. Experiments were also conducted on the 
fluorescence spectrophotometer in parallel with the fluorescence lifetime 
experiments, in order to ensure that the vesicle leakage experiment occurred as 
anticipated and thus acted as a further control (see figure 3.13 C). 
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Figure 3.13: Carboxyfluorescein leakage assay performed using imipramine in 
a cuvette format (fluorescence lifetime data). (A) A graph illustrating the results 
gained for a fluorescence lifetime leakage experiment, upon introducing imipramine to 
vesicles loaded with CF (final concentrations of imipramine and DOPC equal to 1.6 
and 0.1 mM respectively). The dotted red lines are included to indicate where the 
control measurement lies on this graph. (B) A graph illustrating the fluorescence 
lifetime results gained for the control experiment, i.e. where no drug has been 
introduced to the vesicle suspension. Data were fitted to a bi-exponential model,  
I(t)=I0(A1e(-(t/τ1))+A2e(-(t/τ1))),249 where A1 and A2 are pre-exponentials factors 
associated with lifetime components τ1 and τ2 respectively. (C) Graph illustrating the 
fluorescence intensity measurement gained using the same vesicle and drug sample, 
thus acting as a additional control. 
 
The most important conclusion that one can draw from these initial data is that 
the fluorescence lifetime is found to increase with time only after imipramine is 
introduced to the vesicle suspension, where a 50 mM CF solution has been 
incorporated into the vesicle lumens. This increase in lifetime infers a decrease 
in the dye concentration, which in turn can be attributed to the induction of 
leakage from the vesicles upon introducing imipramine molecules into the 
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vesicular solution. Figure 3.13 C further supports that dye leakage occurs as 
expected: the kinetic measurement, using fluorescence intensities, was gained 
in an analogous manner to previous experiments (as detailed in section 3.3.2.5). 
Note that the same vesicle and drug samples were used for both this 
measurement and the lifetime measurement detailed in figure 3.13 A.  
The control experiment for the lifetime data, displayed in figure 3.13 B, 
illustrates that the lifetime remains constant over the course of the kinetic 
experiment (as indicated by the linear fits of the data, whose gradients are 
approximately zero). It can be observed that the fluorescence lifetime is 
comprised of a short (ca. 500 ps) and a long (ca. 4000 ps) component. The 
former relates to the quenched CF solution residing within the internal volume 
of the vesicles, with the latter component most probably due to a small 
amount of the dye present in the vesicular solution. This may be due to dye 
that has either leached out of the vesicle interiors or has not been fully 
excluded during a single passage through the Sephadex column. Interestingly, 
Chen et al. report that the long component may be due to molecules of CF 
associated with the lipid.218 Although the experiments were conducted as soon 
as possible after having removed the free dye present in the external regions of 
the vesicular suspension, the sample had to be taken to a different laboratory in 
a different department to conduct the lifetime measurements, and as such the 
experiments could not be conducted immediately. The control measurement 
recorded during the fluorescence intensity leakage experiment (see figure 3.13 
B) indicates that there is virtually no leakage of dye; however, the fluorescence 
intensity measurement will not be sensitive to the presence of such low dye 
concentrations.  
In summary, it has been demonstrated that the fluorescence lifetime only 
deviates from the 500 ps baseline when imipramine molecules are introduced 
into the vesicle suspension, therefore inducing leakage of the dye. These data 
suggest that fluorescence lifetime measurements may provide an alternative 
way in which to perform the CF leakage assay. 
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3.4.2.3 Carboxyfluorescein calibration experiment performed using a 
microfluidic format  
The ultimate aim of this chapter is to demonstrate that it is feasible to translate 
a bulk vesicular leakage assay into a microfluidic format, thus opening avenues 
for one to conduct future investigations that may involve understanding the 
interaction of drugs or proteins, for example, with vesicle populations. In order 
to achieve this goal, the first step involved establishing the fluorescence 
lifetime for a variety of different CF samples, present at different 
concentrations in solution, when using a flow format. In this instance 
measurements are conducted using a microscope, as opposed to a fluorimeter. 
These experiments were conducted in an analogous manner to the calibration 
experiments described previously in section 3.4.2.1, with the main difference 
being that each solution was flowed through a microfluidic device (see section 
3.3.2.8 for details). The results are displayed in figure 3.14 A (see also 
Appendix 10). 
As one can see from figure 3.14 A and B, the calibration curve agrees well with 
the literature data. Specifically, both sets of data yield a fluorescence lifetime of 
approximately 300 ps for a 50 mM CF solution, which increases in a linear 
manner upon dilution to yield a lifetime of approximately 4000 ps at ca. 1E-02 
M. Upon further dilution, the lifetime of these solutions remains constant at 
approximately 4000 ps. However, these data contrast with the calibration data 
gained, using the cuvette set up (discussed in section 3.4.2.1). Figure 3.14 C 
illustrates both sets of calibration data plotted on one graph, i.e. the data 
gained in both the cuvette and microfluidic formats. Here, one can observe 
that data collected when using the microfluidic format do not show the 
prominent increase in the fluorescence lifetime between 1E-02 and 1E-04 M. 
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Figure 3.14: Fluorescence lifetime calibration measurements conducted in a 
microfluidic format and compared to experiments conducted in a bulk format 
/ literature values. (A) Graph representing the results of the fluorescence lifetime 
calibration experiment, performed with the ten different solutions of CF in a 
microfluidic format. (B) Graph illustrating the literature data for CF, included to 
provide a means for comparison. Reproduced from the paper by Chen et al.218 (C) 
Here, the data for the calibration experiments, conducted first in a cuvette (section 
3.4.2.1) and then in a microfluidic format, are included on the same graph to enable 
comparisons to be made between the two.   
 
 
It is thought personally that this difference may originate from differences in 
the experimental techniques employed. As alluded to previously, in section 
3.4.2.1, it is thought that the prominent increase present in the data measured 
using the fluorimeter, in a cuvette-based system, was due to reabsorption of 
the fluorescence emission, due to the use of a longer path length. In the 
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microfluidic format the path length is much smaller, therefore less 
reabsorption occurs; there does appear to be a slight increase in the 
fluorescence lifetime in the region of interest. However, it is thought that the 
relationship between the fluorescence lifetime and dye concentration, 
ascertained during the calibration step for the microfluidic set up, will be more 
advantageous with respect to interpreting the leakage data. The fluorescence 
lifetime of the dye in solution increases upon dilution, which plateaus at 
approximately 3.2E-03 M and does not exceed ca. 4 ns upon further dilution 
(as seen in figure 3.14 A). 
 
3.4.2.4 Carboxyfluorescein leakage assay, performed using imipramine in a 
microfluidic format 
The final challenge involved conducting the leakage assay in a microfluidic 
device. First of all, the microfluidic device had to be optimised, in order to 
determine which flow rates would be suitable to yield stable droplet formation 
using the flow focussing approach. Figure 3.7 (section 3.3.2.8) details the 
arrangement of the aqueous and oil streams used for droplet formation in this 
particular set of experiments. Importantly, the microfluidic device was 
designed such that it would enable kinetic experiments to be monitored over 
longer timescales, on the order of minutes, thus yielding a suitable time period 
for monitoring the leakage of encapsulated CF by imipramine, for example. 
However, a compromise has to be made in order to maximise the experimental 
time window in order to generate ca. 5-10 minutes of data. Ideally, one requires 
as low a total flow rate as possible in order to achieve this. However, it is not 
always possible to gain stable droplet generation at very low total flow rates. 
This therefore had to be investigated and the results for such experiments are 
displayed in figure 3.15 and table 3.3. 
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Figure 3.15: Optimisation of the flow conditions in a microfluidic device for 
performing the carboxyfluorescein leakage assay. (A), (B) and (C) illustrate how 
the droplet volume and density changed upon altering the flow rates of the oil and 
aqueous streams (Aq1 and Aq2). Images 1-4 in (A) were gained using the following 
flow regimes: oil = 3 μl / min, Aq1 = Aq2 = 0.3 μl / min (total flow rate = 3.6 μl / 
min). Images 1-4 in (B) were gained using the following flow regimes: oil = 1 μl / min, 
Aq1 = Aq2 = 0.3 μl / min (total flow rate = 1.6 μl / min). Images 1, 2 & 4 in (C) were 
gained using the following flow regimes: oil = 0.4 μl / min, Aq1 = Aq2 = 0.3 μl / min 
(total flow rate = 1.0 μl / min).  (B) The red boxes indicate where the four images (1-
4) were taken in (A), (B) and (C). Scale bar is equal to 300 μm. Channel depth is 50 
μm. 
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It can be observed from figure 3.15 A, B and C that droplet formation could 
be successfully attained. Although the images in figure 3.15 C illustrate that 
droplet formation was possible for this set up, under the conditions employed 
(oil flow rate = 0.4 μl / min, Aqueous1,2 = 0.3 μl / min, total flow rate = 1.0 μl 
/ min; see figure 3.15 C and table 3.3), these conditions did not always yield 
stable droplet formation. The relationship between the oil and aqueous flow 
rates was not ideal and therefore droplet formation was not always efficient. As 
a result, these conditions were not suitable and were excluded from further use. 
The flow conditions employed in figure 3.15 A (oil flow rate = 3.0 μl / min, 
Aqueous1,2 = 0.3 μl / min, total flow rate = 3.6 μl / min; see table 3.3) and B 
(oil flow rate = 1.0 μl / min, Aqueous1,2 = 1.6 μl / min, total flow rate = 1.0 μl 
/ min; see table 3.3), however, were sufficient to afford stable droplet 
formation. These data are summarised in table 3.3. 
 
 Flow rate (μl / min) Total flow rate 
(μl / min) 
Droplet 
Volume (nl) 
Stable 
flow? Experiment Oil Aq1 Aq2 
A 3 0.3 0.3 3.6 ~ 0.5 Yes 
B 1 0.3 0.3 1.6 ~ 1.4 Yes 
C 0.4 0.3 0.3 1.0 ~ 4.2 No 
Table 3.3: Summary of results regarding the optimisation of the aqueous (Aq1 
and Aq2) and oil flow rates in the microfluidic device, used to perform the 
carboxyfluorescein leakage assay. The images in A, B, and C in figure 3.15 refer to 
experiments A, B and C described in this table.  
 
In addition to achieving stable droplet generation and maximising the amount 
of kinetic data that may be gained, one wants to ensure that there are a 
sufficient number of droplets passing through the microfluidic channels. This 
is particularly important in order to ensure that the number of photons 
reaching the detector is maximised, hence improving the signal-to-noise ratio. 
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It was found that a higher packing density of droplets (per set volume in the 
channel) is observed, upon decreasing the flow rate of the oil fraction and 
maintaining the flow rate of Aqueous1,2 constant at 0.3 μl / min. This is 
illustrated in images A3, A4 and B3, B4, in figure 3.15, where the droplet 
packing density in the channels is greater in B.  
Moreover, it was found that decreasing the flow rate of the oil fraction, whilst 
maintaining both aqueous flow rates at 0.3 μl / min (Aqueous1,2), resulted in an 
increase in the droplet volume, as well as an increase in the droplet packing 
density per unit volume. This can be observed when comparing images A2, B2 
and C2, and images A4, B4 and C4 in figure 3.15, where the flow rate of the oil 
fraction is reduced from 3 μl / min, to 1 μl / min, to 0.4 μl / min in A, B, and 
C respectively; this corresponds to an increase in the droplet volume from ca. 
0.5 nl, to ca. 1.4 nl, to ca. 4.2 nl respectively. The data are tabulated in table 3.3.  
In summary, the conditions described in experiment B (see table 3.3) were 
employed to perform the CF leakage assay in a microfluidic format. Firstly, 
these conditions afford stable droplet generation, where the total flow rate is 
low enough to allow a sufficient amount of kinetic data to be collected. 
Moreover, the density of droplet packing per unit channel volume and droplet 
volume are sufficient in order to maximise the signal-to-noise ratio.  
Having optimised the flow conditions for the device, the next step involved 
attempting to perform the CF leakage assay in a microfluidic format. 
Imipramine was again used to induce leakage, for reasons explained previously 
(see section 3.4.2.2), and the experiment was conducted as described in section 
3.3.2.5. Figure 3.16 A (and appendix 11) displays the analysed kinetic data for 
the leakage assay performed with two different concentrations of imipramine, 
specifically 1.6 and 0.8 mM (final concentration).  
It can be observed that upon introducing imipramine to CF-containing vesicles 
the fluorescence lifetime increases with time, as indicated by the results 
illustrated in figure 3.16 A, thus indicating that dye is released from the interior 
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regions of the vesicles to the exterior solution. Moreover it can be observed 
that the rate of change in the lifetime is dependent upon the number of 
imipramine molecules introduced into the system, i.e. the final drug 
concentration. As expected, the more highly concentrated imipramine sample 
(1.6 mM final concentration) affords a greater rate of CF release compared to 
the imipramine sample possessing fewer imipramine molecules (0.8 mM final 
concentration). 
 
 
 
 
 
 
 
Figure 3.16: Comparison of the relative initial rates of change in the 
fluorescence lifetime and intensity measurements when 0.8 and 1.6 mM 
imipramine is introduced to carboxyfluorescein-containing vesicles. (A) Graph 
illustrating the change in the fluorescence lifetime upon introducing different amounts 
of imipramine to the CF-containing DOPC vesicles (concentration of DOPC = 0.1 
mM). (B) An analogous experiment to that described in A, except graph B monitors 
the change in the fluorescence intensity over time. (C) Tabulated data describing the 
relative relationship between the initial rates of reaction for both the intensity and 
lifetime experiments conducted in the presence of 0.8 and 1.6 mM imipramine. The 
associated errors are included. Further information can be gained by consulting 
Appendices 11 and 12.  
C   
 
Rate1.6 
mM/ 
Rate0.8 mM 
Error 
Intensity 
Measurement 2.3 ± 0.3 
Lifetime 
Measurement 2.8 ± 1.6 
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When considering the relative initial rate of change in the fluorescence lifetime 
of the two samples, which one can assume relates directly to the initial rate of 
CF leakage, the 1.6 mM sample yields an initial rate that is faster by a factor of 
2.8 ± 1.6 in comparison to the 0.8 mM sample (see figure 3.16 C and appendix 
12). This agrees with the data gained using an intensity measurement on the 
fluorescence spectrophotometer (in an analogous experiment), where it was 
found that the initial rate of CF release for the 1.6 mM sample was greater by a 
factor of 2.3 ± 0.3 compared to the 0.8 mM sample (see figure 3.16 C and 
appendix 12). Although the error associated with the lifetime measurements 
conducted in a microfluidic chip is large, compared to the intensity 
measurement, if even a small error, for example, of ± 0.3 was applied (if the 
spread of data about the fit was reduced) then the two values would still be 
comparable within error. It is apparent that this large error is associated with 
the greater spread of data about the fit in the lifetime measurements; such an 
error is not atypical of experiments conducted in a microfluidic environment 
and is most likely to originate from the averaging of the fluorescence lifetime 
over the equivalent of three portions of the winding microfluidic channel for 
each data point. Repeats of the entire experiment should be conducted, as well 
as averaging the fluorescence lifetime over smaller time increments, in order to 
reduce this error, but unfortunately it was not possible to do this due to time 
constraints.  
According to the leakage data conducted in the fluorescence 
spectrophotometer, using fluorescence intensity measurements, approximately 
30 and 60 % of CF leakage was observed, after ca. 5 minutes, in the presence 
of 0.8 and 1.6 mM imipramine respectively (see figure 3.16 B). However, how 
does the lifetime data compare with this absolute percentage release? Table 3.4 
indicates the theoretical concentration of CF present in the vesicle lumens and 
regions exterior to the vesicle after varying degrees of leakage have occurred. 
However, this assumes that leakage of the dye from each vesicle lumen occurs 
at an equivalent rate and from the exact same number of vesicles. In reality, 
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this scenario will not occur and hence the theoretical calculation can only be 
used as a guide.  
Figure 3.17 illustrates an enlarged section of the calibration curve gained using 
a microfluidic format – the original graph is depicted in figure 3.14, section 
3.4.2.3. Specifically, the first three data points in the region between 1E-01 M 
and 1E-2.5 M CF are displayed, and a line of best fit indicated. This graph can 
be used to ascertain a predicted value for the fluorescence lifetime after a 
certain percentage of dye has been released from the vesicle lumens. 
As stated previously, the presence of 0.8 mM imipramine induces ca. 30 % CF 
leakage after ca. 5 minutes, as determined using fluorescence intensity 
measurements. Hence according to the data presented in table 3.4, a 30 % 
release of the dye will yield an internal concentration in the vesicle lumens of 
ca. 0.035 M (or a value of ca. 1.5 if one takes the negative log of the 
concentration), which corresponds to a predicted lifetime value of just less 
than 1 ns as indicated by figure 3.17. This predicted value agrees well with that 
determined experimentally, specifically ca. 1 ns, as illustrated in figure 3.16 A. 
Similarly, if ca. 60 % of the internalised CF is released, which was found to 
occur in the presence of 1.6 mM imipramine during fluorescence intensity 
measurements, the internal dye concentration will be ca. 0.020 M (or a value of 
ca. 1.7 if one takes the negative log of the concentration) thus affording a 
predicted lifetime value of ca. 1.5 ns (see table 3.4 and figure 3.17). This again 
concurs with the data gained experimentally in a microfluidic format, where the 
value of the lifetime was c.a 1.5 ns after having left the mixed drug and vesicle 
solution for 5 minutes (see figure 3.16). Hence the absolute values of CF 
release for the intensity and lifetime data are comparable, which certainly 
suggests that this method is exploitable. 
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  Interior of vesicles Exterior of vesicles 
CF 
release 
(%) 
Amount 
of CF 
(moles) 
Amount 
of CF 
(mol / L) 
-log 
([CF]/M) 
Amount 
of CF 
(moles) 
Amount 
of CF 
(mol / L) 
-log 
([CF]/M) 
0 6.00E-09 0.050 1.30 0.00E+00 0.00E+00 0.00 
10 5.40E-09 0.045 1.35 6.00E-10 1.00E-06 6.00 
20 4.80E-09 0.040 1.40 1.20E-09 2.00E-06 5.70 
30 4.20E-09 0.035 1.46 1.80E-09 3.00E-06 5.52 
40 3.60E-09 0.030 1.52 2.40E-09 4.00E-06 5.40 
50 3.00E-09 0.025 1.60 3.00E-09 5.00E-06 5.30 
60 2.40E-09 0.020 1.70 3.60E-09 6.00E-06 5.22 
70 1.80E-09 0.015 1.82 4.20E-09 7.00E-06 5.15 
80 1.20E-09 0.010 2.00 4.80E-09 8.00E-06 5.10 
90 6.00E-10 0.005 2.30 5.40E-09 9.00E-06 5.05 
100 0.00E+00 0.000 0.00 6.00E-09 1.00E-05 5.00 
 
Table 3.4: Theoretical concentration of carboxyfluorescein present in the 
interior and exterior regions of the vesicles after varying amounts of leakage. 
Hence the theoretical position on the calibration curve can be predicted (indicated by 
the values in the column labelled –log([CF]/M). 
 
 
Figure 3.17: Predicted lifetime values based on the theoretical concentration of 
carboxyfluorescein present in the interior regions of the vesicles after leakage 
induced by the presence of 0.8 and 1.6 mM imipramine. This results in 
approximately 30 and 60 % CF release after ca. 5 minutes respectively. The former 
situation yields a lifetime value of just less 1 ns, with the latter resulting in a lifetime 
value of ca. 1.5 ns.  
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3.4.2.5 Comparison of the leakage data gained in the cuvette and microfluidic 
formats 
The leakage data gained using the two experimental formats described in this 
chapter, i.e. the cuvette and microfluidic formats, are illustrated collectively in 
figure 3.18 A and B. 
It has been determined that the introduction of imiprimine affords a change in 
the fluorescence lifetime, which corresponds to CF leakage, but the absolute 
change is not consistent between the two experimental formats. The main 
difference between the two formats is that the fluorescence lifetime appears to 
increase at a ‘faster’ rate initially (i.e. during the first 5 minutes) for the leakage 
assay performed in the cuvette system, when compared to the assay performed 
in the microfluidic format (for 1.6 mM imipramine data). However, it is 
thought that this occurrence persists due to the nature of the calibration curve 
gained using the cuvette format, where a bigger change in the fluorescence 
lifetime with concentration is observed. 
After 10 minutes, ca. 80 % leakage of the dye is observed when 1.6 mM 
imipramine is introduced (figure 3.16 B), which according to table 3.4 
corresponds to an average CF concentration of ca. 0.010 M (or a value of ca. 
2.0 if one takes the negative log of the concentration) retained within the 
liposomes. As illustrated by the enlarged calibration graph displayed in figure 
3.18 C, this degree of leakage corresponds to an approximate fluorescence 
lifetime of 4 ns. This concurs with the experimental data gained, displayed in 
figure 3.18 A.   
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Figure 3.18: Comparison of leakage data gained in the cuvette and microfluidic 
formats. (A) Graph showing the change in the fluorescence lifetime upon introducing 
1.6 mM imipramine to CF-containing vesicles using a cuvette format. (B) Graph 
showing the change in the fluorescence lifetime upon introducing 0.8 and 1.6 mM 
imipramine to CF-containing vesicles using a microfluidic format. (C) Enlarged region 
of the calibration curved gained using a cuvette format.  
 
 
It is also important to appreciate that differences in fluidic mixing between the 
two experimental formats may have had a small affect the observed kinetics. 
For example, the samples used in the cuvette format are mixed together by 
inverting the cuvette, whereas the microfluidic device relies on the weaving of 
the microfluidic channel to mix the droplets’ contents. As the total flow rate 
used during these experiments was particularly low (1.6 µl / min) and the 
number of ‘weaves’ in the channel for mixing also low, the microfluidic format 
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perhaps did not afford conditions for mixing that were as efficient as in the 
cuvette system. The cuvette system, however, lacks the ability to collect good 
kinetic data within the first minute of the experimental window, owing to 
mixing having to occur offline before data collection can occur. 
However, despite these differences, the microfluidic format offers a suitable 
system in which to work and one where the data are easy to 
manipulate/interpret (c.f. the cuvette system); namely, it affords calibration 
data, which agree well with that present in the literature and the dependence of 
the lifetime is less complicated in the region of interest (from 1E-01 to just 
below ca. 1E-02 M). 
3.4.2.6 Problems associated with the microfluidic format 
Although the data gained using the microfluidic format are promising, this 
experimental format can be challenging to work with. One particular problem 
that persisted (in virtually 100 % of devices that were assembled) involved dust 
becoming trapped in the devices, thus resulting in the majority of devices being 
rendered unusable. In those that were suitable to use, the presence of dust 
particles lying across the winding microfluidic channel at several points resulted 
in some of the droplets merging and splitting in these regions. This problem 
originates from the particularly large size of the microfluidic devices, where the 
probability of gaining dust particles in the devices is increased (even though the 
greatest of care was taken in order to avoid this problem). Hence, the merging 
/ splitting events may have had an effect on the quality of the kinetics gained. 
However, these experiments are monitoring the effect of drugs on bulk vesicle 
populations and droplet merging / splitting does not appear to have been 
detrimental, when comparing the lifetime data to the intensity data collected in 
the fluorescence spectrophotometer (discussed previously in sections 3.4.2.4 
and 3.4.2.5). Additionally, only half the length of the microfluidic channel in 
the devices was used during these experiments, thus offering the potential to 
gain up to 10 minutes’ worth of data in future experiments. 
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Another problem that persisted during these experiments involved the 
presence of static droplets adsorbed to the channel at numerous points, as is 
illustrated in figure 3.19. Although initially quite annoying, these droplets do 
provide some interesting information. It can be observed that the fluorescence 
lifetime of the static droplets is much longer than the lifetime of the main 
channel: the blue and green droplets in figure 3.19 C possess fluorescence 
lifetimes of approximately 3.1 ns and 2.3 ns respectively, whist the droplets 
flowing in the main channel have an associated lifetime of 0.8 ns. Note that the 
droplets flowing in the main channel cannot be resolved as their speed is too 
fast, compared to the refresh rate of the camera. As these droplets are static, 
the presence of longer lifetimes (c.f. the droplets flowing in the main channel) 
can only be due to the continual leakage of CF from the interior of the vesicles 
into the exterior regions. Hence, this provides further evidence in support of 
the method and also indicates that such an assay could be performed in a 
different format, using static droplets as opposed to flow measurements to 
gain kinetic information.   
 
 
Figure 3.19: Static droplets adsorbed to the channel in a microfluidic device. 
(A) The red box illustrates where the images in B and C were attained in the 
microfluidic device, i.e. over 3 channels. (B) Grayscale image of the fluorescence 
lifetime data and (C) a false colour image with colour scale (ranging from red = 0 ns to 
blue = 4 ns). The two white circles in C illustrate two droplets that are adsorbed to the 
channel; the blue droplet (left hand side) has a lifetime of 3.1 ns, whilst the green 
droplet (right hand side) possesses a lifetime of 2.3 ns. The lifetime of the droplets 
flowing in the main channel is 0.8 ns Scale bar represents 300 µm. 
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Nevertheless, although there are some problems associated with the method, 
and hence improvements that can be made, these experiments have shown that 
it possible to translate bulk vesicle assays into a microfluidic format, with 
fluorescence lifetime imaging offering a solution to the original problem at 
hand. 
 
3.5 CHAPTER SUMMARY 
In summary, chapter 3 has demonstrated that it is feasible to translate the CF 
leakage assay into a microfluidic format, using microfluidic droplet 
technologies. Importantly, this chapter has revealed that fluorescence lifetime 
measurements are suitable for measuring the rate of CF leakage, and therefore 
assessing the leakage properties that drug molecules of interest portray, 
overcoming problems associated with fluorescence intensity measurements. 
Hence the results described in chapter 3 demonstrate the potential for 
translating other assays into a microfluidic format, which involve performing 
fluorescence measurements on bulk vesicle populations, as well as the potential 
for screening drug-membrane interactions in high-throughput. 
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Chapter 4 
 
Droplet interface bilayers (DIBs) for probing drug-
membrane interactions 
 
 
 
“Science never solves a problem without creating ten more.” 
George Bernard Shaw 
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4.1 OVERVIEW 
Chapter 4 is concerned with using artificial planar lipid bilayers, as a potential 
means for investigating the interaction of drug molecules upon a single lipid 
bilayer. This contrasts with the approaches described in chapters 2 and 3, 
where measurements of bulk vesicle systems have been considered. Droplet 
interface bilayers, or DIBs, have been chosen as the method of choice for 
artificial planar bilayer formation, offering many advantages over traditional 
methods and opening avenues for their formation and screening in high-
throughput. 
Specifically, this chapter demonstrates that the formation of DIBs can be 
reproduced easily using the lipid 1,2‐diphytanoyl‐sn‐glycero‐3‐phosphocholine 
DPhPC, cited in all literature associated with DIBs. Additionally, the successful 
formation of DIBs comprised of the more biologically relevant lipid, DOPC, 
has been achieved for the first time. Finally, the approaches taken to build a 
proof-of-concept leakage assay across DIBs using pH gradients, for assessing 
drug-membrane interactions, have been detailed. The problems associated with 
the manual manipulation of droplets have also been highlighted, hence 
justifying the need for an approach able to form DIBs reliably and in a uniform 
manner.  
 
4.2 INTRODUCTION 
4.2.1 Liposomes versus artificial planar bilayers 
As we have seen previously, the development of assays for the study of drug-
and protein-membrane interactions is extremely important. The work detailed 
in chapters two and three has employed an experimental format where bulk 
measurements, i.e. the effect of exogenous species on vesicle populations, are 
predominant. In this instance the average effect of the overall system is 
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monitored, where noise (with respect to both vesicle size and lipid 
composition for example) ensues. Although such a format is important, it is 
also desirable to understand how drug molecules and proteins behave when 
they are subjected to a single lipid bilayer. 
Artificial planar bilayers and vesicle assays each have their own merits. 
However, the former experimental format is attractive as it enables the 
researcher to alternate the compositions of the aqueous compartments on 
either side of the membrane, which is small and inaccessible in vesicular 
formats. Additionally the use of planar bilayers enables: (i) events taking place 
in the aqueous compartments to be measured independently and (ii) 
asymmetric membranes to be formed. 
4.2.2 Traditional methods for forming artificial planar bilayers 
Artificial planar bilayers have been utilised for many years, most notably as a 
tool for probing the functional properties of pore forming proteins, such as 
alamethicin and gramicidin.250 “Black lipid membranes” (or BLMs) were the 
first artificially produced planar membranes, developed in the early 1960s. 
Their formation involves carefully spreading a solvent containing lipid across 
an aperture, ranging typically from 0.1 to 1 mm in diameter, and waiting for the 
onset of black spots to form. These black spots then grow to yield a 
completely ‘black’ membrane, which corresponds to the solvent being 
removed from the membrane towards the annulus and its appearance as 
visualised in reflected light. Such membranes are often referred to in the 
literature as ‘painted’ membranes, an expression originating from the technique 
itself. However, this terminology could equally refer to the care required in 
mastering this tricky technique. 
Advancements were made on the first approaches for artificial planar bilayer 
formation and include the Montal-Mueller method,251 a method pioneered in 
the early 1970’s and classed as a “folded membrane” technique.250 In brief, this 
technique involves forming artificial lipid membranes by displacing a septum, 
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armed with a thin Teflon® film (ca. 25 μm in thickness) containing a small 
aperture, vertically through a Langmuir-Blodgett lipid film.252 Consequently, 
the two lipid monolayers formed at the air-water interface are drawn in a 
downwards direction, where they meet to form a lipid bilayer at the point when 
the aperture is lowered beneath the water level. A typical experimental setup 
and illustration of the mechanism of bilayer formation across the aperture is 
displayed in figure 4.1. Other folded membrane approaches include raising the 
water levels above the aperture, either independently or simultaneously.250 
Additionally, it can be observed from figure 4.1 that the folded membrane 
method enables the formation of the asymmetric bilayers, as there are two 
distinct aqueous environments. 
Folded membranes arose due to the need to reduce the amount of solvent 
residing in the membrane, typical of the painted membrane method. However, 
membranes formed in this manner are still not completely solvent-free, due to 
the use of highly volatile solvents (i.e. hexane / pentane) for depositing the 
lipid at the air-water interface. As these molecules are small, they are therefore 
more soluble in the membrane. Additionally, the aperture is pre-treated with a 
much less membrane-soluble organic solvent, such as hexadecane, to aid the 
tethering of the bilayer to the aperture in the region of the annulus.  In spite of 
this, bilayers exhibiting specific capacitances comparable to those calculated for 
true bilayers (0.8 μF / cm2) have been produced using folded membrane 
methods, as compared to values of 0.4 μF / cm2 for membranes formed via 
painted methods.250 
One way of eliminating the need for lipid soluble solvents, and hence create 
effectively solvent-free bilayers, is to incorporate vesicle suspensions into the 
aqueous compartments for the formation of lipid monolayers at the air-water 
interface.253 Note that pre-treatment of the aperture with hexadecane is still 
required, even if the aperture is very small, as otherwise the membranes are too 
unstable.   
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Figure 4.1: Montal-Mueller method for the formation of artificial planar 
membranes. (A) Illustration demonstrating the experimental set-up (figure adapted 
from Montal and Mueller).251 A Teflon® film, containing a small aperture, is attached 
to a septum (highlighted by the red box). The septum is displaced vertically through a 
Langmuir-Blodgett lipid monolayer in order to form the artificial lipid membrane. (B) 
and (C) further illustrates this process (prior to and after displacement of the aperture 
beneath the water level respectively). Note that the diagram is not to scale and no 
attempt has been made to describe the orientation of the lipid monolayer upon 
contact to the trough / septum.  
 
4.2.3 Droplet interface bilayers (DIBs) 
“Droplet Interface Bilayers” (or “DIBs”), a term coined in recent years, are a 
modern advancement on the original concept of artificial bilayer formation. A 
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DIB corresponds to the act of forming a lipid bilayer as a result of bringing 
together two aqueous droplets that are submersed in an oil environment and in 
the presence of lipid molecules. Lipids, being amphiphilic in nature, act as 
surfactant molecules and partition at the aqueous-oil interface, reducing the 
interfacial surface tension and preventing the aqueous droplets from merging 
instantaneously upon contact. Consequently, a lipid bilayer is formed as a result 
of two monolayer leaflets coming into contact with one another. Figure 4.2 
illustrates the nature of a DIB. Importantly, specific capacitances of ca.  
0.7 μF / cm2 have been gained for DIBs comprised of DPhPC,204 which are 
comparable to theoretical calculations of specific capacitance gained for a lipid 
bilayer (ca. 0.8 μF / cm2, as discussed in section 4.2.2).254  
 
 
Figure 4.2: Droplet Interface Bilayer (DIB) formation. (A) If two aqueous 
droplets are submersed in an oil environment, their interfacial surface tension is 
reduced upon the introduction of surfactant molecules, i.e. lipids. As these molecules 
are characteristically amphiphillic in nature, they will reside at the aqueous-oil interface 
and form lipid monolayers. (B) Formation of a droplet interface bilayer proceeds after 
the two lipid monolayers are brought into contact with one another. (C) This image is 
an example of a DIB gained experimentally. 
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The concept of DIBs, as they exist in their current form, was first pioneered by 
Funakoshi et al.202 and Holden et al.203 However, one of the first recorded 
methods of DIB formation was published by Tsofina et al. in 1966, as noted by 
Bayley et al. in their review on DIBs.204 The major advantages of employing 
DIBs over traditional methods for planar bilayer formation are summarised in 
table 4.1.  
 
Advantage Practicality Consequence 
Ease of formation no specialist equipment required quick to master 
Stability lifetime of days to weeks c.f. hours 
larger experimental 
window 
Smaller aqueous 
compartments 
setup transportable & 
more economical 
e.g. can be visualised 
under a microscope 
Ability to form >1 
bilayer 
formation of DIB 
networks 
larger experimental 
window 
 
Table 4.1: Summary of the advantages that the DIB system has over 
conventional methods for artificial planar bilayer formation. 
 
Importantly, the Bayley laboratory has made several advances in recent years 
with regard to the way in which DIBs are formed, subsequently classifying two 
different approaches. Lipids may be doped into the oil phase (termed the 
“lipid-out” approach) or conversely into the aqueous phase in the form of 
vesicles (termed the “lipid-in” approach),204 as illustrated in Figure 4.3 A and B 
respectively. The lipid-in approach is advantageous, not only because the time 
taken to achieve monolayer formation is greatly reduced and also more 
economical, but because asymmetric bilayer formation can be realised by 
incorporating different vesicle populations into different droplets. Figure 4.3 C  
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Figure 4.3: Methods for forming DIBs, including asymmetric DIBs. (A) The 
“lipid-out” approach. (B) The “lipid-in” approach. (C) asymmetric DIB (aDIB) 
formation. The three steps detailed in A, B and C relate to: (i) submersing two 
aqueous droplets into oil (either containing or not containing lipids), (ii) movement of 
the two droplets towards one another (denoted by red arrows) after sufficient time has 
been given for monolayer formation to occur at the aqueous-oil interface and (iii) DIB 
formation. The small circular entities represent vesicles. Note, diagram not to scale. 
 
demonstrates how asymmetric bilayer formation is achieved using the DIB 
format. 
4.2.4 Summary and chapter aims  
For the aforementioned reasons, DIBs present an excellent means by which to 
interrogate the interaction of molecular species upon model membranes, 
particularly in relation to the specific influence that a membrane may have 
upon the interacting species. For example, the membrane composition of each 
leaflet may or may not be altered by the same degree, thus either maintaining 
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or destroying lipid symmetry across the two monolayers respectively. The 
specific interaction of drug molecules upon a lipid membrane, using a DIB 
format, has not been investigated previously in this manner. This chapter 
therefore aims to: 
 
1. Demonstrate that DIB formation with DPhPC is reproducible, as 
detailed by Funakoshi et al. and Holden et al. (discussed previously in 
section 4.2.3).  
2. Demonstrate that the DIB technique is amenable for use with lipids 
other than DPhPC, such as the more biologically relevant lipid DOPC. 
3. Detail the various steps involved in the development of a proof-of-
concept leakage assay, which employs pH gradients and could monitor 
indirectly the extent to which the membrane is perturbed by exogenous 
species.  
4. Demonstrate an appreciation for the limitations surrounding the 
practical approach used in this chapter to achieve DIB formation, i.e. 
manual manipulation. A solution to this problem is offered, providing 
the rationale for chapter 5.   
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4.3 MATERIALS AND METHODS 
The following section details the materials required and methods employed in 
performing each of the experiments described in this chapter. 
4.3.1 Materials 
4.3.1.1 Lipids 
The following lipids were used in the experiments detailed in this chapter: 
1,2‐diphytanoyl‐sn‐glycero‐3‐phosphocholine (DPhPC, Avanti Polar Lipids) 
and 1,2‐dioleoyl‐sn‐glycero‐3‐phosphocholine (DOPC, Avanti Polar Lipids).  
4.3.1.2 Dye and buffer solutions 
The following components, all of which were purchased from Sigma-Aldrich®, 
were used to make the dye and buffer solutions for the experiments described 
in this chapter, namely 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES), potassium chloride (KCl), sodium hydroxide (NaOH), 5(6)-
carboxyfluorescein (CF) and 8-hydroxypyrene-1,3,6-trisulfonic acid trisodium 
salt (pyranine). Hereafter, the specific aqueous solutions will be referred to as 
follows: 
 
Solution 4.1:  10 mM HEPES, 200 mM KCl, pH 7.07 
Solution 4.2:  1.3 µM CF, 1 mM HEPES , 200 mM KCl pH 4.6 
Solution 4.3:  10 mM HEPES , 200 mM KCl pH 8 
Solution 4.4:  1.3 µM CF, 1 mM HEPES , 200 mM KCl pH 8 
Solution 4.5:  1 mM pyranine, 10 mM HEPES, 200 mM KCl pH 4 
Solutions 4.6-4.9: As solution 4.5, but instead adjusted to pH 6, 7, 8 and 
10 respectively. 
Solution 4.10:  1 mM pyranine  
Solution 4.11:  60 μM pyranine, pH 5.5 
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Solution 4.12:  60 μM pyranine, 1 mM HEPES, 200 mM KCl, pH 5.5 
Solutions 4.13-4.16: As solution 4.12, but instead adjusted to 6.4, 6.7, 6.9 
and 8 respectively. 
 
4.3.1.3 DIB formation 
Hexadecane oil (99%, Sigma‐Aldrich®) was used as the oil of choice to aid the 
formation of DIBs. Glass chambers, having an open channel configuration to 
enable droplet dispensing and manipulation, were constructed from standard 
microscopy slides (VWR), Araldite® and silicone rubber compound (both RS 
Components Ltd.). The basic chamber design can be viewed in figure 4.4. 
Metal needles (BD Microlance 25G 1” – Nr. 18, 0.5 × 25 mm) were used to 
move the droplets in the chamber and create DIBs. Their tips were cut, 
flattened and shaped in order to form suitable metal prongs. 
4.3.1.4 IFT measurements 
IFT measurements were conducted using an Easy Drop tensiometer (Krüss). 
A 0.5 ml glass syringe (Hamiliton, bore inner diameter = 3.256 mm), equipped 
with a disposable needle (Krüss, diameter = 1.830 mm), was used to dose and 
hence interrogate the solution of interest (see figure 2.6 in chapter 2, section 
2.3.2.4 for further details regarding equipment set up). A glass cuvette (Starna 
Scientific Ltd., Type 3 (2 cm x 1 cm x 5 cm) and cover plate (Krüss) were also 
required to conduct these measurements. 
 
4.3.2 Methods 
4.3.2.1 Vesicle preparation 
Vesicle suspensions were comprised of either DPhPC or DOPC and prepared 
as described previously (chapter 2, section 2.3.2.1). Thin lipid films were 
prepared with 2 mg of lipid and hydrated with 1 ml of an aqueous solution to 
yield a concentration of 2 mg / ml. Note that films composed of DOPC were 
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hydrated with 0.5 ml of an aqueous solution to afford a 4 mg / ml lipid 
concentration. The various solutions used to hydrate lipid films and form 
vesicle suspensions for DIB formation are specified in section 4.3.1.2, 
specifically solutions 4.1, 4.2, 4.3, 4.11 and 4.12. Hydrated lipid films were 
freeze-thawed five times and subsequently extruded 20 times through 100 nm 
polycarbonate membranes (Avanti Polar Lipids) and wrapped in foil and stored 
in the dark when not in use. 
4.3.2.2 DIB formation 
DIB formation was achieved using the ‘lipid-in’ approach, as detailed 
previously in section 4.2.3. Approximately 0.2 µl aliquots of aqueous vesicle 
suspension were pipetted into hexadecane: the hexadecane and aqueous 
droplets were contained within glass chambers (see figure 4.4 for design). After 
having been left in the oil for a period of time, to enable monolayer formation 
at the oil-water interface, two droplets were brought into contact with one 
another to form a DIB.  
4.3.2.3 Leakage experiments 
For each leakage experiment two vesicle populations were prepared; one using 
a solution of low pH and containing a fluorescent dye (either solutions 4.2, 
4.11 or 4.12 as detailed in section 4.3.1.2), the other at higher pH (solution 4.3, 
see section 4.3.1.2). The standard protocol for the production of small 
unilamellar vesicles (SUVs) was adopted (see section 4.3.2.1 for details). Note 
that special care was taken when extruding the two vesicle populations. Each 
was extruded using a separate extruder, which was freshly cleaned and rinsed 
with the solution of interest prior to use. This was particularly important in 
order to maintain the true pH of each vesicle population.  
4.3.2.4 Control experiments 
Control experiments involved testing whether aqueous solutions, containing 
either CF or pyranine, leak from the aqueous phase into the oil phase. Equal 
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volumes of the aqueous fluorescent solution (either solution 4.2, 4.4, 4.12 and 
4.15, as described in section 4.3.1.2) and hexadecane oil were placed in the 
same glass vial, thus forming an aqueous‐oil interface, and left for one week in 
a concealed and dark environment. Aliquots of each phase were then 
transferred into a 96 well‐plate (Fisher Scientific Ltd) and fluorescence 
measurements carried out on a Cary Eclipse fluorescence spectrophotometer 
(Varian Inc.). Emission scans, with excitation at 490 or 475 nm (for CF- and 
pyranine-containing solutions respectively) and emission collected from 500 to 
600 nm, were then performed on each of the samples. Both the excitation and 
emission slits were set to 5 nm, and a medium scan rate and photomultiplier 
tube detector voltage (PMT) of 500 V employed. Comparisons were then made 
with fresh samples of hexadecane and original fluorescent solutions (where no 
aqueous-oil interface was allowed to form). 
4.3.2.5 Pyranine fluorescence spectra 
All fluorescence spectra conducted for pyranine-containing samples were 
conducted on a Cary Eclipse fluorescence spectrophotometer (Varian Inc.) 
using a well-plate reader (96 wells). Excitation spectra, determined in the 300-
500 nm range, were attained using a fixed emission wavelength of 510 nm, a 
PMT of 500 V, a medium scan rate and excitation / emission slits both set to 5 
nm. Emission spectra were gained using an excitation wavelength of 460 or 
475 nm and emission collected in the region between 500-600 nm. The PMT, 
scan rate and excitation / emission slits used to gain the emission spectra were 
identical to those used to gain the excitation spectra. 
4.3.2.6 Imaging 
All experiments described herein were conducted on a Nikon Eclipse TE 
2000-E fluorescence microscope. A QICAM camera (QImaging, Media 
Cybernetics UK) was used to capture both bright field and fluorescence 
images. Figure 4.4 illustrates the experimental setup for the experiments  
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Figure 4.4: Experimental set-up for DIB experiments using manual 
manipulation. The Nikon Eclipse TE 2000-E microscope, used to conduct the 
experiments described in this chapter, is displayed. A close up view of the microscope 
indicates where hand-built glass chambers, used for holding droplets and hence 
viewing DIB formation, are slotted into the microscope stage accordingly. 
 
conducted in this chapter. The software used to drive the equipment was 
home-built, designed and built by Dr. Nick Brooks in LabView. 
The combinations of excitation filters, emission filters and dichroic mirrors 
used in the filter cubes (Nikon) during the fluorescence experiments detailed in 
this chapter are specified as follows: 
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Carboxyfluorescein 
Channel 1: Excitation: 465-495 nm 
    Emission: 515-555 nm 
Dichroic: 505 nm 
 
Pyranine 
Single channel fluorescence recordings: 
` Channel 1: Excitation: 457-487 nm 
    Emission: 515-555 nm 
    Dichroic: 495 nm 
 
Dual channel fluorescence recordings: 
Channel 1: Excitation: 330-380 nm 
    Emission: 515-555 nm 
    Dichroic: 505 nm 
 
Channel 2: Excitation: 457-487 nm 
    Emission: 515-555 nm 
    Dichroic: 495 nm 
 
The exposure times used during ratiometric experiments when taking bright 
field, channel 1 and channel 2 recordings were 4 ms, 3000 ms and 1500 ms 
respectively. Note that the ratio of fluorescence intensities, r, is defined as: 
nm
average
nm
average
F
F
r 380330
490460
−
−
=     Equation 4.1 
 
where F = average fluorescence intensity (collected between 515-555 
nm) when the sample is excited at either 460-490 nm or 330-380 nm. 
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4.3.2.7 Image analysis 
ImageJ, Image Processing and Analysis in Java (freeware, Wayne Rasband, 
National Institute of Mental Health USA), was used to analyse and hence gain 
quantitative information from the microscopy images presented in this chapter. 
Regions of interest (ROIs) around each fluorescent droplet were defined in 
order to gain the average fluorescence intensity for the relevant droplet in each 
image. Note that circular ROIs were used and defined using the bright field 
images as a guide. The absolute area of the ROI remained constant within each 
experiment. A screen dump of the graphical user interface is illustrated in 
figure 4.5. 
 
 
Figure 4.5: Screen dump of the ImageJ software used for analysing 
fluorescence microscopy images. Example images of aqueous, lipid-containing 
droplets in hexadecane oil are displayed after having been subjected to both 
fluorescence and bright field illumination. The region of interest (ROI), used to 
calculate the average fluorescence intensity of a specified region, is highlighted by the 
yellow circle. The area of the ROI, in addition to the mean, minimum and maximum 
fluorescence intensity, can be ascertained. 
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4.3.2.8 IFT measurements 
Measurements of IFT at the oil-water interface required the droplets to be 
suspended in an oil environment, hence a glass cuvette was used to 
accomodate the embedding phase. As the oil phase is less dense than the 
aqueous phase (ρhexadecane = 0.773 g / ml),255 the experiments were conducted in 
the typical manner of water-in-air measurements, where the drop is suspended 
in a top-down manner. For experiments investigating the surface activity of 
surfactant molecules at the air-water interface, droplets were suspended in a 
closed environment containing a few millilitres of aqueous solution in order to 
maintain a constant drop volume (see figure 2.6 C in chapter 2, section 2.3.2.4 
for further information).  
All data were collected using the software programme “Drop Shape Analysis”. 
The Trackerman programme was utilised to determine the dependency of a 
particular surfactant-containing solution on the IFT over time, where the IFT 
will tend to an equilibrium value (IFTeq) as t → ∞. This programme was set up 
to record an IFT measurement at regular time intervals (every 10 s) for a total 
duration of up to 40 minutes. All experiments were conducted at room 
temperature and the lights in the vicinity of the tensiometer turned off to 
ensure that good contrast, between the drop circumference and background, is 
maintained. 
 
4.3.3 Movie 
4.3.3.1 Movie 4.1: ‘Formation of droplet interface bilayer (DIB)’ 
This movie shows DIB formation between a non‐fluorescent droplet  
(2 mg / ml DPhPC) and a fluorescent droplet (2 mg / ml DPhPC with  
250 μM fluorescein). The stills from the movie are displayed in figure 4.6; note 
that the time increment between each image is 1 s and the scale bar represents 
ca. 400 µm. Please find the movie on the CD accompanying this thesis. 
Chapter 4 
165 
 
 
Figure 4.6: Stills from Movie 4.1: ‘Formation of droplet interface bilayer (DIB)’. 
 
4.4 RESULTS AND DISCUSSION 
As described in section 4.2.3, droplet interface bilayers (DIBs) provide an 
alternative means to probe the effect of exogenous species upon a lipid 
membrane, offering several advantages over conventional methods for planar 
bilayer formation. Herein, the following section will discuss the steps taken in 
achieving successful DIB formation, both with DPhPC and the more 
biologically relevant lipid DOPC, and detail proof-of-concept experiments, 
involving the use of pH sensitive dyes, which can be envisaged to offer an 
indirect means for monitoring the extent to which lipid bilayers are perturbed 
by drug molecules, or proteins, for example. 
 
4.4.1 Formation of droplet interface bilayers (DIBs)  
4.4.1.1 Open channel format for DIB formation 
In the first instance it was desirable to reproduce the DIB formation process, 
reported by the Bayley group. Hand-built chambers were produced for this 
purpose (see figure 4.4 for chamber design). Open channels thus allowed 
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droplets to be manually pipetted into the oil and enabled the DIB formation 
process to be performed in a simple and uncomplicated manner. 
Approximately 0.2 µl aliquots of 2 mg / ml DPhPC vesicle suspensions were 
pipetted into hexadecane, i.e. the same lipid, lipid concentration, aqueous 
solution (solution 4.1, see section 4.3.1.2) and oil employed by the Bayley 
group. It is worthy to note that hexadecane is used, as opposed to other 
members of the decane family, because it is much less soluble in lipid. Lipid 
bilayers formed in the presence of hexadecane, e.g. using soya bean lecithin, are 
reported to give higher specific capacities and are more true to native 
membranes.250 It would be desirable to use oils possessing longer carbon 
chains, however this is not possible practically due to their inherent physical 
properties. Specifically, increasing chain length leads to an increase in the phase 
transition temperature (see table 4.2, values gained from sigma Aldrich 
website). 
 
 
Chemical Name Chemical Formula Melting Point (oC) 
Tetradecane CH3(CH2)12CH3 ~ 6 oC 
Pentadecane CH3(CH2)13CH3 ~ 9 oC 
Hexadecane CH3(CH2)14CH3 ~ 18 oC 
Heptadecane CH3(CH2)15CH3 ~ 22 oC 
Octadecane CH3(CH2)16CH3 ~ 28 oC 
Table 4.2: Melting points of different solvents, including hexadecane.255-259 
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Upon submersing two droplets in hexadecane, they were then manually 
brought together using a small metal prong. Notably, as soon as droplets came 
into contact with one another an initiation point was obvious, from which the 
‘zipping up’ of two monolayers in opposing directions to form a droplet 
interface bilayer (DIB) could clearly be monitored. The images in figure 4.7 
illustrate DIB formation between two droplets containing DPhPC vesicle 
solutions. A movie of this event was captured and can be viewed using the CD 
accompanying this thesis (Movie 4.1, see section 4.3.3). Characteristic 
shadowing present on either side of the DIB was observed in every system 
described herein and is akin to observations made by others previously.204 As 
reported by Funakoshi et al., this phenomenon is thought to be due to 
refraction associated with differing membrane thicknesses in the vicinity of the 
DIB (i.e. monolayer vs. bilayer).202 Hence, it was apparent that DIBs could be 
formed successfully, as determined using optical methods (electrical methods 
for assessing the formation of DIBs are not currently available in our 
laboratory).  
As these experiments were performed by hand, it was found that the droplets 
required: (i) enough time for monolayer formation to occur and hence were 
left in the oil for 5-10 minutes prior to DIB formation and (ii) to be brought  
 
 
 
Figure 4.7: Experimental evidence for the formation of droplet interface 
bilayers (DIBs). The sequence of images displayed show two droplets participating 
in DIB formation. The scale bars represent 400 µm. 
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together with care (i.e. gently/slowly). Small droplets appeared to stick together 
very easily, most probably due to the heightened probability of lipid exchange 
with the interface and thus resulting in more rapid monolayer formation.  
It was also confirmed that monolayers participating in DIB formation can be 
separated once formed, as has been reported elsewhere.203 The reversibility of 
DIB formation is therefore of particular use as a mechanism for controlling a 
system, where commands of a “stop / start” nature may be employed.  
4.4.1.2 DIB formation with different lipids: DPhPC versus DOPC 
In addition to forming DIBs comprised solely of DPhPC, which has been the 
only lipid used in DIB production to date, it would be desirable to create DIBs 
that contain more biologically relevant lipids (or indeed mixtures of lipids) in 
order to expand their utility. For example, the use of DOPC would be highly 
relevant since this lipid has been the major lipid of choice in the biophysical 
assays described previously (in chapters 2 and 3). The chemical structures of 
DPhPC and DOPC can be viewed in figure 4.8, as well as an example of their 
ability to participate in DIB formation. 
Inspection of figure 4.8 shows that DIBs formed using DOPC display 
comparable characteristics to DIBs comprised of DPhPC, as assessed using 
optical measurements. The characteristic shadowing effects reside in both  
 
 
Figure 4.8: DPhPC and DOPC for DIB formation. (A) and (B) represent DPhPC 
and DOPC respectively. An exemplar image of DIB formation for each lipid type has 
also been included; red boxes indicate DIBs. 
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cases, indicating that DIB formation has been achieved (highlighted by the red 
boxes in figure 4.8). That is to say, droplets containing DOPC also form a 
‘seed’ point upon initial contact of the two lipid monolayers, in an analogous 
manner to that of DPhPC, from which they proceed to zip up to form a 
droplet interface bilayer. The only experimental observations that were notably 
different when using DOPC included: (i) the time required to gain sufficient 
monolayer formation at the aqueous-oil interface and (ii) the lipid 
concentration used. Subsequently, droplets containing DOPC vesicle 
suspensions were left in the oil for a minimum of 15 minutes before any 
attempt was made to form a DIB, as otherwise the droplets simply merged, 
and a higher DOPC concentration was used to form DOPC DIBs. 
Interfacial surface tension measurements were conducted as a means to 
understand these observations, providing a more quantitative indication of the 
extent of DPhPC / DOPC interaction at the aqueous-oil interface. Figure 4.9 
summarises the interfacial surface tension measurements conducted with 
DOPC and DPhPC. One major observation that was made from these 
experiments included realising the extent to which DPhPC lowers the 
interfacial surface tension, as compared to DOPC, for vesicle suspensions 
composed from a solution with a lipid concentration equal to 0.2 mM. It was 
found that the presence of DPhPC results in a greater decrease in the 
interfacial surface tension, as illustrated by figure 4.9 A, therefore suggesting 
that DPhPC stabilises the interface more quickly than that of DOPC at this 
concentration. This concurs with experimental observations i.e. that for a fixed 
lipid concentration, it is not possible to form DOPC DIBs after only leaving 
the lipid-containing droplets in the oil for a few minutes.  
It would have been interesting to have left the droplets for extended periods of 
time, to see if both vesicles samples reached the same interfacial surface 
tension values at equilibrium. However, the droplets were found to fall off 
after ca. 10 minutes (in the case of the buffer droplets / DOPC containing 
droplets) and 20 minutes (for the DPhPC containing droplets). As observed in 
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figure 4.9 A, the interfacial tension of the buffer drop alone decreases with 
time. This suggests that the gravitational pull on the droplet is far greater than 
that of the opposing interfacial tension (restorative force) and as such the 
droplets fall off the needle. It is possible to circumvent such a problem, which 
is typical of systems possessing lower surface tensions, by using larger needle 
diameters to support the required drop size. However the needle diameter used 
in this instance was already very large, and correspondingly could not be 
increased due to the limitation imposed by the camera’s field of view. 
Nevertheless, these data do support and help explain the observations made 
experimentally. 
 
 
Figure 4.9: IFT measurements of DOPC and DPhPC. Graph A demonstrates 
how IFT is affected upon introducing aqueous droplets of 0.2 mM DOPC and 0.2 
mM DPhPC into hexadecane. Graph B demonstrates the effect of various 
concentrations of DOPC on the IFT in air.  
 
Another experimental observation that has been made is that an increase in the 
concentration of lipid used per set volume appears to increase the propensity 
for DOPC DIB formation. It is therefore proposed that the lipid 
concentration used to form the DOPC vesicle suspension (0.2 mM) may not 
be high enough for the particular system measured on the drop tensiometer, 
displayed in figure 4.9 A. Perhaps the energetic requirement for DOPC 
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molecules in vesicles to convert to DOPC molecules residing at the interface is 
less favourable c.f. DPhPC molecules? Hence a higher concentration may be 
required in order to increase the chance of DOPC monolayer formation at the 
interface. DPhPC has been found to possess a negative spontaneous curvature 
(a numeric value could not be found in the literature),260,261 owing to the 
presence of bulky acyl chains,262 and is therefore a Type II lipid (see chapter 1, 
section 1.2.2.3). DOPC has a spontaneous curvature of approximately zero and 
is a Type 0 lipid. Therefore this suggests that vesicles comprised of DOPC will 
be less frustrated (i.e. possess lower levels of curvature elastic stress), c.f. 
vesicles comprised of DPhPC, and so do not have the same desire to depart 
from their vesicular form. 
Surface tension measurements that were conducted with DOPC at the air-
aqueous interface, thus omitting problems associated with taking interfacial 
surface tension measurements in hexadecane (see figure 4.9 B), support this 
hypothesis. In this instance it can be observed that a DOPC concentration of 
0.4 mM reduces the IFT by only a few mN / m, whereas a 2.5-10 fold increase 
in the concentration results in a larger reduction in the surface tension. In fact, 
it appears that total surface coverage has been achieved with only a 2.5 fold 
increase in lipid concentration (i.e. 1.0 mM). Although this measurement has 
been taken at the air-aqueous interface it is feasible to extrapolate such results 
to the liquid-liquid system, where interactions between DOPC acyl tails and 
hexadecane are more favourable.  
 
4.4.2 Proof-of-concept DIB-leakage experiments  
As section 5.4.1 details, successful DIB formation can be attained both with 
DOPC and DPhPC. Therefore, it is desirable to use this system to further our 
understanding of the interaction of both synthetic and biological species upon 
lipid membranes. As such, it was thought interesting to develop a leakage assay 
for use across DIBs, which in turn can act as a measure of the extent of such 
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interactions. Here, proof-of-concept experiments are detailed, the principle 
idea for which involves developing an assay able to monitor proton leakage 
across a bilayer using a pH sensitive dye as a reporter. The illustrations 
presented in figure 4.10 demonstrate the principle behind this idea. 
 
 
Figure 4.10: Principle of DIB-leakage experiments. (A) Diagram illustrating the 
theoretical set-up; two lipid-containing droplets in oil are brought together to form a 
DIB, one containing a pH sensitive dye at low pH and the other a buffer at high pH 
(thus creating a pH gradient across the bilayer). (B) An increase in the fluorescence 
intensity with time would occur if proton transport across the bilayer takes place, as 
illustrated by the graph, levelling off when the pH gradient diminishes. 
 
4.4.2.1 Carboxyfluorescein  
Initial experiments involved using the pH sensitive dye, CF (experimental 
information provided in section 4.3.2.3). Chapter 2, section 2.2.1 has discussed 
the properties of CF in detail, including specific details of self-quenching at 
high concentrations (millimolar regime). In this instance, the dye concentration 
is fixed and it is the change in environmental pH that is of interest.  
The general format of these experiments involved bringing together two 
droplets containing DOPC, with the aqueous component of one droplet being 
at a higher pH than the other, in order to create a pH gradient across the DIB. 
It was decided to look for an increase in the fluorescence intensity, as opposed 
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to a decrease. Hence the dye was incorporated into the low pH droplet, as the 
fluorescence intensity of CF increases with decreasing proton concentration.218 
Figure 4.11 demonstrates the change in the average fluorescence intensity of 
the fluorescent droplets upon DIB formation (A) and alone (B). 
 
 
Figure 4.11: Carboxyfluorescein as a pH sensor for use in leakage experiments 
across DIBs. (A) Graph showing the change in the average fluorescence intensity of 
a CF-containing droplet (droplet on the right, made using solution 4.2, pH 4.6) after 
having formed a DIB with a non-fluorescent droplet (droplet on the left, made using 
solution 4.3 pH 8). The corresponding bright field and fluorescence microscopy 
images are displayed below the graph. (B) Graph and images illustrating that the 
average fluorescence intensity of a CF-containing droplet in oil alone (i.e. not 
participating in DIB formation) does not increase. Scale bar represents 400 µm. See 
section 4.3.1.2 details about the nature of the solutions used.  
Note that the average fluorescence intensity of the control droplet initially is 
higher than that of the fluorescent droplet participating in DIB formation as it 
is larger in volume. 
The decision to monitor an increase in the fluorescence intensity was taken as a 
means to act as an internal control. If proton loss to the oil is occurring, then 
an increase in the fluorescence intensity of lone droplets present in the oil 
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environment would be observed. It is important to note here that for all 
control experiments associated with the experiments presented in this chapter, 
there were no instances where the fluorescence intensity of a dye-containing 
droplet increased when present in the oil alone (i.e. if not participating in DIB 
formation with another droplet). The fact that an increase in the fluorescence 
intensity is only observed when a DIB is formed informs one that the setup is 
effective in measuring proton transport. 
However, the average fluorescence intensity of a CF-containing droplet was 
found to diminish alone, having not been illuminated with the relevant 
excitation wavelengths previously (see figure 4.12 A & B). Therefore it was 
concluded that it must be the dye that is leaching out of the droplet and into 
the oil, due to the protonation and neutralisation of CF, therefore making it 
more hydrophobic so it can cross the membrane. This observation was 
supplemented by control data measured using the spectrophotometer (two 
experimental repeats were conducted). Specifically, aliquots of the CF-
containing aqueous solution at pH 4.6 (solution 4.2, see section 4.3.1.2), and 
also an analogous solution at pH 8 (solution 4.4, see section 4.3.1.2), were 
placed in contact with the oil and left for one week. The results indicate that 
the fluorescence intensity of the aqueous fraction at pH 4.6 was greatly 
diminished when compared to the original aqueous sample, whereas the 
fluorescence intensity of the aqueous fraction at pH 8 did not differ to the 
control (see figure 4.12 C and D). Furthermore, when the two droplets 
displayed in figure 4.12 A and B were brought into contact with one another to 
form a DIB the average fluorescence intensity started to increase, but 
subsequently proceeded to diminish shortly afterwards at approximately 50 
minutes (see figure 4.12 E, F and G). These results suggest that CF may not be 
the most suitable dye for use in this application, and as such the decision was 
taken to use another dye, specifically pyranine. 
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Figure 4.12: Evidence for carboxyfluorescein leakage into the oil phase. The 
average fluorescence intensity of a CF-containing aqueous droplet (solution, 4.2, pH 
4.6) in oil diminished after having been left in the dark for ca. 45 minutes; the images 
in (A) and (B) show the fluorescent droplet at 0 m and 45 m respectively. This data 
was substantiated with control experiments conducted on the fluorimeter. Aliquots of 
CF-containing solutions at pH 4.6 (solution 4.2) and pH 8 (solution 4.4) were left in 
contact with oil for one week; the emission spectra (excitation at 490 nm) for the 
aqueous and oil fractions (denoted by “Aqueous fraction” and “Oil fraction” 
respectively) are displayed in (C) and (D) for the pH 4.6 and pH 8 tests respectively. 
The aqueous fractions were compared to the original solutions, i.e. those that had not 
been left in contact with oil (denoted “Control”), as illustrated in C and D. 
Additionally, upon bringing the CF-containing droplet (right-hand droplet, pH 4.6) 
into contact with the non-fluorescent droplet (left-hand droplet, made using solution 
4.3, pH 8) to form a DIB ((E) represents the fluorescence microscopy images and (F) 
the brightfield images at various time points), the average fluorescence intensity 
increased initially but shortly arrested, as illustrated quantitatively in graph (G). Scale 
bars represent 400 μm. See section 4.3.1.2 details about the nature of the solutions 
used. 
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4.4.2.2 Properties of pyranine 
Pyranine, 8-hydroxypyrene-1,3,6-trisulphonic acid, is a pH sensitive 
fluorophore that has the advantage of being very economical, extremely water 
soluble and membrane-impermeable. The latter two points are highly desirable 
and are predominantly due to the presence of three strongly acidic sulfonate 
groups, ensuring that the molecule remains ionised over an extended range of 
pH values.263 Figure 4.13 illustrates the chemical structure of this dye. 
 
 
Figure 4.13: Chemical structure of pyranine, 8-hydroxypyrene-1,3,6-trisulphonic 
acid (trisodium salt). 
 
As an initial starting point, aqueous, pyranine-containing samples (solutions 
4.5-4.9, see section 4.3.1.2) were prepared and their fluorescence properties 
explored at a variety of different pH values. After exciting the samples at 460 
nm, an unexpected relationship between the observed fluorescence intensity 
and pH was found to exist, when compared to the published InvitrogenTM 
literature (see figure 4.14 A and B respectively).264 Specifically, the emission 
maximum at 510 nm first increased with pH (from pH 4 to 6), after which a 
decrease in the fluorescence intensity was observed (most prominently from 
pH 6 to pH 7). Upon viewing the excitation spectra (fixed emission at 510 nm) 
it was found that the nature of the spectra, both above and below the 
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isosbestic point at 405 nm, differed quite substantially to the published 
literature. For example, it was found that the main peak present within the 400-
500 nm region is actually comprised of two peaks, whose intensities change in 
an opposing manner to one another upon changing the pH. Consequently, it 
was decided that a system comprised solely of pyranine in water should be 
investigated. 
 
 
Figure 4.14: Fluorescence properties of pyranine solutions. (A) Excitation and 
emission spectra for a 1 mM pyranine solution measured at different pH values 
(solutions 4.5-4.9, see section 4.3.1.2) are displayed. An emission wavelength of 510 
nm was used to generate the excitation spectrum. An excitation wavelength of 460 nm 
was employed to gain the emission spectrum, as indicated by the dotted line on the 
excitation spectrum. (B) Absorption spectra for a variety of pyranine solutions, as 
published on the InvitrogenTM website.264 
 
Upon diluting a 1 mM stock solution of pyranine in water (solution 4.10), it 
was found that the excitation spectrum (gained using a fixed emission 
wavelength of 510 nm) was strongly dependent upon the concentration of 
pyranine in solution, the results of which are displayed in figure 4.15 (green 
curves). The most notable features present in these graphs is the change in the 
nature of the peaks(s) present in the 350-400 nm region upon dilution, where 
an inversion occurs at approximately 125 µM. This effect can be observed 
more clearly in figure 4.15 A and B (two repeat experiments), where the spectra 
have been collated and the regions of interest highlighted with circles. 
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Figure 4.15: The dependence of pyranine’s excitation spectrum upon its 
concentration and pH in water. The excitation spectra displayed in this figure, 
attained using a fixed emission wavelength of 510 nm, illustrate how the nature of 
pyranine’s excitation spectrum is influenced by the concentration of pyranine in water, 
as well as the presence of both acid and alkali.  
The effect of adding both acid and alkali to the system was also monitored for 
each concentration, as illustrated in figure 4.15. Upon adding acid, the peak 
present in the 425-500 nm region of the excitation spectrum subsides relative 
to the original trace (see also the collated spectra in figure 4.16 C). When the 
pH is raised, this peak increases in intensity with respect to the original trace, 
for samples below 125 µM, and interestingly splits into two (see figure 4.16 D 
for collated spectra). This was observed previously in figure 4.14 and is 
particularly important for choosing suitable excitation filters in fluorescence 
microscopy.  
Additionally, the increase in the peak intensity in the 425-500 nm region 
observed under alkaline environments (relative to the original trace) is coupled 
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with a concomitant decrease in the peak intensity in the 350-400 nm region 
(relative to the original trace). This phenomenon is only observed at dye 
concentrations below 100 µm. The reverse situation (i.e. a decrease occurring 
concomitantly with an increase of the peak intensities) is observed under acidic 
environments and again is also only true for this concentration range, though 
the effect is less prominent. Hence it appears that the typical behaviour of 
pyranine, where the peak intensities above and below the isosbestic point exist 
as part of a symbiotic relationship, is only valid for systems within a certain 
concentration range. Therefore pyranine concentrations less than 100 µM have 
been employed in all current experiments. 
 
 
Figure 4.16: Collated excitation spectra for serially diluted 1 mM pyranine 
stocks (in water) and in the presence of acidic and alkaline conditions. (A) and 
(B) Graphs representing the excitation spectra (gained using a fixed emission 
wavelength of 510 nm) of 1 mM pyranine stock solutions serially diluted in water (two 
experimental repeats). The highlighted regions (circles) indicate the point at which the 
peak in the 350-400 nm region inverts. (C) and (D) Graphs illustrating the effect of 
introducing both acid and alkali solutions to each pyranine concentration respectively, 
in order to monitor the changes in fluorescence properties (excitation spectra, gained 
using 510 nm fixed emission). The arrows indicate the general direction of peak 
movement upon addition of acid or alkali, when compared to the original traces. 
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4.4.2.3 DIB leakage assay with pyranine 
The first attempt at performing the leakage assay with pyranine as the 
fluorescent pH indicator involved using an 60 µM aqueous pyranine solution 
(solution 4.11, pH 5.5, see section 4.3.1.2) to form the ‘fluorescent droplet’. As 
expected, an increase in the average fluorescence intensity was obtained, after 
having formed a DIB with another droplet containing an aqueous 
compartment at pH 8 (solution 4.3, see section 4.3.1.2), therefore indicating 
that the pH of the pyranine-containing droplet is changing with time. 
In this instance, however, the DIB collapsed after approximately one hour (see 
figure 4.17 A and B), which in retrospect can be attributed to an imbalance in 
osmolarity across the membrane; the non-fluorescent droplet (pH 8) contains 
200 mM KCl, which the fluorescent droplet does not. This always occurred 
when repeat experiments were attempted. Further evidence to support this 
includes the observation that the pyranine-containing droplet was found to 
decrease in size (by approximately 36 %) after 35 minutes (see figure 4.17 B). A 
decrease in the droplet volume is not normally observed as the droplets reside 
on the bottom of the device, owing to the aqueous phase being more dense 
than the oil phase. Hence a net movement of water across the DOPC bilayer is 
taking place due the high concentration of potassium chloride present on the 
opposite side of the membrane. This concurs with the deviation away from 
linearity, observed and indicated in the graph presented in figure 4.17 A, where 
the concentration of pyranine effectively increases with time. As previously 
determined (see figure 4.16 A and B), an increase in pyranine concentration 
leads to an increase in fluorescence intensity in the region that is being 
monitored here (460-490 nm). Note that the fluorescence intensity remains 
constant after the two droplets have merged and is lower than may be expected 
due to the dilution of pyranine. 
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Figure 4.17: First attempt at performing a DIB leakage assay, using a 60 µM 
aqueous pyranine solution (solution 4.11, pH 5.5, section 4.3.1.2). (A) Graph 
representing the average fluorescence intensity of each pyranine-containing droplet 
displayed in (B) (right-hand droplets). Note that the bright field and fluorescence 
microscopy images at t > 70 m are not displayed. The droplets merged after ca. 60 m 
due to a difference in osmolarity across the bilayer, as indicated by the red arrow in 
(A), and the average fluorescence intensity found to deviate away from linearity  
(indicated by the dotted line in (A)) at t ~ 35 m. Scale bar represents 400 µm. 
 
The aforementioned merging event is an important observation, providing 
further evidence to support the presence of a lipid bilayer between the two 
droplets, and moreover, that transport across the bilayer is achievable and can 
be monitored. However in order to make the system more robust and prevent 
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droplet merging, the presence of salt is required on both sides of the 
membrane.  
Consequently an aqueous solution was prepared, incorporating an analogous 
concentration of salt to that of the high pH droplet (200 mM KCl, solutions 
4.12 and 4.3 respectively, see section 4.3.1.2), to ensure that the osmolarity 
across the membrane is balanced. Figure 4.18 A illustrates that the properties 
of this fluorescent solution behave as expected when the pH of the solution is 
changed. Additionally a linear relationship exists between the observed 
fluorescence intensity and pH, as illustrated by the graph in Figure 4.18 B. 
Control experiments, assessing the tendency of pyranine to leak into the oil 
phase, were also performed with this solution (see figure 4.18) and conducted 
in the same format as described previously for CF-containing solutions (see 
figure 4.12 and section 4.3.2.4). Both the pH 5.5 and pH 8 analogues of the 
pyranine-containing aqueous solution were tested over a period of a week, the 
results of which are displayed in figure 4.18 C and D respectively. These results 
indicate that no discernable leakage of the dye from the aqueous phase and 
into the oil phase is observed. 
A major problem associated with past experiments conducted within this 
chapter concerns the ability to compare results from one experiment to the 
next. This problem arises from the variability in droplet size gained when they 
are pipetted into the oil. Therefore it is proposed that the use of ratiometric 
measurements can offer a potential solution to this problem, where the results 
should be independent of droplet size. Note that this statement assumes that 
the system is identical in every other manner during each experiment, such as 
the ratio between droplet volumes on either side of the DIB and DIB contact 
area for example. Hence, a second reason for choosing pyranine is that it also 
offers the opportunity to conduct ratiometric fluorescence measurements. 
Excitation of the dye in the regions between 330-380 nm and 460-490 nm  
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Figure 4.18: Dependency of excitation spectra on sample pH for 60 µM 
pyranine-containing solutions, plus control experiment. (A) Graph representing 
the excitation spectra (gained using a fixed emission wavelength of 510 nm) of a 
pyranine-containing solution at different pH values (solutions 4.12-4.15), with graph 
(B) indicating that a linear relationship exists between the ratio of fluorescence 
intensities, r, (see equation 4.1, section 4.3.2.6) and pH (conducted on a 
spectrophotometer). Graphs (C) and (D) represent control experiments conducted on 
the fluorimeter to test for loss of pyranine to the oil at pH 5.5 and 8 respectively. 
Aliquots of pyranine-containing solutions at pH 5.5 (solution 4.12) and pH 8 (solution 
4.16) were left in contact with oil for one week. The aqueous fractions that had been 
left in contact with the oil (denoted “Aqueous fraction”) were compared to the 
original solutions (denoted “Control” – these had not been left in contact with oil). 
These emission spectra were collected using an excitation wavelength of 475 nm. See 
section 4.3.1.2 details about the nature of the solutions used. 
  
results in a change in the fluorescence emission at 510 nm, with the 
fluorescence change of the former being very subtle compared to the latter 
(figure 4.18 A). 
Figure 4.19 represents the analysed data for three DIB leakage experiments, 
using ratiometric fluorescence measurements, as well as the control 
experiments (seven repeats, taken on at least three different days, with three 
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different sample populations and at different times of the day). Appendix 13 
provides specific information about each of the droplets participating in DIB 
formation, displayed in figure 4.19 (numbered 1-6, the fluorescent droplet is 
represented by even numbers); droplet diameter, volume and DIB contact area 
are included. Appendix 14 contains each of the bright field and fluorescence 
microscopy images of the droplets participating in DIB leakage experiments 
plus one control experiment. 
It can be observed that three distinct relationships, between the ratio of 
fluorescence intensities and time, are represented by the data presented in 
figure 4.19. The first relates to the control system, represented by the black 
data in figure 4.19.  
The control experiments yield a flat base line; hence it is apparent that the ratio 
between each of the average fluorescence intensities does not change within 
the population sampled (over a period of nearly three hours). Upon forming a 
DIB between two aqueous droplets, one of which contains pyranine (the even 
numbered droplets in figure 4.19), the ratio of fluorescence intensities deviates 
from the control. Three DIB experiments are detailed, though two different 
relationships, between the ratio of fluorescence intensities and time, can be 
identified in these data. These are the second and third relationships alluded to 
previously, and are represented by: (i) the red and orange curves and (ii) the 
blue curve displayed in figure 4.19 respectively.  
Upon analysing the droplet properties, it can be observed that the volumes of 
droplets 1 and 3 (0.17 and 0.18 µl respectively, see Appendix 13) are 
approximately the same, as are the volumes of droplets 2 and 4 (0.11 and 0.09 
µl respectively). Furthermore, the DIBs formed between each of these pairs of 
droplets are approximately equal in area (ca. 1 E-04 cm2). Hence, they should 
portray the same leakage characteristics; this is certainly apparent when viewing 
the relevant curves in figure 4.19 (the red data points relate to droplet 2, with 
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Figure 4.19: Observed relationships between the ratio of pyranine fluorescence 
intensity and time for different DIB systems (including control). The control 
experiment (black data points) represents the first relationship observed, i.e. a flat 
baseline, thus indicating that there is no proton leakage throughout the duration of the 
experiment. Droplets 1 and 2 (red data points) and droplets 3 and 4 (orange data 
points) represent the second observed relationship, where the fluorescent droplet is 
always smaller than the non-fluorescent droplet. Droplets 5 and 6 (blue data points) 
represent the third observed relationship, where the fluorescent droplet is larger than 
the non-fluorescent droplet. Specific information about the droplet properties (droplet 
diameter, DIB contact area and droplet volume) is afforded in Appendix 13. Scale bar 
represent 400 µm. 
 
the orange data points relating to droplet 4). Although there are differences in 
the initial rate of change, where ambiguities may be introduced due to 
uncontrollable factors, such as the time taken to complete DIB formation, the 
curves ultimately tend towards the same value as the system reaches 
equilibrium. 
The third relationship can be identified by the blue data points in figure 4.19 
and refers to the situation represented by droplets 5 and 6 in figure 4.19. In 
this instance, it is the larger droplet of the two which contains fluorescent 
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pyranine (droplet 6). The response attained for this situation reflects the nature 
of the DIB system. Note that the DIB contact area formed between droplets 5 
and 6 is approximately the same as those formed between droplets 1 and 2, 
and 3 and 4. 
The variation in the observed trends for proton leakage between droplets 5 
and 6, and 1 and 2, for example (blue and red data points respectively, 
illustrated in figure 4.19), arises due to differences in the relative volumes of 
the fluorescent and non-fluorescent droplets present on either side of the DIB. 
The non-fluorescent droplet is only 62 % of the volume of the pyranine-
containing droplet, if you consider droplets 5 and 6 respectively (0.08 µl and 
0.13 µl, see Appendix 13). Conversely, droplet 1 (non-fluorescent, 0.17 µl) is 
ca. 160 % of the volume of droplet 2 (pyranine containing, 0.11 µl). Hence the 
kinetics associated with proton transfer across each DIB, and thus pH, will 
differ. Although initially this observation could be seen as a disadvantage, the 
observation could actually be used to one’s advantage, providing the ability to 
tune the system to suit a specific need. Two factors that could easily be 
manipulated include: (i) droplet volume and (ii) the size of the DIB contact 
area.  
If, for example, the volume of the non-fluorescent droplet and DIB contact 
area are fixed, and only the volume of the fluorescent droplet is altered, two 
important factors will change: (i) the time taken to reach equilibrium (where 
the proton concentration on either side of the DIB is equal) and (ii) the 
magnitude of that equilibrium value. If the volume of the fluorescent droplet is 
smaller than the volume of the non-fluorescent droplet, the time taken to reach 
equilibrium will be reduced, compared to the reverse situation (where the 
volume of the non-fluorescent droplet is larger than the fluorescent droplet). 
Furthermore, the magnitude of the equilibrium value will be greater for the 
former situation (where the volume of the fluorescent droplet is smaller than 
the volume of the non-fluorescent droplet). The same number of protons will 
transport across the DIB contact area per unit time in both situations, however 
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this will translate to a bigger change in the pH with time for the fluorescent 
droplet that is of a smaller volume and equilibrium will be reached more 
quickly. Hence, changes in the relative droplet volumes (for a set DIB contact 
area) can lead to subtle differences in the kinetic properties of these systems. 
The other factor that can be altered in order to manipulate the rate of proton 
leakage involves changing the area of the droplet interface bilayer. An increase 
in the area of the droplet-droplet contact area (i.e. DIB), where the droplet 
volume on either side of the DIB remains constant, will result in an increase in 
the rate of change of proton transfer. The converse situation also holds. Note 
that the same equilibrium pH value will be afforded as an analogous system 
containing a smaller contact area. 
It is also important to note that the rate of proton transfer observed in the 
experiments detailed in figure 4.19 is slow, in comparison to vesicular systems 
detailed in the literature.265 However, this is unsurprising, when considering the 
extremely small area (ca. 1 E-04 cm2) through which proton permeation is 
occurring in these DIB systems, compared to the combined surface area of a 
suspension of vesicles (> 2600 cm2).265 It would be interesting to determine 
whether flux is comparable between DIBs and vesicles. However, owing to the 
variety in experimental conditions employed  in the literature (lipid type, pH 
gradient etc.), the best way in which to determine this would be to conduct a 
vesicle leakage assay using analogous experimental conditions c.f. the DIB 
assay. 
4.4.2.4 Limitations of method 
Sections 4.4.2.1, 4.4.2.2, 4.4.2.3 and 4.4.2.4 have detailed the various steps 
involved in setting up a proton leakage assay for monitoring small molecule-
membrane interactions. However, it is important to stress that there are some 
key issues that need to be addressed before further work is attempted.  
The first issue that needs to be tackled involves the control of droplet size. The 
ability to control droplet size using this system, and hence the droplet interface 
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bilayer area, is a major issue. As discussed previously, and demonstrated by the 
last set of experimental results in figure 4.19 (section 4.4.2.3), the size of the 
droplets taking part in DIB formation will ultimately affect the kinetics of the 
system (i.e. the rate of proton transfer). Therefore in order to ensure that 
comparable, reproducible data is collected, a system whereby uniform droplet 
size can be attained is desirable: it was found extremely hard to maintain a 
constant droplet size and manoeuvre the droplets using manual manipulation. 
Implementation of a controlled system for droplet generation would mean that 
each experiment is performed in an equivalent environment, where the droplet 
properties can be highly conserved between experiments. 
Another issue which is of importance, if this assay is to be implemented in 
future investigations, includes increasing the experimental throughput. This is 
paramount, as it currently takes a long time to set up each DIB experiment 
using manual manipulation. The number of experimental repeats would ideally 
have to be increased substantially in order to fully characterise the system: the 
ability to produce and bring droplets together in quick succession would 
provide a good way in which to increase the number of experimental repeats. 
In turn this would mean that factors that are difficult to control, such as the 
droplet size and area of the DIB, could be managed more easily c.f. the manual 
method. Additionally, if the droplet size can be controlled, then the rate of 
proton leakage can be reliably tuned by tuning the size of droplets on either 
side of the DIB. A system that could offer these options would be highly 
beneficial, opening up various new avenues for experimental design. 
One limitation concerned with the leakage aspect of these proof-of-concept 
experiments involves monitoring the effect of a particular species upon different 
lipid bilayer compositions. Composition will affect bilayer thickness, which in 
turn will affect the permeability coefficient of H+.266 Also, it has been reported 
that the rate of proton transfer can significantly differ to what would be 
theoretically expected, upon the incorporation of different lipids: Gensure et 
al.265 state that the inclusion of cholesterol into a lipid bilayer results in a 
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significant increase in the rate of proton transfer, opposing initial hypotheses. 
Ultimately, this has to be controlled for when making comparisons between 
data sets of the same molecular species acting upon different membranes.  
 
4.5 CHAPTER SUMMARY 
In summary, chapter 4 has demonstrated that the formation of DIBs with 
DPhPC is reproducible. Additionally, it has been demonstrated that DIBs may 
also be comprised of more biologically relevant lipids, such as DOPC. The 
inclusion of more biologically relevant lipids in DIB systems is particularly 
important, with respect to investigating the effects of exogenous species on 
different lipid combinations. 
Chapter 4 has also detailed the various steps involved in the development of a 
proof-of-concept leakage assay, employing pH gradients, which has the 
potential to be used to monitor (indirectly) the extent to which the membrane 
is perturbed by exogenous species. The limitations surrounding the practical 
approach used to achieve DIB formation in this chapter, i.e. the manual 
manipulation of droplets, have been discussed. The major issue surrounds the 
fact that droplet size, and hence the area of the DIB, cannot easily be 
controlled and ultimately affects the rate of proton leakage. Hence, a technique 
that can control droplet size, as well as increase the throughput of experiments 
performed, is highly desirable. The issues discussed in this chapter (section 
4.4.2.4 therefore provide the rationale for chapter 5, which details a 
microfluidic approach for the high-throughput formation of droplet interface 
bilayers.  
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Chapter 5 
 
A microfluidic approach for high-throughput 
droplet interface bilayer (DIB) formation 
 
 
 
“Art is science made clear.” 
 Wilson Mizner 
 
Elements of the work contained within this chapter have been published in the journal Chemical 
Communications. The artwork presented here (designed and drawn by C. E. Stanley) was also 
accepted and published as the inside cover for the issue in which the aforementioned work was 
published.213 
C. E. Stanley et al., Chem. Commun., 2010, 46, 1620–1622 
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5.1 OVERVIEW 
This chapter presents the development of a microfluidic approach for the 
formation of droplet interface bilayer (DIB) networks in a high-throughput 
and controlled manner. Specifically, an automated system has been set-up, 
where the size of water-in-oil droplets participating in DIB formation is highly 
uniform and tuneable. Additionally the ability to form three dimensional DIB 
networks, where droplets are able to fill predefined structures of any desired 
shape or size, and the possibility for asymmetric DIB formation has been 
demonstrated. Elements of the work contained within this chapter have been 
published in the journal Chemical Communications.213 
 
5.2 INTRODUCTION 
Since the advent of DIB technologies in 2006, several advances have been 
detailed with respect to enhancing their screening capacity. These have 
included the use of microfluidic principles, electrical methods for the 
movement of droplets as well as other, more high-throughput, approaches.  
 
5.2.1 Use of mechanical pumping for bilayer formation 
The first systems to use ‘microfluidic’ concepts, i.e. mechanical pumping of 
fluids through microchannels, to form lipid bilayers were published in papers 
by Malmstadt et al.267 and Funakoshi et al.202 in 2006. Although technically DIBs 
were not formed using these methods (as the fluid either side of the bilayer is 
not contained within a droplet surrounded by a monolayer of lipid), 
nevertheless this work instigated the idea to utilise microfluidic tools for DIB 
formation. Two device set-ups were detailed: both involved pumping two 
aqueous streams through microchannels in opposing directions, towards one 
another (see figure 5.1). 
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The device by Malmstadt et al. relies on solvent extraction through PDMS to 
bring the two lipid-containing interfaces into contact with one another, as 
illustrated in figure 5.1 A. Although this was a pioneering study, the 
complicated device set-up only accommodates one lipid bilayer per device and 
the aqueous chambers are relatively large. Moreover, no comments on the 
stability of the bilayer were made. The approach described by Funakoshi et al. 
essentially achieves the same goal, but using a far simpler device design. Their 
device is made out of poly(methyl methacrylate) (PMMA) and so does not rely  
 
 
 
Figure 5.1: Devices for forming artificial lipid bilayers using microfluidics. (A) 
This device relies on solvent extraction through poly(dimethylsulfoxane) (PDMS) for 
bilayer formation, as illustrated in images 1-3. (B) This device utilises a cross-channel 
chip made of poly(methyl methacrylate) (PMMA); the process of bilayer formation is 
illustrated. (C) A photograph of the device displayed in B. Images reproduced from 
Malmstadt et al.267 and Funakoshi et al.202 
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on solvent extraction; rather, it simply pumps two aqueous streams towards 
one another, in the presence of a lipid-containing oil stream (see figure 5.1 B 
and C). This system is advantageous as the bilayer interface can quickly be 
discarded and a fresh bilayer reformed, meaning that successive experiments 
can be conducted with ease.   
 
5.2.2 Formation of DIB networks 
In addition to forming experimental platforms that possess one lipid bilayer for 
interrogation, of which the first DIB systems were described by Funakoshi et 
al.202 and Holden et al.,203 the formation of DIB networks has also been 
achieved.203,206 
Figure 5.2 A illustrates the concept of a DIB network. Simply, many  
lipid-containing droplets are submersed in an oil environment and brought into 
contact with one another. However, a network containing only tens of droplets 
has been achieved to date. The size of the network created is therefore limited 
by the manual manipulation of droplets, where typically 100 μm-diameter  
Ag / AgCl electrodes are employed. Hence, no automation of the process is 
afforded. 
Figure 5.2 B demonstrates how such networks can be utilised to attain higher 
order systems, comprised of simple components that act in a collective 
manner. Such a system has been described by Maglia et al.,268 where 
staphylococcal α-haemolysin pores have been shown to process electrical input 
signals differently, depending on their orientation in the bilayer. 
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Figure 5.2: Droplet interface bilayer networks and their application. (A) The 
images show a network of DIBs and demonstrate that droplets can be removed from 
(images 2-3) and replaced (images 3-4) into the network. (B) Illustration of the 
potential use of such networks, where input signals may be processed. Figures 
reproduced from Holden et al.203 and Maglia et al.268 The scale bar in A represents 700 
μm. 
 
5.2.3 Electrical methods 
Electrical methods have also been implemented to manipulate droplets for 
participation in DIBs. These have included methods that use dielectrophoresis 
(DEP) and electrowetting on dielectric (EWOD) principles. Such methods 
provide an alternative to the conventional microfluidic set-up, where electrical 
signals are used to control the generation and manipulation of aqueous 
droplets accordingly (as opposed to continuous flow).  
The first endeavour to realise DIB formation using digital microfluidics was 
published by Adhdaei et al. in 2008, where a device based on DEP was used.269 
In 2009, Poulos et al.270 demonstrated a more sophisticated approach to DIB 
formation; here EWOD was used, where essentially only 2-4 electrodes are 
required to move two droplets together (as opposed to eight in DEP), no Joule 
heating occurs and Ag / AgCl electrodes are incorporated into the device 
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design. Figure 5.3 illustrates the EWOD set-up used and the procedure for 
DIB formation. The application of an electric field across a droplet, which is 
sandwiched between electrodes covered in a dielectric material, enables it to 
interact more favourably with the surface i.e. to wet the surface. Activation of 
specific electrodes can therefore result in the manipulation of droplets. 
 
 
Figure 5.3: EWOD for DIB formation. (A) Here the EWOD set-up used can be 
viewed; indium tin oxide (ITO) electrodes are highlighted with white boxes and the 
black lines are Ag / AgCl electrodes. (B) The red box highlights successful DIB 
formation using EWOD (the set of droplets to the right have not been manipulated). 
(C)-(E) Illustration of the process of DIB formation. The ITO pads are inactive in C, 
but are activated in D (thus drawing each droplet in the direction of the other). The 
droplets subsequently relax to form a DIB (highlighted by red box in E) upon 
deactivation of the pads. Images in A and B have been reproduced from Poulos et 
al.270  
 
The use of small sample volumes (2-5 µl) and automation make these devices 
suitable for lab-on-a-chip processes, where biological assays are easily 
translatable. However, in terms of their capacity for forming DIB networks, 
the most advanced set-up that has been published to date is comprised only of 
a linear sequence of three droplets. One limitation of this work is that droplet 
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size cannot easily be changed, meaning that the whole device has to be 
redesigned if this is a requirement. Hence there is a limitation on the size of 
DIB contact area per device that can be created and so the formation of 
droplet chains, containing droplets of different size and thus differing in 
membrane properties, would not be easily achieved. 
 
5.2.4 High-throughput approaches 
Several approaches have also been described, which demonstrate the use of 
high-throughput methods for screening transmembrane ion channel currents. 
In these systems, bilayers are orientated in a horizontal position and formed 
either by dispensing aqueous droplets on top of aqueous compartments, both 
possessing preformed monolayers (in the presence of oil, as illustrated in  
figure 5.4 A),207 or using more conventional black lipid membrane (BLM) 
techniques as demonstrated in figure 5.4 B.209,271 Syeda et al.212 have used a 
slightly different type of approach where a suspended droplet, containing 
protein, is moved across an array of static aqueous compartments and 
participates in DIB formation at each compartment (figure 5.4 C). Here, 
staphylococcal α-haemolysin pores are synthesised in situ and various 
ions/drugs screened as potential blockers of this channel.  
One disadvantage common to each of these systems, is the ability to form only 
one bilayer per experimental unit. Hence the creation of multiple drop systems 
has not been reported and, as such, no method exists for scrutinising events 
occurring across multiple bilayers. Additionally, devices using more traditional 
approaches often involve very complex device designs and hence multiple 
fabrication steps. Syeda’s method has only been achieved via manual 
manipulation to date, though it has been postulated that this approach could 
be used to screen larger array chips if automated. However, despite there being 
no reported contamination of the suspended droplet between the nine samples 
tested, a larger array chip may be more susceptible to spoiling events.  
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Figure 5.4: Current methods for using planar lipid bilayers in high-throughput 
screens. (A) The method described by Poulos et al. 207 is illustrated. Here, an aqueous 
lipid-containing droplet (1 μl) is dispensed and falls onto a preformed oil-aqueous 
interface (see step 1); the aqueous phase also contains lipid molecules and hence a 
DIB is formed (see step 4). A wire (Ag / AgCl) is inserted into the droplet (step 2) in 
order to make electrical measurements – an enlarged image of the DIB/droplet/wire 
is displayed in step 3. (B) Illustration of an example of the use of black lipid 
membranes (BLMs) in high-throughput screens, specifically by Le Pioufle et al.209,271 
The complicated device design is displayed in image 1, with image 2 displaying an 
enlarged region of an upper recording well. BLMs can be formed across the apertures 
present in the parylene sheet, pictured in image 3. (C) Illustration of the ion channel 
screening chip published by Syeda et al.212 A lipid-containing droplet, suspended on a 
moveable Ag / AgCl electrode, can participate in DIB formation with multiple static 
aqueous compartments (as shown in step 1). Step 2 illustrates the well and electrode 
configuration in more detail; the red box indicates DIB formation. Images are adapted 
from the aforementioned papers.  
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5.2.5 Summary and chapter aims 
As a result of the observations made and experiences gained whilst conducting 
the experiments detailed in Chapter 4, and upon reviewing the literature, it is 
evident that the following requirements are desirable for advancing high-
throughput DIB systems:  
 
1. The ability to automate droplet manipulation.  
2. The ability to control droplet size / DIB contact area with ease.  
3. The ability to form extensive networks of DIBs. 
4. The ability to form asymmetric DIB systems. 
5.  The ability to make droplets quickly. 
 
Each of these requirements has been achieved, the details of which are 
described in the following sections. 
 
5.3 MATERIALS AND METHODS 
The following section details the materials required and methods employed in 
order to perform each of the experiments described in this chapter, specifically 
relating to the development of a novel microfluidic approach for high-
throughput droplet interface bilayer formation. 
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5.3.1 Materials 
5.3.1.1 Lipids 
The following lipids were used in the experiments detailed in this chapter: 
1,2‐diphytanoyl‐sn‐glycero‐3‐phosphocholine (DPhPC, Avanti Polar Lipids) 
and 1,2‐dioleoyl‐sn‐glycero‐3‐phosphocholine (DOPC, Avanti Polar Lipids).  
5.3.1.2 DIB formation 
The buffers used to prepare vesicle suspensions for DIB formation 
incorporated: 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), 
potassium chloride (KCl), sodium hydroxide (NaOH) and fluorescein, all of 
which were purchased from Sigma-Aldrich®. Hexadecane oil (99%, 
Sigma‐Aldrich®) was used as the oil of choice to aid the formation of DIBs. 
5.3.1.3 Devices 
First generation devices (“device 1, 2 and 3”) 
Materials required for the production of microfabricated structures via soft-
lithography included: 100 mm silicon-wafers (thickness 525 ± 25 μm & single 
sided polish, IDB Technologies UK Ltd), SU-8 50 photoresist (Chestech Ltd), 
Microposit EC-Solvent (Chestech Ltd), Sylguard 184 Elastomer Kit (VWR) 
and PTFE (polytetrafluoroethylene) ultramicrobore tubing (0.004” ID, 
Cole‐Parmer Instrument). A UV lamp was used to irradiate the exposed SU-8 
50 photoresist. Silicon wafers and glass slides (VWR) were cleaned prior to use 
with a 1:2 mixture of hydrogen peroxide and concentrated sulfuric acid 
(‘piranha’ solution) (Sigma-Aldrich®). Distilled water and isopropylalcohol 
(IPA, Sigma-Aldrich®) were used for rinsing. 
Second generation devices (“device 4”) 
In order to construct the new devices the following materials were required: 
hollow square capillaries (borosilicate glass, 1 mm x 1 mm x 50 mm, 
Composite Metal Services Ltd), ‘thin’ PTFE ultramicrobore tubing (0.004” ID, 
Chapter 5 
200 
Cole‐Parmer Instrument), ‘thick’ polyethylene (PE) tubing (380 μm ID, 
Harvard Apparatus UK) and Araldite (RS Components). Plastic syringes (3 ml, 
disposable BD Plastipak Syringes) and needles (BD Microlance 25G 1” – Nr. 
18, 0.5 × 25 mm) were used to collect the carrier fluid and aqueous waste. 
 
5.3.2 Methods 
5.3.2.1 Vesicle Preparation 
Vesicle suspensions were comprised of either DPhPC or DOPC and prepared 
as described previously (chapter 2, section 2.3.2.1). Thin lipid films were 
prepared with 2 mg of lipid and hydrated with 1 ml of buffer to yield a 
concentration of 2 mg / ml. The two buffer solutions, specifically solution 5.1 
(non-fluorescent) or 5.2 (fluorescent), prepared for use in experiments detailed 
in this chapter, are specified as follows: 
 
Solution 5.1:  10 mM HEPES, 200 mM KCl, pH 7.07 
Solution 5.2: 250 μM fluorescein, 10 mM HEPES, 200 mM KCl, pH 
7.60 
 
The hydrated lipid films were freeze-thawed five times and subsequently 
extruded 21 times through 100 nm polycarbonate membranes (Avanti Polar 
Lipids), wrapped in foil and stored in the dark when not in use. 
5.3.2.2 Device fabrication 
First generation devices: preliminary investigations (“device 1, 2 and 3”) 
First generation devices tested in the preliminary investigations were made 
using traditional photolithographic approaches. The procedures used were 
detailed explicitly in chapter 3, section 3.3.2.4. To recap, the steps used are 
shown in figure 5.5. The devices used in the preliminary investigations (devices 
1-3) are described in figure 5.6. 
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Figure 5.5: Method of device assembly. Procedures followed in order to assemble 
the various microfluidic devices tested in this chapter (in the preliminary experiments).  
 
 
 
Figure 5.6: First generation device used during preliminary investigations 
(devices 1-3). “Device 1” is comprised of three stages: (i) water-in-oil droplets are 
generated using the T-junction technique, (ii) the droplets are collected into thin 
PTFE tubing and (iii) the droplets are then inserted into a chamber for DIB 
formation. Note that these diagrams are not drawn to scale, however section 5.4.1.1 
includes an image of the actual device (to scale). “Device 2” generates droplets using 
the flow-focusing unit – droplets are then introduced into a chamber for DIB 
formation. Scale bar represents 50 µm. “Device 3” also generates droplets using the 
flow-focusing approach – the droplets then pass through a wider microfluidic channel 
in order to slow down the flow and therefore aid DIB formation (DIB formation 
region). Scale bar represents 100 µm.   
1. Create master 
2. Create micro-patterned 
substrate
3. Cast PDMS replica
4. Assemble device
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Second generation devices (“device 4”) 
To assemble second generation devices, ‘thin’ PTFE tubing was sealed in place 
at one end of the glass capillary and ‘thick’ PE tubing to the other (see section 
5.3.1.3 for materials); Araldite was used as the sealant. The devices were then 
carefully placed in an oven (60 oC) and left for 1 hour to allow the Araldite to 
set. Figure 5.7 details how each of the components are assembled in order to 
form a new generation device (device 4). 
 
Figure 5.7: Schematic of the second generation device (device 4). A projection 
of the device is displayed (top view) indicating how the PTFE and PE tubings are 
attached to the glass capillary. Note that the image is not to scale. 
 
 
5.3.2.3 Water-in-oil droplet formation 
Aqueous droplets comprised of vesicle suspensions (detailed in section 5.3.2.1) 
were created in hexadecane oil. Traditional microfluidic approaches were used 
to form water-in-oil droplets. Specifically, a syringe pump (PHD 2000, Harvard 
Apparatus) was used to withdraw oil and aqueous solutions in an alternating 
manner through the thin PTFE tubing and into the chamber. An auto-sampler 
was used to manage this process, having the additional benefit of possessing 
two channels and thus enabling more than one type of aqueous droplet to be 
introduced into the tubing. Figure 5.8 explains how the auto-sampler generates 
water-in-oil droplets.   
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Figure 5.8: Water-in-oil droplet formation using an auto-sampler. (A) A cuvette 
is used to hold the oil and aqueous solutions required to form water-in-oil droplets. 
Note that a second solution of vesicles may be included to generate more than one 
type of aqueous droplet in succession (i.e. for asymmetric droplet interface bilayer 
(aDIB) formation). (B) Thin PTFE tubing, attached to a syringe pump working in 
refill mode, is held by a mobile metal arm. In order to create water-in-oil droplets, the 
thin PTFE tubing is: (i) lowered from the oil, into the aqueous solution and (ii) raised 
from the aqueous solution back into the oil. This process occurs in rapid succession 
and is repeated constantly in order to generate a series of water-in-oil droplets. The 
syringe pump operates in refill mode for the duration of this process, i.e. 
‘withdrawing’ oil and aqueous solutions in an alternate fashion. (C) In order to create a 
series of droplets that alternate in lipid or aqueous composition, two different aqueous 
droplets can also be formed in succession. The same process occurs as in B, except 
for the fact that the auto-sampler then moves across to a second channel (containing a 
second aqueous sample), as detailed in step (iii), before then repeating the sampling 
process (as illustrated by steps (iv), (v) and (vi)). (D) After droplet generation, the thin 
PTFE tubing then feeds the droplets into the main channel of the device (device 4, 
section 5.3.2.2) where DIB formation can proceed.   
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5.3.2.4 Fluorescence leakage experiments 
Fluorescein leakage assays were achieved by forming DOPC DIBs between 
non-fluorescent and fluoresecent droplets (as detailed in section 5.3.2.1) 
arranged in an ABAB format, where A and B are fluorescent and non-
fluorescent droplets respectively. Such droplet arrangements were achieved 
using the two channel auto-sampler, as described previously in section 5.3.2.3. 
Figure 5.9 illustrates the nature of the set-up. 
 
 
Figure 5.9: Format of the fluorescein leakage assay. Both fluorescent and non-
fluorescent droplets containing DOPC vesicles (denoted by A and B respectively) are 
introduced into the device (device 4, section 5.3.2.2) using the two-channel auto-
sampler. DIBs are formed downstream upon stopping the flow. Note that the diagram 
is not to scale. 
 
After introduction of the droplets into the glass capillary and DIB formation, 
the syringe pump was stopped. Both bright field and fluorescence images were 
taken using exposures of 20 ms and 2 s respectively and a 5x objective. 
Fluorescence images were gained via illumination of the fluorescent sample 
using a mercury lamp (Olympus); a fluorescein filter was employed (480 / 40 
nm excitation, 488 nm long pass, Chroma Technology Corp.) as well as two 
neutral density filters (25ND6 and 25ND25, Olympus) to prevent 
photo‐bleaching. In order to monitor fluorescein leakage, images were taken 
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every 20 min up to 1 hour, then every 30 min up to 2 hours and finally at 3 
hours and 20 hours after the start of the experiment (note that not all images 
are shown section 5.4.2.4).  
5.3.2.5 Control experiments 
Two control experiments have been performed. The first simply involved 
proving that DIB formation only occurs in the presence of lipid molecules, as 
otherwise droplets merge.  
The second involved testing whether fluorescein leaks from the aqueous phase 
into the oil phase. Equal volumes of fluorescent buffer (solution 5.2, prepared 
as described in section 5.3.2.1) and hexadecane oil were placed in the same 
glass vial, thus forming an aqueous‐oil interface, and left for five days in a 
concealed environment. Aliquots of each phase were then transferred into a 96 
well‐plate and fluorescence measurements carried out on a Cary Eclipse 
fluorescence spectrophotometer (Varian Inc.). Emission scans, with excitation 
at 490 nm and emission collected from 500 to 700 nm, were then performed 
on each of the samples. Both the excitation and emission slits were set to 5 
nm, and a medium scan rate and photomultiplier tube detector voltage of 600 
V employed. Controls were also conducted with fresh samples of hexadecane 
and fluorescent buffer (where no aqueous-oil interface was allowed to form) 
for comparison. 
5.3.2.6 Imaging 
An Olympus DP71 CCD camera mounted on an Olympus BX51 upright 
microscope was used to capture all images illustrated in this chapter. Images 
were acquired using analySIS (Olympus Soft Imaging Solutions GmbH, 
Version 5.0) and fluorescence images were processed using IrfanView 
(freeware by Irfan Skiljan, 2009).  
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5.3.3 Movies 
The following movies have been included as supplementary information for 
the experiments detailed in this chapter: 
 
(i) Movie 5.1: ‘Small droplets filling the chamber in device 4’ 
(ii) Movie 5.2: ‘‘Large droplets filling the chamber in device 4’ 
(iii) Movie 5.3: ‘Formation of large droplet DIB network in device 4’ 
(iv) Movie 5.4: ‘‘Formation of DIBs with DOPC in device 4’ 
 
The movies were filmed using device 4, as detailed in section 5.3.2.2, as well as 
the microscope and software detailed in section 5.3.2.6. Stills from each movie 
have been included for completion as well as a description for the reader to 
refer to.  Please find the movies on the CD accompanying this thesis. 
5.3.3.1 Movie 5.1: ‘Small droplets filling the chamber in device 4’ 
This movie shows the successful formation of water-in-oil droplets at the point 
of entry into the glass chamber of device 4 (section 5.3.2.2). The thin PTFE 
tubing (inner diameter 102 μm) is present in the lower left hand corner. Here 
the droplets contain vesicle suspensions comprised of DPhPC (2 mg / ml) and 
are formed using a volumetric flow rate of 3 μl / min. The stills from the 
movie are displayed in figure 5.10. Note that the time increment between each 
image is 1 s and the scale bar represents 200 µm.  
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Figure 5.10: Stills from Movie 5.1: ‘Small droplets filling the chamber in device 
4’. The scale bar represents 200 µm. 
 
 
5.3.3.2 Movie 5.2: ‘Large droplets filling the chamber in device 4’ 
This movie demonstrates that large droplets can be formed and successfully 
introduced into the chamber in device 4 (section 5.3.2.2), again using DPhPC 
vesicle suspensions (2 mg / ml). The volumetric flow rate employed is  
6 μl / min. The PTFE tubing where droplets are carried can be seen in the 
lower left hand corner, the interior diameter of which is 102 μm. The stills 
from the movie are displayed in figure 5.11. Note that the time increment 
between each image is 3 s and the scale bar represents 400 µm. 
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Figure 5.11: Stills from Movie 5.2: ‘Large droplets filling the chamber in device 
4’. The scale bar represents 400 µm. 
 
 
5.3.3.3 Movie 5.3: ‘Formation of large droplet DIB network in device 4’ 
This movie shows that successful DIB networks can formed with large 
droplets in two dimensions, again using device 4 (section 5.3.2.2). The 
conditions used are identical to those stated in section 5.3.3.2. The stills from 
the movie are displayed in figure 5.12. Note that the time increment between 
each image is 2 s and the scale bar represents 400 µm. 
 
Figure 5.12: Stills from Movie 5.3: ‘Formation of large droplet DIB network in 
device 4’. The scale bar represents 400 µm. 
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5.3.3.4 Movie 5.4: ‘Formation of DIBs with DOPC using device 4’ 
Here, the successful formation of DIBs between multiple droplets containing 
DOPC vesicle suspensions (2 mg / ml) is demonstrated. Droplets were formed 
with volumetric flow rates of 12 μl / min using device 4 (section 5.3.2.2). The 
stills from the movie are displayed in figure 5.13. Note that the time increment 
between each image is 2 s and the scale bar represents 400 µm. 
 
 
Figure 5.13: Stills from Movie 5.4: ‘Formation of DIBs with DOPC using device 
4’. The scale bar represents 400 µm. 
 
5.4 RESULTS AND DISCUSSION 
As the results described in Chapter 4 corroborate, it was found that the 
movement of the droplets by hand is difficult and that the uniformity of 
droplet size was poor and uncontrollable. Hence, the idea to generate droplet 
interface bilayers (DIBs) using a microfluidic approach was thought to be 
advantageous. Several attempts were made initially to try and achieve this goal 
using the first generation devices. However, problems were found, which in 
turn resulted in the development of a simple design (second generation 
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devices) able to produce DIB networks using microfluidics. The various steps 
taken in order to achieve these developments are discussed herein. 
 
5.4.1 Preliminary investigations using first generation devices 
5.4.1.1 Device designs  
Several attempts were made to use a variety of microfluidic devices for DIB 
formation, specifically using the three devices designs detailed in section 5.3.2.2 
(devices 1-3). Initially it was assumed that the droplets would not merge due to 
the presence of lipid monolayers situated at, and hence stabilising, the droplets’ 
oil-aqueous interfaces. However this was not found to be the case – stable DIB 
formation could not be gained in any of these devices. The three formats 
tested, illustrated in figures 5.14, 5.15 and 5.17, are described and discussed 
below. 
The first attempt, which uses “device 1” (see section 5.3.2.2), involved using a 
T-junction to form aqueous droplets in oil. Chapter 1, section 1.4.1.4 provides 
an introduction to the traditional microfluidic methods available for water-in-
oil droplet formation. After forming water-in-oil droplets (as illustrated in 
figure 5.14 A) and collecting them in thin PTFE tubing (figure 5.14 B), they 
were then inserted into a chamber contained within the latter portion of the 
device (illustrated by figure 5.14 C). It was found that one of the major 
problems preventing DIB formation was actually associated with the point at 
which the droplets exited the thin PTFE tubing and entered into the chamber: 
drops were found to merge, resulting in the formation of very large droplets. 
This was attributed to the fact that the oil gaps between droplets were not large 
enough to enable the droplets to enter into the large chamber and move away 
from the entrance point, a limitation of the of T-junction technique for droplet 
generation. Additionally, it was not possible to form stable DIBs between the 
larger droplets, owing to the large interaction between the droplet and PDMS 
surfaces.  
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Figure 5.14: Device 1. (A) The first device trialled for the formation of DIBs in high-
throughput utilised a T-junction technique to form water-in-oil droplets. (B) After 
formation, the aqueous droplets were then collected into thin PTFE tubing. (C) The 
final part of the device involved inserting the droplets into a chamber for DIB 
formation. (D) Bright field image of the area highlighted in C (red box). The dotted 
circles (white) represent the region where droplets were anticipated to settle and form 
DIBs. Scale bar represent 100 μm. Note that A-C are not drawn to scale. 
 
Accordingly, a device that could generate droplets and form DIBs concurrently 
was desired, in order to overcome the problems associated with the first 
attempt. The second approach therefore utilised a single part device, “device 
2” (section 5.3.2.2), whereby droplets could be generated and then held in a 
chamber downstream for participation in DIB formation. Figure 5.15 
illustrates the nature of device 2. 
Water-in-oil droplets were created in device 2, as a result of utilising a flow-
focusing approach (see chapter 1, section 1.4.1.4 for further information). 
Figure 5.15 A illustrates the nature of device 2 and the flow-focussing unit 
employed.  
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After formation, the aqueous droplets proceed through the microfluidic 
channels until they reach a pillared section (figure 5.15 B). This pillared section 
acts in a passive manner and is normally used to reduce the speed of the 
droplets, holding them in close proximity to one another and thus enabling 
them to merge in a controlled fashion.121 It was hypothesised that by 
performing the same process, but in the presence of lipid molecules (especially 
DPhPC, see chapter 4, section 4.4.1.2), DIB formation would ensue. However, 
the droplets were found to merge when they came into contact with one 
another. 
 
 
Figure 5.15: Device 2. (A) The second device possesses a flow focussing unit to 
form water-in-oil droplets followed by a pillared section, where it was anticipated that 
droplets could participate in DIB formation. (B) A bright field image illustrating the 
region in A highlighted by a red box (pillared section). Scale bar represents 100 µm. 
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It is believed that the droplet merging events are associated with the pressures 
exerted upon the droplets being held in the pillared chamber area. That is to 
say that the pressure exerted upon the droplets, by the flow of oil running 
through the microfluidic channels in the device dominates monolayer-
monolayer interactions. Hence droplet merging occurs as a result. Additionally 
the pillared structures probably do not assist DIB formation, due to the 
interaction of the droplet area with the PDMS substrate (even though the 
PDMS area in close proximity to the droplets is reduced when compared to 
droplets filling a single channel). An observation made in a microfluidic 
channel supports this hypothesis, i.e. that the extensive interaction of lipid-
containing, aqueous droplets with a PDMS substrate lessens the chances of 
DIB formation, and is illustrated in figure 5.16. These results indicate that DIB 
formation does occur, but that it is not stable: the DIB is present for 
approximately 16 s, after which it ceases to exist (figure 5.16 A). 
 
 
Figure 5.16: Observations of potential on-chip DIB formation. (A) DIBs were 
found to occur in PDMS channels, though their lifetimes are short. DIB formation 
can be observed, however the DIB ruptures after ca. 16 s (highlighted by the white 
box) due to the excessive interaction of the droplet with the PDMS substrate. (B) A 
bright field image which indicates where this observation was made, i.e. in a 
microfluidic channel. Scale bars represent 50 μm. 
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Finally, it was decided to try using a device that would enable droplet 
generation and DIB formation to occur concurrently on-chip, but without a 
holding chamber. The key aspect of the device design is illustrated in figure 
5.17 A and B, where the droplets travel from a narrow channel into a wider 
channel, hence slowing their rate of movement. Droplets in these devices do 
form DIBs, but only momentarily: DIB formation and merging events are 
 
 
Figure 5.17: Device 3. (A) The device design is illustrated, where a flow focusing unit 
is again utilised for water-in-oil droplet generation. The aim of the experiment was to 
bring droplets together in an environment where unfavourable interactions with the 
PDMS substrate are reduced. (B) A bright field image of the highlighted region in A 
(red box). (C) Here DIB formation can be observed, where contact with the substrate 
is minimised (indicated by the black boxes in the image taken at 2 s). However, the 
speed at which the droplets come together in this type of device is too fast, resulting 
in droplet merging (indicated by black boxes in the image captured at 3 s). Scale bars 
represent 100 μm. 
Chapter 5 
215 
highlighted in the images captured at 2 s and 3 s respectively (presented in 
figure 5.17 C). Although substrate-monolayer interactions were minimised in 
this device, the speed at which the droplets approach one another is thought to 
be the most significant factor contributing to the merging events. 
5.4.1.2 First observation of stable DIB formation on-chip 
In summary, it was observed that there was a problem associated with the 
channel dimensions used in these PDMS microfluidic devices. When using the 
regimes outlined in section 5.4.1.1, the aqueous droplets tend to fill the entire 
channel, possessing a cigar-like structure, or at the very least significantly 
interact with the PDMS substrate. However it was observed, in one of the side 
channels adjacent to the chamber in device 1, that it would be possible to form 
stable DIBs using a microdroplet approach. Figure 5.18 illustrates this 
observation.   
In this instance a larger droplet (indicated in figure 5.18 A, but out of the frame 
of view in figure 5.18 B) was slowly being squeezed through the pillars of the 
chamber to yield smaller droplets that are stored in the peripheral space. This 
larger droplet formed as a result of the small droplets merging instantly in the 
chamber. The first DIB (present in the first image of figure 5.18 B, captured at 
0 s) is present for the entire 15 s of video footage, and is able to withstand the 
introduction of three droplets in succession. It was therefore concluded that 
one of the important factors for stable DIB formation is the introduction of 
one drop to another in a controlled and ‘gentle’ manner so as to not disrupt 
the DIB. Additionally, it is also important to ensure that substrate-monolayer 
interactions are minimised, by allowing droplets to adopt a spontaneous, 
spherical shape. 
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Figure 5.18:  First observation of stable DIB formation on-chip. (A) Schematic of 
the device in which this event was observed (device 1, section 5.3.2.2). The formation 
of a large droplet in the main chamber resulted, due to each of the smaller droplets 
merging, and is indicated on the diagram. Note that the diagram is not to scale. This 
large droplet was unintentionally squeezed through the pillars of the chamber to yield 
smaller droplets that formed DIBs. (B) A series of images demonstrating that DIBs 
are able to withstand the introduction of successive droplets into the region of interest 
(red box highlighted in A). This demonstrates that stable DIB formation can occur in 
a microfluidic device, under suitable conditions. Scale bars represent 100 μm. 
 
5.4.2 Second generation of devices 
5.4.2.1 Device design 
As a result of the observations detailed in section 5.4.1, a new device was 
designed and implemented. A major problem associated with using PDMS in 
device fabrication, for this specific set-up, is the fact that hexadecane: i) 
‘leaches’ out of the PDMS and ii) causes the PDMS to swell.272,273 Therefore it 
was desirable in the first instance to move to a system that employed glass.  
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The device that was therefore designed, “device 4” (see section 5.3.2.2), 
consisted predominantly of a glass capillary with thin polytetrafluoroethylene 
(PTFE) tubing (inner diameter = 100 μm) assembled at the entrance point and 
thick polyethylene (PE) tubing at the exit. A diagram of the device can be 
viewed in figure 5.19 A. Four lengths of thin PTFE tubing were inserted and 
secured at the entrance, one of which was used to introduce droplets into the 
device using a two-channel auto-sampler (see section 5.3.2.3 for information 
on how the auto-sampler is used to generate water-in-oil droplets) and the 
remainder used to maintain a uniform flow of oil along the channel. As a result 
 
 
Figure 5.19: Device 4 for high-throughput droplet interface bilayer (DIB) 
formation. (A) The device is comprised of a square glass capillary with tubing 
inserted at the entrance and exit. Droplets are formed at point (i) and come together 
to form DIBs downstream at point (ii). Four pieces of thin PTFE tubing (100 μm 
inner diameter) are used at the entrance in order to create a uniform flow across the 
channel (arrow represents direction of flow). (B) Water-in-oil droplets are generated 
using a two-channel auto-sampler. A time course of their formation at point A (i) is 
illustrated by the series of images. Scale bar represents 200 μm. (C) Illustration 
demonstrating how DIB networks can also be formed at point A (ii) using device 4. 
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of thin input tubing, having an inner diameter smaller than that of the channel 
dimensions, droplets do not fill the entire channel and can hence adopt a 
spherical shape, fulfilling one of the key requirements stated in section 5.4.1.2. 
The series of images in figure 5.19 B illustrate the nature of droplet formation. 
Please also consult Movie 5.1, ‘Small droplets filling the chamber in device 4’ 
(see section 5.3.3 for further information), to observe the generation of 
droplets in real time. Movie 5.1 illustrates that stable droplet formation was 
attained, affording droplets that are highly uniform in size. It was found that 
the size of droplets produced in this manner (ca. 200 µm in diameter) was very 
reproducible. Figure 5.20 illustrates the error associated with the cross-
sectional area of the droplets, when compared to the mean value for a sample 
of 13 droplets. In summary, this corresponds to an average size variation of 
only 3.3 %. 
 
Figure 5.20: Size variation of water-in-oil droplets. The graph illustrates how the 
cross-sectional area of a sample of 13 droplets compares to the mean value gained for 
the population. Correspondingly, the percentage error for each droplet is indicated, 
which gives rise to an average size variation of only 3.3 %.  
  
 
5.4.2.2 High-throughput DIB formation 
High-throughput DIB formation was achieved primarily by introducing water-
in-oil droplets, containing lipid vesicles comprised of either DPhPC or DOPC, 
into the device (device 4) and allowing them to form DIBs downstream of the 
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initial point of entry, as indicated by point (ii) figure 5.19 A and figure 5.19 C. 
Traditional microfluidic concepts were utilised to introduce water-in-oil 
droplets into the device. More specifically, a syringe pump, programmed to 
function in refill mode, was used to withdraw both oil and aqueous vesicle 
suspensions into the thin PTFE tubing. A two channel autosampler enabled 
specific volumes of each to be introduced in an alternating fashion, hence 
affording water-in-oil droplets (as detailed in section 5.3.2.3).  
Notably, droplets do not merge at the point at which they enter into the glass 
channel, rather they travel along the channel forming DIBs downstream. 
Figure 5.21 illustrates some examples of DIBs formed in this manner. 
 
 
Figure 5.21: Examples of droplet interface bilayer (DIB) formed in high-
throughput. (A) An example of high-throughput DIB formation using the lipid 
DPhPC. (B) An example of the formation of three-dimensional DIB networks in 
high-throughput (also using DPhPC). (C) An example of high-throughput DIB 
formation using the lipid DOPC. (D) An illustration indicating how DIB formation 
occurs between two aqueous droplets in an oil environment. The red boxes indicate 
DIB formation. The scale bars represent 200 µm. 
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It can be observed from the images displayed in figure 5.21 that the device in 
question (device 4) provides an ideal environment whereby: (i) successful 
monolayer formation has ensued, (ii) droplet diameters are not confined to 
channel dimensions and (iii) droplets are able to approach one another at a 
suitable rate, thus preventing merging. 
5.4.2.3 Control of droplet size 
A further benefit of this platform, which cannot be achieved with conventional 
methods and has not knowingly been described previously in the literature for 
the production of DIBs, is the ability to tune droplet size in a controlled and 
automated fashion. The formation of water-in-oil droplets, as described 
previously, is central to this microfluidic approach; it is therefore perceivable 
that changes to properties affecting volumetric flows rates can lead to changes 
in droplet characteristics.  
The droplets displayed in figure 5.22 A, which contain DPhPC vesicle 
suspensions, are approximately 5 nl in volume (200 μm in diameter) and are 
formed using a relatively low volumetric flow rate of  
3 µl / min (see Movie 5.1 and section 5.3.3 for further information). The 
droplet volume can be increased if the volumetric flow rate is increased and 
sampling frequencies lowered, as displayed in figure 5.22 B (~ 100 nl volume, 
600 μm diameter, 6 µl / min flow rate) and Movies 5.2 and 5.3 (see section 
5.3.3 for further information). It was noted that when droplets contained 
DOPC vesicle suspensions, higher volumetric flow rates (12 µl / min) were 
required to create droplets of intermediary size (~35 nl, 400 μm diameter, see 
figure 5.22). It is proposed that these anomalies could be due to differences in 
the interaction of DPhPC and DOPC with the PTFE tubing or viscosities of 
the aqueous phase. Note that Movie 5.4 (see section 5.3.3 for further 
information) illustrates an example of DIB formation with DOPC. Here, the 
use of a microfluidic approach is particularly valuable. As discussed in  
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Figure 5.22: Ability to tune droplet size, hence controlling droplet interface 
bilayer (DIB) contact area and the number of DIBs each droplet participates 
in. (A) The image illustrates small droplets (~5 nl, 200 μm in diameter) that are 
formed using device 4 (using a volumetric flow rate of 3 µl / min) and pack in three-
dimensions, hence forming multiple DIBs per droplet. (B) The image illustrates larger 
droplets (~ 100 nl, 600 μm in diameter) that are formed using higher volumetric flow 
rates (6 µl / min), but at a lower frequency, and create a chain of single droplets 
attached via DIBs stacking in two-dimensions. The scale bars represents 200 μm. 
DPhPC was used to form DIBs in both A and B. The red boxes indicate DIB 
formation.  
 
Chapter 4, section 4.4.2.4, forming DOPC DIBs by manual manipulation led 
to problems in size control. It is observed that the use of microfluidics offers a 
successful route to forming bilayers that may be more delicate in nature, as well 
as having the ability to control droplet size. 
Furthermore, the ability to control droplet size impacts upon two crucial 
factors that one may wish to access: (i) the size of the DIB contact area and (ii) 
the number of contact points, i.e. DIBs, achieved per droplet. The former is a 
natural consequence of the size of the droplet, with the latter being dependent 
upon the area available for packing. 
Figure 5.22 A illustrates that multiple DIBs per droplet can be attained using 
this experimental platform due to the formation of ‘small’ droplets, i.e. droplets 
possessing cross sectional areas less than half that of the channel. Each droplet 
has up to twelve nearest neighbours (exceptions being droplets participating in 
the first and last complete layers, and the incomplete top layer), thus having the 
potential to pack in either a hexagonal close-packed (HCP) or face-centred 
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cubic (FCC) manner and forming up to twelve DIBs per droplet. It is difficult 
to ascertain the exact nature of the packing (i.e. HCP vs FCC) due to optical 
ambiguities present at the channel edges, caused by the diffraction of light in 
the square capillary. The presence of an HCP lattice is most probable due to 
the increased probability in forming an A-type layer as the top layer (if only 
three complete layers reside in this device); the potential HCP and FCC 
packing arrangements of droplets in this device are displayed in figure 5.23. 
 
 
Figure 5.23: Potential packing arrangements of droplets participating in DIBs. 
(A) Schematic demonstrating how small droplets containing lipid vesicles can pack in 
an hexagonal close-packed (HCP) arrangement. (B) Schematic illustrating the potential 
for face-centred cubic (FCC) packing. The view depicted here looks down through the 
channel, from the top to the bottom, with ω indicating the width of the channel.  
 
It suffices to say here that it has been demonstrated that this platform can be 
utilised to change droplet size, which is attractive due to the ability to produce 
DIBs that differ in contact area and hence membrane stress. Additionally it is 
possible to use this system to pack droplets into three-dimensional space, 
advancing the experimental possibilities for the DIB platform and enabling 
more sophisticated operations to be probed. 
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5.4.2.4 Asymmetric droplet systems 
As described previously in chapter 4 (section 4.2.3), it is also possible to form 
asymmetric droplet interface bilayers (aDIBs). This is of key importance as it 
enables the researcher to create artificial membranes that more accurately 
mimic those present in the natural world (chapter 1, section 1.2.1.2). However, 
the ability to produce networks of aDIBs using a microfluidic approach has 
not been performed previously. This platform therefore lends itself to forming 
networks of aDIBs in a high-throughput manner, as droplets containing 
different vesicle compositions may easily be introduced into the thin PTFE 
tubing in an alternating fashion.  
To prove this concept, a linear sequence of ABAB droplets, containing DOPC 
vesicles in the presence of fluorescent (A) and non-fluorescent (B) buffer (see 
section 5.3.2.1 for compositions), were introduced into the microfluidic device 
using a two channel auto-sampler (see sections 5.3.2.3 and 5.3.2.4); the 
experimental configuration is illustrated in figure 5.24. Specifically this included 
incorporating a fluorescent dye, in this instance fluorescein, into droplets and 
monitoring its leakage across a DOPC DIB over time. Fluorescein is well 
known to leak more readily across DOPC bilayers, in comparison to dyes such 
as CF, owing to the lack of an additional carboxylic acid group.216 The first 
signs of leakage could be observed after approximately 60 minutes, in regions 
close to the DIBs. Importantly, the droplet sequence presented in figure 5.24 is 
arranged in an ABABB format, therefore influencing the rate of leakage 
observed. Upon inspection it is evident that there are two specific 
environments into which the dye can leak; the first will see leakage from two 
fluorescent droplets whereas the second will see contributions from just one, 
therefore leading to an asymmetric rate of leakage. Note that bright field 
images confirm that the droplet configuration is stable over the time course of 
the entire experiment and that experimental conditions remained the same 
throughout. 
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Figure 5.24: Asymmetric DIB (aDIB) formation and fluorescein leakage assay 
showing successful DIB formation with DOPC. The leakage of fluorescein across 
DOPC bilayers is monitored and both bright field (BF) and fluorescence (FITC, i.e. 
using a fluorescein isothiocyanate filter) images captured at various time points, 
specifically 0 h, 1 h, 1.5 h, 2 h, 3 h and 20 h; the first signs of leakage can be observed 
after 1 h. Note that the rate of leakage is asymmetric due to the ABABB droplet 
configuration, where A and B denote fluorescent and non-fluorescent droplets 
respectively (the fifth droplet lies outside the region of interest) and there is a slight 
variation in droplet size due to an artefact of the tubing at the droplet formation site. 
Scale bar represents 1600 μm (total length, i.e. 4 × 400 μm). 
 
Control experiments were also performed (see figure 5.25), whereby equal 
volumes of fluorescein buffer and hexadecane oil were placed in the same vial 
and left in dark room for five days; no discernable leakage of fluorescein into 
the oil phase was discovered when compared to the original solutions (which 
had not been left in direct contact with one another).  
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Figure 5.25: Results of fluorescein control experiments. (A) Graph showing the 
fluorescence traces for hexadecane (solid black line) and fluorescein buffer (dashed 
red line) fractions taken from samples that have been stored in the same glass vial for 
five days. (B) Graph showing the fluorescence traces for hexadecane and fluorescein 
buffer samples that have not been kept in contact with one another. (C) and (D) 
Enlarged regions of the fluorescence traces shown for hexadecane in A and B 
respectively. 
 
It is apparent that microfluidic approaches will facilitate the formation of 
highly complex DIB systems. For example, it is clear that in addition to the 
simple AAAA, BBBB and ABAB systems that have been produced using this 
set-up, the formation of higher order systems (such as ABCABC droplet 
formats) are also feasible. ABAB linear arrangements allow one type of a-DIB 
to reside, whereas ABCABC systems enable the formation of three (between 
AB, BC and CA), as clarified by figure 5.26. Moreover, this approach can allow 
the user to tailor the format to their specific need, i.e. by introducing any 
combination of droplets that they may require, i.e. AABBAA etc. One can 
envisage future advances to extend the a-DIB linear network into the three-
dimensional regime. 
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Figure 5.26: Formation of higher order a-DIBs. (A) ABAB formats can easily be 
formed, enabling the user to conduct experiments using one type of aDIB (i.e. 
comprised of membrane A and B only). (B) The formation of higher order aDIBs, 
with the inclusion of >2 droplet types can also be envisaged. The schematic illustrates 
how the incorporation of three types of droplet, arranged in an ABCABC format, can 
lead to the formation of three different aDIBs (comprised of either AB, BC or CA).  
 
 
5.5 CHAPTER SUMMARY 
In summary, this chapter has investigated the factors affecting successful DIB 
formation, in the context of a microfluidic environment, and consequently 
demonstrated the formation of a simple, microfluidic device (device 4, section 
5.4.2) able to form DIBs in an automated manner. Moreover, this device 
creates a suitable environment for bringing droplets together in a controlled 
manner to form DIBs. This addresses problems associated with the manual 
manipulation of droplets, where droplets containing lipids such as DOPC are 
more delicate to handle and, more often than not, simply merge.  
This approach enables the researcher to control droplet size with ease and 
hence the DIB contact area. These factors are extremely important with 
respect to creating stable platforms for replicating experimental conditions, in 
order to conduct repeat measurements and standardise assays for example. 
Additionally, the use of a microfluidic approach further widens the 
experimental opportunities, enabling the researcher to change the droplet 
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volume, and hence the size of the DIB contact area, as well as the complexity 
of the DIB network (i.e. whether the droplets stack in 1-, 2- or 3D). The latter 
point is dependent upon the relationship between the droplet radius and 
channel dimensions (height, width and length). The following statements will 
therefore hold:274 
(i) For 1D stacking of droplets 
 h < 4r  AND w < 4r  AND l  ≥ 4r    
Therefore: 0.25 < r/h  AND 0.25 < r/w  AND 0.25  ≥ r/l    
(ii) For 2D stacking of droplets 
 h < 4r  AND w ≥ 4r  AND l  ≥ 4r    
Therefore: 0.25 < r/h  AND 0.25 ≥ r/w  AND 0.25  ≥ r/l    
(iii) For 3D stacking of droplets 
 h ≥ (2√6/3)r + 2r   AND w ≥ √3r + 2r  AND l  ≥ 4r    
 i.e. h ≥ 3.63r   AND w ≥ 3.73r  AND l  ≥ 4r    
Therefore: 0.28 < r/h  AND 0.27 ≥ r/w  AND 0.25 ≥ r/l    
Where: r = radius of droplet  
 h, w, l = height, width and length of channel respectively 
 
Furthermore, the ability to incorporate more than one type of droplet in an 
automated manner will open opportunities for forming more complex DIB 
networks, in terms of being able to alter the lipid composition present with the 
two monolayers of the DIB, but also in terms of incorporating droplets 
possessing different aqueous conditions. 
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Chapter 6 
 
Future directions 
 
 
 
“Learn from yesterday, live for today, hope for tomorrow. The important thing is not to stop 
questioning.” 
 
Albert Einstein 
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6.1 OVERVIEW 
This chapter details suggestions for future work, based on the experiments 
detailed in this thesis. 
 
6.2 CHAPTERS 2 AND 3 
6.2.1 Critique of chapters 2 and 3 
Chapter 2 has detailed the development of a CF leakage assay, for the study of 
drug-membrane interactions, where the reproducibility of the assay and the 
effect of lipid composition on the rate of CF leakage have been investigated. 
Importantly, chapter 3 has demonstrated the potential for translating vesicle 
assays, such as the CF leakage assay, into a microfluidic format, hence offering 
the possibility to rapidly screen drug- (and protein-) membrane interactions in 
high-throughput. Specifically an increase in the fluorescence lifetime with time 
was observed, due to the decrease in concentration of CF from the interior of 
the vesicle. Future work could involve extrapolating more detailed kinetic 
information from the lifetime data, i.e. by fitting the data to more complex 
functions. For example, the contribution of the long and short components to 
the lifetime data over time could be examined, in addition to assessing any 
changes in the associated amplitudes.  
During device fabrication, dust particles were often trapped in the devices and 
thus blocked the channel. The devices used for these experiments are 
particularly large, hence there is a heightened probability of the dust becoming 
trapped, despite great care being taken during device assembly. A thin cover 
slip was used to seal the microfluidic chamber to meet the requirements 
imposed by the microscope. In retrospect, a very thin layer of PDMS could 
have been used instead. After PDMS is poured and allowed to set, it can be 
bonded immediately to another layer of PDMS without the washing steps 
detailed in section 3.3.2.4, thus reducing the chances of dust adsorption to the 
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surface of the substrates. Not only should this help to relieve any problems 
associated with dust becoming trapped in devices and blocking channels, it 
should also alleviate problems associated with adsorption of droplets to the 
glass substrate.  
Unfortunately, due to time restrictions, the measurements described in chapter 
3 only considered one drug. Ideally we wish to perform high-throughput 
experiments that survey the effects of many different drugs upon the 
membrane, such as those described in chapter 2. Therefore a dosing system 
may be implemented to achieve this, such as the method employed by 
Ismagalov’s group.275 This dosing system involves drawing a sufficient amount 
of drug, required for each assay, into a piece of Teflon tubing. Each solution is 
separated by an air bubble, which is an efficient way to prevent cross 
contamination between each drug solution.276,277 Figure 6.1 illustrates the nature 
of the dosing system. The Teflon tubing, containing the desired drug solutions, 
can then be connected to the device. In order to perform dose-dependent 
assays, a third aqueous inlet can easily be introduced into the device design (i.e. 
the spare inlet, as denoted in figure 3.7, chapter 3). This third inlet would 
contain solely buffer solution, enabling the drug stream to be diluted by  
 
 
Figure 6.1: Dosing system. Example of how a dosing system may be used to 
introduce several drug samples into a device to enable high-throughput screening 
assay to be performed. Each sample is separated by a gas droplet, thus eliminating 
cross contamination between drug samples. 
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varying the ratio of the drug and buffer flow rates (i.e. Aqueous2 and 
Aqueous3).  
The only major disadvantage of this experimental format is the need to scan 
across the device constantly to gain the required kinetic information. Perhaps a 
system whereby pairs of droplets are merged (i.e. one containing the vesicle 
solution and the other drug solution, thus initiating the reaction) and held in an 
array format, may serve as an effective way in which to exclude the need to 
scan constantly. The adsorbed static droplets, observed using the microfluidic 
format and presented in figure 3.19 (section 3.4.2.6), indicate that fluorescence 
lifetime imaging microscopy would be a suitable method if this approach was 
adopted. Additionally, more data points per experiment can easily be gained 
using this approach, thus enhancing the resolution of the kinetic traces. 
However, such a method would be limited by the field of view of the 
microscope and the hence the number of experiments that one can conduct at 
any one time. One major advantage of the current experimental design, and 
hence a reason justifying why it was chosen, is the fact that thousands of 
droplets are sampled for each data point recorded during the kinetic 
measurement. If the microscope stage and the syringes could be programmed 
to perform numerous leakage experiments, the potential for using such a 
technology in automated, high-throughput screens would be enhanced. 
 
6.2.2 Non-specific binding (NSB) in positron emission tomography (PET) 
Positron emission tomography (PET) is a non-invasive imaging technique, 
used to quantitatively measure in vivo processes in clinical investigations.278-280 
Compounds of therapeutic interest are labelled with radioisotopes, including 
11C, 13N, 15O and 18F (t1/2 = 20, 10, 2 and 110 min respectively).281 Such species 
decay by positron emission to form a positron (and neutron), which upon 
collision with an electron annihilates to form two 512 eV gamma rays at 180o 
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to one another. Subsequent co-incidence detection of these rays enables 3D 
image reconstruction.  
PET studies are becoming an increasingly popular technique in which to assist 
the drug development process,282 in particular CNS drug development.283 
However, non-specific binding (NSB) of radiolabelled drug molecules is often 
a major problem in PET imaging. High levels of NSB result in a poor signal-
to-noise ratio, thus vastly reducing the quality of the PET image.284 As a result, 
it is desirable to understand the molecular basis of this phenomenon and how 
levels of NSB can be reduced by enhancing our understanding of how drugs 
interact with membranes. The work detailed in chapters 2 and 3 will therefore 
enable high-throughput investigations to be performed, with the aim of 
furthering our understanding of drug-membrane interactions in general and the 
origins of NSB.  
6.3 CHAPTERS 4 AND 5 
6.3.1 Expansion of droplet interface bilayer (DIB) system for use with additional 
lipids 
It is felt that an important area to investigate further, with respect to expanding 
the scope of the work described in this thesis, is the compatibility of different 
lipid types with DIB systems. DPhPC was the major lipid cited in the literature 
concerning DIBs (other than the small mole percents of fluorescently tagged 
lipids used to create asymmetric lipid bilayers)205 until the work detailed in 
chapter 5 had been published. Such investigations are extremely important if 
one wishes to consider the effect of different lipid compositions on protein 
function, for example, hence further characterisation is required. 
It is also worthy to note that not all lipids may be suitable for use in DIB 
formation. Here preliminary observations with 1,2-didodecanoyl-sn-glycero-3-
phosphocholine (DLPC) are commented upon, with regards to suggesting 
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avenues for future exploration, as well as considering the possibility of using 
cholesterol in such systems. 
6.3.1.1 DLPC observations 
As a brief aside, droplets containing vesicles comprised of DLPC were 
administered into hexadecane during a preliminary investigation. Although this 
lipid can be used to form stable vesicle suspensions, unexpected observations 
were found to occur upon monolayer formation at the aqueous-oil interface. 
Upon depositing the lipid suspension into the oil, the droplets were left as 
usual in order to allow time for monolayer formation. After having left the 
droplets for approximately one minute, it was observed that the aqueous-oil 
interface started to fluctuate. Images A and B in figure 6.2 illustrate this effect, 
where A shows the droplet after having just been submersed in the oil and B 
details the development of the effect over time. The red boxes in B highlight 
the regions where large undulations develop at the aqueous-oil interface with 
time. The short lipid acyl chains appear to pose a problem in this system, 
despite being saturated and thus potentially offering stable monolayer 
formation. The presence of comparatively short chain lengths may enable a 
degree of flexibility to reside within the system, which would otherwise not 
occur if, for example, DOPC or DPhPC lipids are used. It appears that the 
chain-chain interactions are not prevalent enough to prevent the lipid 
monolayer from bending both towards and away from itself, therefore enabling 
flexibility in the monolayer. 
Interestingly if this system is left in the oil for a matter of minutes, the aqueous 
phase was found to ‘crystallise’. Figure 6.2 C and D show a droplet containing 
a DLPC vesicle suspension that has been submersed in hexadecane for 
approximately 1 and 10 minutes respectively. It is quite apparent that the 
appearance of the droplet has changed dramatically within this period; a fern-
like, fingering pattern was found to develop quite rapidly, noticeably growing  
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Figure 6.2: Effects of DLPC in hexadecane. (A) A droplet pipetted into oil and 
containing DLPC vesicles. (B) After having left the droplet for approximately one 
minute, the aqueous-oil interface started to fluctuate. The red boxes highlight the 
regions where large undulations develop at the aqueous-oil interface with time. (C) 
and (D) show a droplet containing a DLPC vesicle suspension that has been 
submersed in hexadecane for approximately 1 and 10 minutes respectively. The 
appearance of the droplet changes dramatically after 10 minutes (D). (E) Images 
showing the development of this change in appearance with time. 
 
in a radiative manner. This growth phenomenon is highlighted in the images 
displayed in figure 6.2 E. Note that although the droplet displayed in these 
images contained CF-containing aqueous solution, this effect was still observed 
in the absence of the dye. 
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Although this effect was repeatable on the same day, it did not appear to be 
repeatable when attempted on a separate occasion, where a different stock of 
DLPC was employed. Whether it be that the original lipid stock had degraded, 
or that a very specific set of conditions are required in order to achieve this 
effect, it is nevertheless, very interesting. The ability to control a system in a 
controlled and predictable manner, for instance possessing the ability to 
instigate a phase change, may be highly desirable for the future development of 
this technology.  
6.3.1.2 Cholesterol 
If, for example, one would wish to produce cholesterol-containing DIBs, 
hence aligning the complexity of the lipid content towards that of more 
biologically relevant mammalian membranes, potential problems associated 
with cholesterol demixing into the oil phase may be foreseen. Sterol-modified 
phospholipids (SMLs),285 a novel family of synthetic lipids synthesised by the 
Szoka group, therefore provide an opportunity to interrogate DIBs comprised 
of cholesterol-containing lipid mixtures in model membrane systems. 
Specifically, cholesterol is chemically attached to a glycerophospholipid 
molecule, i.e. its chemical motif consists of cholesterol substituted at either the 
sn-1 or -2 positions in place of an aliphatic tail. Interestingly it has been 
observed that the biophysical properties of the chimeric form of cholesterol 
behave in a similar manner to that of free cholesterol. Although the immediate 
application of SMLs by the Szoka group is concerned with enhanced liposomal 
drug delivery, where SML-doped liposomes are highly resistant to contents 
leakage due to the enhanced liposome stability associated with a reduction in 
cholesterol exchange with biomembranes, such lipid molecules are of great 
interest to anyone conducting studies of a biophysical nature on model 
membranes. Consequently, SMLs could be of great use in the field of droplet-
interface bilayers (DIBs). 
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6.3.1 Expansion of automated approach for DIB formation 
As a result of the experiments conducted in chapter 5, future developments of 
automated approach for DIB formation may include the following:  
1. Searching for different types of oils that are more compatible with 
PDMS devices. 
2. Incorporating electrodes into the device design to enable conductivity 
measurements to be performed. 
3. The ability to enable microinjection into aqueous compartments on 
either side of the DIB. 
4. Fully characterise the effect of changing parameters such as volumetric 
flow rates and sampling frequencies on droplet characteristics, and also 
the effects of using different lipid compositions.  
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APPENDIX 1: Column calibration 1 
 
 
Figure A1.1: Column calibration. Graph indicating the fractions into which the 
lipid, i.e. DOPC doped with Rh PE (99.5 : 0.5 mol %), is eluted. The fluorescence 
intensities of each fraction at 591 nm were measured and the percentage of lipid in 
each calculated accordingly. Fractions 6-9 were collated and used to perform efflux 
measurements. Errors represent ± 1 s.d. (n > 3). Chapter 2, section 2.4.1.2 should be 
consulted for further information and for discussions of the data. 
 
 
Fraction 
Number 
Lipid per 
fraction (%)  
Error 
(±) 
 
Max lipid per 
fraction (%) 
Min lipid per 
fraction (%) 
6 10.5 2.6 
 
13.1 7.9 
7 28.0 2.8 
 
30.8 25.2 
8 26.5 1.0 
 
27.5 25.5 
9 25.2 0.9 
 
26.1 24.3 
      Total % lipid =  90.2 
  
97.5 82.9 
 
Table A1.1: Column calibration data 1A. The percentage of lipid, and associated 
errors, for fractions 6-9 are tabulated (also displayed in the graph in figure A1.1). The 
total percentage of lipid collected is indicated (90.2 %), as well as the maximum and 
minimum percentages (within error). Hence 90.2 ± 7.3 % lipid is collected. 
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[Lipid](prior to elution)   12.5 mM 
Volume(prior to elution) 300 µl 
Moles(prior to elution) 3.8E-06 mol 
   Moles(post elution) 3.4E-06 mol 
Volume(post elution) 1700 µl 
[Lipid](post elution)   2.0 mM 
   Max moles(post elution) 3.7E-06 mol 
Max volume(post elution) 1700 µl 
Max [lipid](post elution)   2.2 mM 
   Min moles(post elution) 3.1E-06 mol 
Min volume(post elution) 1700 µl 
Min [lipid](post elution)   1.8 mM 
   [Lipid](post elution)   2.0 ± 0.2 mM 
 
 
Table A1.2: Column calibration data 1B. The data displayed in this table indicates: 
i) the number of moles of lipid present prior to elution and ii) the number of moles of 
lipid collected post elution, and hence the lipid concentration, if 82.9, 90.2 and 97.5 % 
of the lipid is retrieved. This translates to a post elution lipid concentration of 2.0 ± 
0.2 M. 
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APPENDIX 2: Exponential fit of efflux data and confirmation of drug-dye 
interaction 
 
Exponential decay model used to fit efflux data: 
0yAey
t
x
+=
−
  Equation A.1 
 
Upon differentiation with respect to x, the gradient of the fit curve may be 
gained for any given value of x.:  
t
x
e
t
A
dx
dy −
−=    Equation A.2 
 
When x = 0, the following is true: 
 
te
t
A
dx
dy 0−
−=
   Equation A.3 
 
t
A
dx
dy
−=
   Equation A.4 
 
Also, when x = 0, y = A+ y0. 
 
The graph illustrated in figure A2.1 illustrates an example of experimental 
efflux data that is fitted to an exponential decay model. The fitted parameters 
are illustrated and their use in determining the initial rate of CF efflux 
indicated.  
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Figure A2.1: Experimental efflux data fitted to an exponential decay model. 
This figure illustrates how the efflux data, induced by the introduction of different 
concentrations of imipramine to CF-containing vesicles, compares to the fitted data. 
Drug concentrations employed (final) are represented as follows: 1.6 mM (●), 0.8 mM 
(●), 0.4 mM (●), 0.2 mM (●), 0.1 mM (●), 0.05 mM (●), 0 mM (●). 
 
 
 
[Imi] 
(mM) 
1.6 mM 0.8 mM 0.4 mM 0.2 mM 0.1 mM 0.05 mM 
Parameter Value Error Value Error Value Error Value Error Value Error Value Error 
y0 96.83 0.26 81.40 0.50 50.65 0.82 24.07 0.77 7.32 0.27 2.20 0.07 
A -61.22 0.99 -71.26 0.46 -48.28 0.74 -22.03 0.71 -7.30 0.23 -3.59 0.08 
t 7.85 0.22 22.68 0.47 49.12 1.47 61.80 3.39 39.46 2.93 18.53 1.28 
 
    
  
    
  
    
  Chi2/DoF 3.15 1.22 0.20 0.07 0.05 0.05 
R2 0.98 1.00 1.00 1.00 0.98 0.95 
 
    
  
    
  
    
  -A/t 7.80 3.14 0.98 0.36 0.19 0.19 
 
Table A2.1: Table collating the different parameters associated with an 
exponential decay fit of the efflux data displayed in figure A2.1.  
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Figure A2.2: Control data confirming drug-dye interaction. This graph illustrates 
the influence of drug concentration (for imipramine, chlorpromazine and WAY) on 
the fluorescence intensity of CF (concentration of CF = 10 μm), confirming the drug-
dye interaction in the absence of lipid vesicles (where the concentration of drug is 
above the CMC). This data concurs with the trends observed in interfacial surface 
tension measurements (see section 2.4.2) and mirrors the CMC data. Notably, the 
CMC of WAY is the lowest, at ca. 0.4 mM (see figure 2.16, section 2.4.2) - dye is 
therefore sequestered by micelles at drug concentrations greater than the CMC. 
Chlorpromazine possesses a CMC of 1.4 mM (see figure 2.16, section 2.4.2) and 
imipramine has not yet reached its CMC at a drug concentration equal to 1.6 mM. 
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APPENDIX 3: Column calibration 2 
 
 
Figure A3.1: Column calibration 2. Graph indicating the fractions into which the 
lipid, i.e. DOPC:DOPE doped with Rh PE (79.5 : 20 : 0.5 mol %), is eluted. The 
fluorescence intensities of each fraction at 591 nm were measured and the percentage 
of lipid in each calculated accordingly. Fractions 6-9 were collated and used to 
perform efflux measurements. Errors represent ± 1 s.d. (n > 3). Chapter 2, section 
2.4.3.1 should be consulted for further information and for discussions of the data. 
 
 
Fraction 
Number 
Lipid per 
fraction (%)  
Error 
(±) 
 
Max lipid per 
fraction (%) 
Min lipid per 
fraction (%) 
6 22.7 5.5 
 
28.2 17.2 
7 27.1 1.1 
 
28.3 26.0 
8 30.4 1.2 
 
31.6 29.2 
9 15.0 4.3 
 
19.3 10.7 
      Total % lipid =  95.2 
  
107.4 83.1 
 
Table A3.1: Column calibration data 2A. The percentage of lipid, and associated 
errors, for fractions 6-9 are tabulated (also displayed in the graph in figure A3.1). The 
total percentage of lipid collected is indicated (95.2 %), as well as the maximum and 
minimum percentages (within error). Hence 95.2 ± 12.2 % lipid is collected. 
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[Lipid](prior to elution)   12.5 mM 
Volume(prior to elution) 300 µl 
Moles(prior to elution) 3.8E-06 mol 
   Moles(after elution) 3.6E-06 mol 
Volume(after elution) 1700 µl 
[Lipid](after elution)   2.1 mM 
   Max moles(after elution) 4.0E-06 mol 
Max volume(after elution) 1700 µl 
Max [Lipid](after elution)   2.4 mM 
   Min moles(after elution) 3.1E-06 mol 
Min volume(after elution) 1700 µl 
Min [Lipid](after elution)   1.8 mM 
   [Lipid](after elution)   2.1 ± 0.3 mM 
 
Table A3.2: Column calibration data 2B. The data displayed in this table indicates: 
i) the number of moles of lipid present prior to elution and ii) the number of moles of 
lipid collected post elution, and hence the lipid concentration, if 83.1, 95.2 and 107.4 
% of the lipid is retrieved. This translates to a post elution lipid concentration of 2.1 ± 
0.3 mM. 
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APPENDIX 4: CF-encapsulated DOPC : DOPE vesicles and chlorpromazine 
 
 
 
 
 
Figure A4.1: Efflux of carboxyfluorescein from vesicle lumens upon the 
addition of chlorpromazine; dependence on mole percent of DOPE in a DOPC 
bilayer. Three repeats of the data are included. The graphs relate to the following: A-
C = DOPC : DOPE (100 : 0), D-F = DOPC : DOPE (80 : 20), G-I = DOPC : 
DOPE (60 : 40) and J-L = DOPC : DOPE (40 : 60). Chlorpromazine concentrations 
employed (final) are represented as follows: 1.6 mM (●), 0.8 mM (●), 0.4 mM (●), 0.2 
mM (●),0.1 mM (●), 0.05 mM (●), 0 mM (●). 
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APPENDIX 5: CF-encapsulated DOPC : DOPE vesicles and WAY 
 
 
 
 
Figure A5.1: Efflux of carboxyfluorescein from vesicle lumens upon the 
addition of WAY; dependence on mole percent of DOPE in a DOPC bilayer. 
Three repeats of the data are included. The graphs relate to the following: A-C = 
DOPC : DOPE (100 : 0) and D-F = DOPC : DOPE (80 : 20). WAY concentrations 
employed (final) are represented as follows: 1.6 mM (●), 0.8 mM (●), 0.4 mM (●), 0.2 
mM (●), 0.1 mM (●), 0.05 mM (●), 0 mM (●). 
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APPENDIX 6: CF-encapsulated DOPC : DOPE vesicles and imipramine  
 
 
 
 
 
Figure A6.1: Efflux of carboxyfluorescein from vesicle lumens upon the 
addition of imipramine; dependence on mole percent of DOPE in a DOPC 
bilayer. Three repeats of the data are included. The graphs relate to the following: A-
C = DOPC : DOPE (100 : 0), D-F = DOPC : DOPE (80 : 20), G-I = DOPC : 
DOPE (60 : 40) and J-L = DOPC : DOPE (40 : 60). Imipramine concentrations 
employed (final) are represented as follows: 1.6 mM (●), 0.8 mM (●), 0.4 mM (●), 0.2 
mM (●), 0.1 mM (●), 0.05 mM (●), 0 mM (●). 
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APPENDIX 7: Fluorescence lifetime data for the carboxyfluorescein calibration 
experiment performed in a cuvette format 
 
 
Table A7.1:  Single exponential fit to carboxyfluorescein calibration data (in 
bulk), thus yielding the corresponding fluorescence lifetime (τ1) and χ2 values. 
 
 
 
Figure A7.1: The fluorescence lifetime gained for each of the ten solutions of 
carboxyfluorescein, present at different concentrations, based on the data 
provided in table A7.1 (above). Chapter 3, section 3.4.2.1 should be consulted for 
further information and for discussions of the data. 
   
Repeat 1 Repeat 2 
Sample [CF] (M) -log ([CF] (M)) τ1 (ns) χ2 τ1 (ns) χ2 
1 5.0E-02 1.30 0.28 1.14 0.27 1.43 
2 2.5E-02 1.60 1.12 1.10 1.03 1.26 
3 6.3E-03 2.20 6.95 1.74 7.20 1.24 
4 1.6E-03 2.80 9.51 1.30 10.3 1.16 
5 3.9E-04 3.41 7.22 1.31 7.60 0.95 
6 1.0E-04 4.00 6.04 1.30 5.90 1.04 
7 2.0E-05 4.70 5.18 1.31 4.93 1.02 
8 6.0E-06 5.22 4.61 1.68 4.56 1.03 
9 2.0E-06 5.70 4.46 1.69 4.67 1.07 
10 4.0E-07 6.40 4.45 1.57 4.47 1.13 
Appendix 8 
248 
APPENDIX 8: Fluorescence lifetime data for the carboxyfluorescein leakage 
assay performed using imipramine in a cuvette format 
 
Time (mins) τ1 (ps) χ2 
0 2729 1.17 
2 3542 1.46 
4 3724 1.58 
6 3804 1.06 
8 4115 1.52 
10 4098 1.28 
12 4282 1.40 
14 4080 1.30 
16 4035 1.04 
18 3973 1.00 
20 3951 1.00 
22 4125 1.26 
24 4062 1.07 
26 4054 1.21 
28 4071 1.05 
30 3936 1.12 
Table A8.1:  Single exponential fit to data gained during the carboxyfluorescein 
leakage assay, performed using imipramine (in bulk), thus yielding the 
corresponding fluorescence lifetime (τ1) and χ2 values. 
 
 
Figure A8.1: The change in fluorescence lifetime over time upon addition of 
imipramine to a DOPC vesicular solution (1.6 and 0.1 mM respectively, final 
concentrations), based on the data provided in table A8.1 (above). Chapter 3, 
section 3.4.2.2 should be consulted for further information and for discussions of the 
data. 
Appendix 9 
249 
APPENDIX 9: Fluorescence lifetime control data performed in a cuvette format 
and used to accompany the carboxyfluorescein leakage assay  
 
Time (mins) α1 τ1 (ps) α2 τ 2 (ps) χ2 
0 56.4 439 43.6 4107 1.32 
3 48.1 354 51.9 3729 1.21 
7 51.4 590 48.6 4403 1.37 
17 50.7 625 49.3 4630 1.37 
31 45.0 447 55.0 3877 1.15 
 
Table A9.1: Double exponential fit to control data, where the fluorescence 
lifetime of carboxyfluorescein-containing vesicles (DOPC, 0.1 mM see chapter 
3, section 3.3.2.5) in solution is measured at various intervals during the time 
course of the experiment. The corresponding fluorescence lifetime (τ1, τ2) and χ2 
values are displayed. 
 
 
 
 
 
Figure A9.1: The change in fluorescence lifetime over time, based on the data 
provided in table A9.1 (above), of carboxyfluorescein-containing vesicles 
suspended in solution (DOPC, 0.1 mM see chapter 3, section 3.3.2.5) i.e. where 
no drug, solely buffer has been introduced. Chapter 3, section 3.4.2.2 should be 
consulted for further information and for discussions of the data. 
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APPENDIX 10: Fluorescence lifetime data for the carboxyfluorescein 
calibration experiment performed in a microfluidic format 
 
Sample [CF] (M) -log [CF] τ1 (ns) 
1 5.0E-02 1.30 0.20021 
2 2.5E-02 1.60 0.82257 
3 6.3E-03 2.20 3.62383 
4 1.6E-03 2.80 4.02521 
5 3.9E-04 3.41 3.85486 
6 1.0E-04 4.00 3.7749 
7 2.0E-05 4.70 - 
8 6.0E-06 5.22 3.80569 
 
Table A10.1:  Single exponential fit to carboxyfluorescein calibration data (in a 
microfluidic format), thus yielding the corresponding fluorescence lifetime (τ1). 
 
 
Figure A10.1: The fluorescence lifetime gained for each of the ten solutions of 
carboxyfluorescein, present at different concentrations, based on the data 
provided in table A10.1 (above). Chapter 3, section 3.4.2.3 should be consulted for 
further information and for discussions of the data. 
Appendix 11 
251 
APPENDIX 11: Fluorescence lifetime data (and fits to data) for the 
carboxyfluorescein leakage assay performed using imipramine in a microfluidic 
format 
 
 
 
 
 
 
 
Table A11.1:  Single exponential fit to the data gained when carboxyfluorescein 
leakage is induced by imipramine in a microfluidic format. Both 1.6 and 0.8 mM 
imipramine solutions (final concentrations) were employed; the corresponding 
fluorescence lifetime values (τ1) are displayed. 
 
 
Figure A11.1: The change in fluorescence lifetime over time upon addition of 
imipramine solutions (1.6 and 0.8 mM, final concentration) to a DOPC 
vesicular solution (0.1 mM, final concentration), based on the data provided in 
table A11.1. Chapter 3, section 3.4.2.4 should be consulted for further information 
and for discussions of the data. 
 
1.6 mM Imipramine 0.8 mM Imipramine 
Time (mins) τ 1 (ps) τ 1 (ps) 
0 841 780 
0.5 987 - 
0.9 834 811 
1.4 950 - 
2.1 - 829 
1.8 1159 - 
2.7 1345 913 
3.6 1285 1056 
4.5 1483 942 
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Linear Regression for 1.6 mM Imipramine: 
 
Y = A + B * X 
 
           Parameter       Value     Error 
------------------------------------------------------------ 
A 833.79665 57.90412 
B 144.13603 23.97019 
------------------------------------------------------------ 
 
R SD N P 
------------------------------------------------------------ 
0.92611 99.41309 8 9.53528E-4 
------------------------------------------------------------ 
 
 
Table A11.2:  Linear regression associated with the data displayed in figure 
A11.1. 
 
 
Linear Regression for 0.8 mM Imipramine: 
 
Y = A + B * X 
 
                                     Parameter    Value      Error 
------------------------------------------------------------ 
A 771.09383 47.71553 
B 50.92917  17.26231 
------------------------------------------------------------ 
 
R SD N P 
------------------------------------------------------------ 
0.82774 64.49041 6 0.04196 
------------------------------------------------------------ 
 
Table A11.3:  Linear regression associated with the data displayed in figure 
A11.1. 
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APPENDIX 12: Fluorescence intensity data (and fits to data) for the 
carboxyfluorescein leakage assay performed using imipramine 
 
 
Figure A12.1: The change in fluorescence intensity over time upon addition of 
imipramine solutions (1.6 and 0.8 mM, final concentration) to a DOPC 
vesicular solution (0.1 mM, final concentration). Chapter 3, section 3.4.2.4 should 
be consulted for further information and for discussions of the data. 
 
Data: 1.6 mM Imipramine, Model: ExpDec1 
 
Equation: y = A1*exp(-x/t1) + y0 
Chi^2/DoF = 2.60918 
R^2 =  0.98936 
 
y0 93.29301  0.44732 
A1 -61.40944 1.01347 
t1 6.2097  0.22224 
------------------------------------------------------------ 
-A/t = gradient of the tangent at (0, A+y0) 
Table A12.1:  Fitted exponential decay associated with the data displayed in 
figure A12.1.  
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Data: 0.8 mM Imipramine, Model: ExpDec1 
 
Equation: y = A1*exp(-x/t1) + y0 
Chi^2/DoF = 1.37612 
R^2 =  0.99491 
   
y0 67.90723  1.04351 
A1 -62.11674 0.89019 
t1 14.40883  0.5861 
------------------------------------------------------------ 
-A/t = gradient of the tangent at (0, A+y0) 
 
Table A12.2:  Fitted exponential decay associated with the data displayed in 
figure A12.1. 
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APPENDIX 13: Properties of droplets 1-6 
 
Drop 1: Non-fluorescent Drop 2: Fluorescent Drop DIB Contact area
Diameter = 689 µm Diameter = 587 µm Diameter = 109 µm
0.07 cm 0.06 cm 0.01 cm
Radius = 345 µm Radius = 294 µm Radius = 55 µm
0.03 cm 0.03 cm 0.01 cm
Volume = 1.7E-04 ml Volume = 1.1E-04 ml Area = 1.E-04 cm2
0.17 µl 0.11 µl
Drop 3: Non-fluorescent Drop 4: Fluorescent Drop DIB Contact area
Diameter = 699 µm Diameter = 547 um Diameter = 117 µm
0.07 cm 0.05 cm 0.01 cm
Radius = 349 µm Radius = 274 µm Radius = 59 µm
0.03 cm 0.03 cm 0.01 cm
Volume = 1.8E-04 ml Volume = 8.6E-05 ml Area = 1.E-04 cm2
0.18 µl 0.09 µl
Drop 5: Non-fluorescent Drop 6: Fluorescent Drop DIB Contact area
Diameter = 539 µm Diameter = 631 µm Diameter = 106 µm
0.05 cm 0.06 cm 0.01 cm
Radius = 270 µm Radius = 316 µm Radius = 53 µm
0.03 cm 0.03 cm 0.01 cm
Volume = 8.2E-05 ml Volume = 1.3E-04 ml Area = 1.E-04 cm2
0.08 µl 0.13 µl  
Table A13.1: Properties of droplets 1-6. The diameter, radius and volumes of 
droplets 1-6 are displayed in the table. These properties relate to the experiments 
discussed in chapter 4, section 4.4.2.3. 
 
 
Figure A13.1: Bright field images of droplets 1-6. This figure displays the nature of 
droplets 1-6, which relates to the experiments discussed in chapter 4, section 4.4.2.3. 
Scale bar represents 400 µm. 
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APPENDIX 14: Bright field and fluorescence images of droplets participating in 
DIB leakage experiments. 
 
 
Figure A14.1: Droplets 1 and 2. Bright field and fluorescence images (see chapter 4, 
section 4.3.2.6 for specific details relating to the fluorescence channels 1 and 2) of 
droplets 1 and 2 participating in DIB leakage experiments described in chapter 4, 
section 4.4.2.3. Scale bars represent 400 µm. 
 
 
Figure A14.2: Droplets 3 and 4. Bright field and fluorescence images (see chapter 4, 
section 4.3.2.6 for specific details relating to the fluorescence channels 1 and 2) of 
droplets 3 and 4 participating in DIB leakage experiments described in chapter 4, 
section 4.4.2.3. Scale bars represent 400 µm. 
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Figure A14.3: Droplets 5 and 6. Bright field and fluorescence images (see chapter 4, 
section 4.3.2.6 for specific details relating to the fluorescence channels 1 and 2) of 
droplets 5 and 6 participating in DIB leakage experiments described in chapter 4, 
section 4.4.2.3. Scale bars represent 400 µm. 
 
 
 
Figure A14.4: Control droplets. Bright field and fluorescence images (see chapter 4, 
section 4.3.2.6 for specific details relating to the fluorescence channels 1 and 2) of an 
exemplar control droplet, used during experiments described in chapter 4, section 
4.4.2.3. Scale bars represent 400 µm. 
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